Index NDX, S&P 500
P/E -
EPS (ttm) -15.38
Insider Own 10.86%
Shs Outstand 382.00M
Perf Week -6.06%
Market Cap 28.02B
Forward P/E -
EPS next Y -7.23
Insider Trans -1.41%
Shs Float 342.64M
Perf Month -10.62%
Income -5867.00M
PEG -
EPS next Q -1.64
Inst Own 67.96%
Short Float 7.30%
Perf Quarter -52.88%
Sales 5.04B
P/S 5.56
EPS this Y 26.10%
Inst Trans 0.89%
Short Ratio 6.61
Perf Half Y -26.73%
Book/sh 30.50
P/B 2.39
EPS next Y 20.68%
ROA -31.24%
Short Interest 25.00M
Perf Year -32.66%
Cash/sh 22.08
P/C 3.30
EPS next 5Y -
ROE -40.94%
52W Range 62.55 - 170.47
Perf YTD -26.71%
Dividend Est. -
P/FCF -
EPS past 5Y -20.02%
ROI -45.28%
52W High -57.24%
Beta 1.68
Dividend TTM -
Quick Ratio 3.92
Sales past 5Y 662.08%
Gross Margin 22.47%
52W Low 16.53%
ATR (14) 3.90
Dividend Ex-Date -
Current Ratio 4.09
EPS Y/Y TTM -601.75%
Oper. Margin -92.09%
RSI (14) 25.56
Volatility 4.00% 3.95%
Employees 5600
Debt/Eq 0.11
Sales Y/Y TTM -52.22%
Profit Margin -116.36%
Recom 2.42
Target Price 124.11
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 8.04%
Payout -
Rel Volume 0.90
Prev Close 73.44
Sales Surprise 87.68%
EPS Surprise 0.54%
Sales Q/Q -29.94%
Earnings Aug 01 BMO
Avg Volume 3.78M
Price 72.89
SMA20 -10.51%
SMA50 -27.96%
SMA200 -31.40%
Trades
Volume 3,418,070
Change -0.75%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Upgrade
HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade
Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade
HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade
Oppenheimer
Perform → Outperform
$142
Nov-29-23 Initiated
Canaccord Genuity
Hold
$82
Nov-03-23 Upgrade
HSBC Securities
Reduce → Hold
$89 → $69
Nov-02-23 Downgrade
Deutsche Bank
Hold → Sell
$125 → $60
Aug-04-23 Downgrade
TD Cowen
Outperform → Market Perform
$145 → $125
Aug-03-23 Downgrade
Deutsche Bank
Buy → Hold
$125
Jul-24-23 Initiated
William Blair
Mkt Perform
$136.28
Jul-14-23 Initiated
HSBC Securities
Reduce
$97
Jun-26-23 Upgrade
UBS
Neutral → Buy
$221 → $191
Apr-26-23 Initiated
Guggenheim
Neutral
Mar-13-23 Upgrade
TD Cowen
Market Perform → Outperform
$150 → $180
Mar-02-23 Initiated
RBC Capital Mkts
Outperform
$200
Feb-24-23 Downgrade
SVB Securities
Market Perform → Underperform
$111 → $93
Dec-19-22 Upgrade
Jefferies
Hold → Buy
$170 → $275
Dec-14-22 Downgrade
Chardan Capital Markets
Buy → Neutral
$186 → $191
Oct-21-22 Upgrade
SVB Leerink
Underperform → Mkt Perform
$174 → $101
Show Previous Ratings
Today 04:31AM
Sep-06-24 02:02PM
07:04AM
(Pharmaceutical Business Review)
07:00AM
(The Wall Street Journal)
Sep-05-24 01:04PM
11:53AM
Loading…
11:53AM
(Pharmaceutical Technology)
08:00AM
Sep-04-24 08:35PM
01:14PM
(Investor's Business Daily)
08:30AM
07:44AM
(Pharmaceutical Business Review)
07:21AM
Sep-03-24 11:32PM
08:30AM
Sep-02-24 10:53AM
(Pharmaceutical Technology)
07:00AM
Loading…
07:00AM
Sep-01-24 04:12AM
Aug-30-24 04:06PM
(Associated Press Finance)
-5.76%
Aug-29-24 12:00PM
08:00AM
Aug-28-24 06:59PM
06:30AM
Aug-27-24 05:45AM
Aug-26-24 07:16AM
(Pharmaceutical Business Review)
Aug-23-24 02:01PM
(The Wall Street Journal)
07:00AM
04:12AM
(Pharmaceutical Technology)
01:25AM
Aug-22-24 05:19PM
04:46PM
02:33PM
Loading…
02:33PM
01:47PM
01:44PM
(The Wall Street Journal)
01:41PM
07:00AM
Aug-21-24 01:32PM
(Investor's Business Daily)
12:42AM
(Pharmaceutical Technology)
12:12AM
(Pharmaceutical Technology)
Aug-20-24 11:34AM
(Pharmaceutical Technology)
Aug-19-24 05:32AM
04:07AM
Aug-16-24 04:21PM
10:21AM
12:22AM
(Pharmaceutical Technology)
Aug-14-24 07:00AM
Aug-13-24 02:43PM
Aug-12-24 08:05AM
03:52AM
Aug-10-24 08:18AM
Aug-06-24 02:42PM
(The Wall Street Journal)
06:30AM
Aug-05-24 04:35PM
(Investor's Business Daily)
11:37AM
09:40AM
06:55AM
Aug-04-24 04:15AM
Aug-03-24 01:05AM
Aug-02-24 06:05PM
05:09PM
07:17AM
06:51AM
12:15AM
(Thomson Reuters StreetEvents)
Aug-01-24 06:44PM
(Morningstar Research) -21.01%
05:09PM
04:36PM
(The Wall Street Journal)
04:02PM
(Investor's Business Daily)
03:22PM
(The Wall Street Journal)
02:31PM
01:55PM
01:19PM
12:45PM
12:23PM
11:54AM
11:49AM
11:18AM
10:46AM
10:02AM
10:02AM
08:58AM
07:40AM
06:38AM
(Associated Press Finance)
06:32AM
06:30AM
06:30AM
Jul-31-24 06:33AM
(Pharmaceutical Technology)
Jul-29-24 09:16AM
07:00AM
06:07AM
Jul-26-24 08:40AM
03:30AM
Jul-25-24 08:00AM
Jul-24-24 07:24AM
Jul-23-24 05:50PM
07:00AM
06:00AM
Jul-18-24 07:00AM
Jul-17-24 05:50PM
08:00AM
Jul-16-24 01:33PM
10:14AM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Klinger Shannon Thyme Chief Legal Officer Sep 03 '24 Sale 76.99 114 8,777 17,566 Sep 04 05:42 PM Hoge Stephen President Sep 03 '24 Sale 76.99 318 24,483 1,443,002 Sep 04 04:26 PM Klinger Shannon Thyme Officer Sep 03 '24 Proposed Sale 76.99 114 8,777 Sep 03 03:58 PM Hoge Stephen Officer Sep 03 '24 Proposed Sale 76.99 318 24,482 Sep 03 03:42 PM Mock James M Chief Financial Officer Aug 29 '24 Sale 78.03 162 12,640 8,767 Aug 30 04:37 PM Klinger Shannon Thyme Chief Legal Officer Aug 29 '24 Sale 78.03 162 12,640 17,447 Aug 30 04:34 PM Hoge Stephen President Aug 29 '24 Sale 78.03 300 23,408 1,442,668 Aug 30 04:32 PM Mock James M Chief Financial Officer Aug 28 '24 Sale 79.39 1,321 104,881 8,600 Aug 29 04:45 PM Klinger Shannon Thyme Chief Legal Officer Aug 28 '24 Sale 79.39 1,319 104,722 17,280 Aug 29 04:03 PM Klinger Shannon Thyme Officer Aug 29 '24 Proposed Sale 78.03 162 12,640 Aug 29 03:52 PM Mock James M Officer Aug 29 '24 Proposed Sale 78.03 162 12,640 Aug 29 03:43 PM Hoge Stephen Officer Aug 29 '24 Proposed Sale 78.03 300 23,408 Aug 29 03:38 PM Mock James M Officer Aug 28 '24 Proposed Sale 79.39 1,321 104,881 Aug 28 04:47 PM Klinger Shannon Thyme Officer Aug 28 '24 Proposed Sale 79.39 1,319 104,722 Aug 28 04:30 PM Hoge Stephen President Aug 12 '24 Sale 84.10 254 21,363 1,442,357 Aug 13 04:33 PM Hoge Stephen Officer Aug 12 '24 Proposed Sale 84.10 254 21,363 Aug 12 04:05 PM AFEYAN NOUBAR Director Jul 31 '24 Sale 119.96 15,000 1,799,443 2,224,015 Aug 02 07:00 PM NOUBAR B AFEYAN Director Jul 31 '24 Proposed Sale 118.84 15,000 1,782,600 Jul 31 04:18 PM AFEYAN NOUBAR Director Jul 24 '24 Sale 117.80 15,000 1,766,972 2,239,015 Jul 26 07:00 PM AFEYAN NOUBAR Director Jul 17 '24 Sale 122.84 15,000 1,842,651 2,254,015 Jul 19 07:00 PM Hoge Stephen President Jul 15 '24 Sale 121.12 15,000 1,816,800 1,442,089 Jul 16 04:08 PM AFEYAN NOUBAR Director Jul 10 '24 Sale 117.08 15,000 1,756,177 2,269,015 Jul 12 07:00 PM Mock James M Chief Financial Officer Jul 08 '24 Sale 118.24 689 81,465 7,269 Jul 09 04:34 PM AFEYAN NOUBAR Director Jun 26 '24 Sale 127.22 15,000 1,908,293 2,284,015 Jun 28 07:00 PM AFEYAN NOUBAR Director Jun 18 '24 Sale 133.57 15,000 2,003,561 2,299,015 Jun 21 07:00 PM Hoge Stephen President Jun 17 '24 Sale 138.16 15,000 2,072,400 1,457,089 Jun 18 04:05 PM AFEYAN NOUBAR Director Jun 12 '24 Sale 147.20 15,000 2,208,071 2,314,015 Jun 14 07:00 PM AFEYAN NOUBAR Director Jun 11 '24 Sale 148.34 202,832 30,087,339 1,528,557 Jun 11 07:01 PM Klinger Shannon Thyme Chief Legal Officer Jun 10 '24 Sale 148.09 5,178 766,785 15,947 Jun 11 04:05 PM AFEYAN NOUBAR Director Jun 05 '24 Sale 151.25 15,000 2,268,804 1,946,931 Jun 07 07:00 PM Mock James M Chief Financial Officer Jun 03 '24 Sale 140.72 691 97,237 6,506 Jun 04 05:27 PM Hoge Stephen President Jun 03 '24 Sale 140.72 339 47,704 1,472,089 Jun 04 05:20 PM Klinger Shannon Thyme Chief Legal Officer Jun 03 '24 Sale 140.72 122 17,168 10,878 Jun 04 05:12 PM AFEYAN NOUBAR Director May 29 '24 Sale 145.08 20,000 2,901,585 1,961,931 May 31 07:00 PM Mock James M Chief Financial Officer May 29 '24 Sale 144.50 183 26,444 5,871 May 30 04:36 PM Klinger Shannon Thyme Chief Legal Officer May 29 '24 Sale 144.50 183 26,444 10,768 May 30 04:27 PM Hoge Stephen President May 29 '24 Sale 144.50 341 49,276 1,471,777 May 30 04:14 PM Mock James M Chief Financial Officer May 28 '24 Sale 162.47 648 105,283 5,726 May 29 04:16 PM Klinger Shannon Thyme Chief Legal Officer May 28 '24 Sale 162.47 1,296 210,566 10,623 May 29 04:12 PM AFEYAN NOUBAR Director May 22 '24 Sale 157.57 15,000 2,363,556 1,981,931 May 24 07:00 PM AFEYAN NOUBAR Director May 15 '24 Sale 127.32 15,000 1,909,863 1,996,931 May 17 07:00 PM Hoge Stephen President May 15 '24 Sale 127.49 15,000 1,912,350 1,471,508 May 17 04:04 PM Hoge Stephen President May 10 '24 Sale 120.96 255 30,844 1,486,508 May 13 04:03 PM AFEYAN NOUBAR Director May 08 '24 Sale 121.68 15,000 1,825,220 2,011,931 May 10 07:00 PM AFEYAN NOUBAR Director May 01 '24 Sale 110.92 15,000 1,663,855 2,026,931 May 03 07:00 PM AFEYAN NOUBAR Director Apr 24 '24 Sale 108.32 15,000 1,624,836 2,041,931 Apr 26 07:00 PM AFEYAN NOUBAR Director Apr 17 '24 Sale 103.38 15,000 1,550,703 2,056,931 Apr 19 07:00 PM Hoge Stephen President Apr 15 '24 Sale 105.02 15,000 1,575,300 1,486,241 Apr 16 04:23 PM AFEYAN NOUBAR Director Apr 10 '24 Sale 107.12 15,000 1,606,865 2,071,931 Apr 12 07:00 PM Mock James M Chief Financial Officer Apr 08 '24 Sale 101.93 705 71,859 5,048 Apr 09 04:09 PM AFEYAN NOUBAR Director Apr 03 '24 Sale 101.68 15,000 1,525,268 2,086,931 Apr 05 07:00 PM AFEYAN NOUBAR Director Mar 27 '24 Sale 109.06 15,000 1,635,864 2,101,931 Mar 29 07:00 PM AFEYAN NOUBAR Director Mar 20 '24 Sale 102.39 15,000 1,535,820 2,116,931 Mar 22 07:00 PM Hoge Stephen President Mar 15 '24 Sale 103.17 15,000 1,547,550 1,501,241 Mar 19 04:39 PM AFEYAN NOUBAR Director Mar 13 '24 Sale 108.54 15,000 1,628,031 2,131,931 Mar 15 07:00 PM Klinger Shannon Thyme Chief Legal Officer Mar 08 '24 Sale 99.05 544 53,884 9,267 Mar 11 09:05 AM Klinger Shannon Thyme Chief Legal Officer Mar 04 '24 Sale 94.34 117 11,038 8,673 Mar 05 05:56 PM Hoge Stephen President Mar 04 '24 Sale 94.34 309 29,151 1,516,241 Mar 05 05:52 PM Mock James M Chief Financial Officer Feb 29 '24 Sale 94.57 647 61,188 4,300 Mar 01 05:33 PM Klinger Shannon Thyme Chief Legal Officer Feb 29 '24 Sale 94.57 670 63,363 8,557 Mar 01 05:29 PM Hoge Stephen President Feb 29 '24 Sale 94.57 2,388 225,838 1,515,898 Mar 01 05:25 PM Hoge Stephen President Feb 22 '24 Sale 100.00 15,000 1,500,000 1,513,433 Feb 23 04:04 PM Hoge Stephen President Feb 16 '24 Sale 88.88 10,542 936,981 1,528,433 Feb 16 04:19 PM Bancel Stephane Chief Executive Officer Feb 16 '24 Sale 88.88 26,351 2,342,098 5,460,224 Feb 16 04:10 PM Hoge Stephen President Feb 12 '24 Sale 86.23 304 26,214 1,516,281 Feb 13 04:13 PM Hoge Stephen President Jan 16 '24 Sale 103.90 15,000 1,558,500 1,516,063 Jan 17 04:12 PM Mock James M Chief Financial Officer Jan 08 '24 Sale 109.75 772 84,731 3,632 Jan 09 04:08 PM Hoge Stephen President Dec 27 '23 Sale 100.01 45,000 4,500,450 1,531,063 Dec 28 08:00 AM Klinger Shannon Thyme Chief Legal Officer Dec 08 '23 Sale 79.09 563 44,525 7,912 Dec 11 04:03 PM Garay Arpa Chief Commercial Officer Dec 06 '23 Sale 78.34 564 44,182 3,690 Dec 07 04:21 PM Klinger Shannon Thyme Chief Legal Officer Dec 04 '23 Sale 79.31 111 8,804 7,336 Dec 05 04:10 PM Hoge Stephen President Dec 04 '23 Sale 79.31 309 24,508 1,576,063 Dec 05 04:07 PM Hoge Stephen President Nov 29 '23 Sale 79.81 1,136 90,666 1,575,721 Nov 30 04:11 PM Hoge Stephen President Nov 10 '23 Sale 68.76 263 18,084 1,574,446 Nov 13 04:02 PM AFEYAN NOUBAR Director Nov 01 '23 Sale 76.00 10,000 760,032 2,146,931 Nov 03 07:00 PM AFEYAN NOUBAR Director Oct 25 '23 Sale 76.99 10,000 769,854 2,156,931 Oct 27 07:00 PM AFEYAN NOUBAR Director Oct 11 '23 Sale 103.30 15,000 1,549,441 2,166,931 Oct 13 07:00 PM Mock James M Chief Financial Officer Oct 06 '23 Sale 102.50 2,858 292,953 2,952 Oct 10 04:51 PM AFEYAN NOUBAR Director Oct 04 '23 Sale 102.72 15,000 1,540,845 2,181,931 Oct 06 07:02 PM AFEYAN NOUBAR Director Sep 27 '23 Sale 98.96 10,000 989,646 2,196,931 Sep 29 07:00 PM AFEYAN NOUBAR Director Sep 20 '23 Sale 104.74 15,000 1,571,090 2,206,931 Sep 22 07:00 PM Hoge Stephen President Sep 15 '23 Sale 112.99 15,000 1,694,850 1,574,187 Sep 18 04:06 PM AFEYAN NOUBAR Director Sep 13 '23 Sale 109.70 15,000 1,645,522 2,221,931 Sep 15 07:00 PM Klinger Shannon Thyme Chief Legal Officer Sep 08 '23 Sale 107.22 557 59,722 7,215 Sep 11 04:02 PM
Index RUT
P/E -
EPS (ttm) -2.36
Insider Own 0.94%
Shs Outstand 81.77M
Perf Week -3.23%
Market Cap 296.10M
Forward P/E -
EPS next Y -2.77
Insider Trans -1.35%
Shs Float 81.70M
Perf Month -12.65%
Income -193.45M
PEG -
EPS next Q -0.78
Inst Own 69.52%
Short Float 20.68%
Perf Quarter -33.89%
Sales 67.03M
P/S 4.42
EPS this Y -44.83%
Inst Trans 2.32%
Short Ratio 8.84
Perf Half Y -59.44%
Book/sh 2.81
P/B 1.28
EPS next Y 5.21%
ROA -41.75%
Short Interest 16.90M
Perf Year -60.64%
Cash/sh 3.38
P/C 1.06
EPS next 5Y 1.70%
ROE -61.23%
52W Range 3.40 - 11.69
Perf YTD -64.56%
Dividend Est. -
P/FCF -
EPS past 5Y 2.88%
ROI -76.61%
52W High -69.29%
Beta 1.99
Dividend TTM -
Quick Ratio 3.85
Sales past 5Y 101.57%
Gross Margin 91.33%
52W Low 5.59%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 3.85
EPS Y/Y TTM 20.53%
Oper. Margin -317.78%
RSI (14) 35.89
Volatility 5.39% 5.57%
Employees 265
Debt/Eq 0.17
Sales Y/Y TTM 247.03%
Profit Margin -288.59%
Recom 2.11
Target Price 13.86
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -45.51%
Payout -
Rel Volume 1.03
Prev Close 3.49
Sales Surprise -89.27%
EPS Surprise -16.48%
Sales Q/Q -82.23%
Earnings Aug 07 BMO
Avg Volume 1.91M
Price 3.59
SMA20 -6.72%
SMA50 -22.05%
SMA200 -48.13%
Trades
Volume 1,964,984
Change 2.87%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-24 Upgrade
BofA Securities
Neutral → Buy
$13 → $15
May-09-24 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$7
Oct-24-23 Upgrade
Citigroup
Neutral → Buy
$11
Oct-18-23 Upgrade
JP Morgan
Underweight → Neutral
$8
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-29-23 Upgrade
Stifel
Hold → Buy
$9 → $17
Jun-12-23 Upgrade
Raymond James
Mkt Perform → Outperform
$17
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$15
Dec-13-22 Initiated
Citigroup
Neutral
$11
Dec-06-22 Resumed
Credit Suisse
Neutral
$13
Nov-18-22 Downgrade
Oppenheimer
Outperform → Perform
$28 → $12
Nov-18-22 Downgrade
Credit Suisse
Outperform → Neutral
$25 → $13
Sep-29-22 Initiated
BofA Securities
Neutral
$18
Oct-19-21 Initiated
SVB Leerink
Mkt Perform
$41
Sep-24-21 Initiated
Stifel
Hold
$65
Sep-10-21 Upgrade
Oppenheimer
Perform → Outperform
$42 → $80
Aug-09-21 Upgrade
Truist
Hold → Buy
$45 → $80
Aug-05-21 Upgrade
Evercore ISI
Underperform → Outperform
$20 → $60
Jun-04-21 Resumed
Robert W. Baird
Outperform
$44
May-04-21 Initiated
RBC Capital Mkts
Sector Perform
$40
Show Previous Ratings
Sep-06-24 11:31AM
Aug-28-24 09:00AM
Aug-08-24 09:33AM
03:39AM
(Thomson Reuters StreetEvents)
Aug-07-24 08:05AM
07:07AM
Loading…
07:07AM
(Associated Press Finance)
07:00AM
Jul-31-24 07:00AM
Jul-17-24 11:30AM
Jul-09-24 07:59AM
Jul-08-24 09:00AM
Jun-29-24 08:40PM
06:30PM
Jun-27-24 09:04AM
Jun-26-24 09:33PM
04:36PM
Loading…
04:36PM
Jun-25-24 08:00AM
Jun-17-24 08:13AM
Jun-14-24 03:01AM
03:00AM
Jun-07-24 11:30AM
May-22-24 07:05PM
May-14-24 07:01PM
04:27PM
10:00AM
May-10-24 06:00AM
May-09-24 03:38PM
01:12PM
12:40PM
11:33AM
08:00AM
Loading…
08:00AM
May-08-24 10:33PM
(Thomson Reuters StreetEvents) -11.36%
11:55AM
08:25AM
07:29AM
(Associated Press Finance)
07:00AM
May-02-24 07:00AM
May-01-24 10:46AM
08:00AM
Apr-29-24 10:26AM
Apr-26-24 10:00AM
Apr-22-24 04:31PM
Mar-29-24 11:30AM
Mar-07-24 03:31AM
Mar-05-24 11:52PM
Mar-04-24 10:30AM
Mar-02-24 09:49PM
Feb-29-24 11:26AM
08:42AM
Feb-28-24 11:15PM
(Thomson Reuters StreetEvents) +24.94%
08:10AM
07:35AM
07:08AM
(Associated Press Finance)
07:00AM
Feb-21-24 07:00AM
Feb-19-24 09:55AM
Feb-10-24 05:09PM
Feb-06-24 12:00PM
Jan-31-24 09:00AM
Jan-28-24 08:45AM
Jan-21-24 09:37AM
Jan-17-24 12:04PM
Jan-15-24 05:19AM
Jan-11-24 04:38PM
Jan-08-24 08:15AM
07:45AM
Jan-03-24 07:00AM
Jan-02-24 10:15AM
Dec-23-23 08:02AM
Dec-14-23 08:32AM
06:30AM
Dec-13-23 05:12PM
04:06PM
12:30PM
09:00AM
Dec-11-23 01:22PM
12:00PM
Dec-10-23 11:59AM
Dec-05-23 07:00AM
Nov-29-23 02:28PM
Nov-22-23 06:30AM
Nov-20-23 05:43PM
(InvestorPlace) +10.84%
-6.64%
05:36AM
Nov-16-23 03:25PM
Nov-09-23 03:37PM
Nov-06-23 09:00AM
Nov-05-23 05:51PM
Nov-03-23 08:45AM
08:34AM
07:17AM
(Associated Press Finance)
07:00AM
Nov-02-23 09:12AM
Oct-30-23 03:46PM
Oct-27-23 07:00AM
Oct-24-23 09:51AM
01:53AM
Oct-18-23 11:05AM
09:52AM
09:30AM
Oct-17-23 11:47AM
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mei Baisong EVP, CHIEF MEDICAL OFFICER Sep 04 '24 Sale 3.42 518 1,774 133,895 Sep 06 04:20 PM O'Neill Gilmore Neil CEO Sep 04 '24 Sale 3.42 1,555 5,325 313,724 Sep 06 04:18 PM O'Neill Gilmore Neil Officer Sep 03 '24 Proposed Sale 3.92 3,000 11,760 Aug 29 04:19 PM Mei Baisong Officer Sep 03 '24 Proposed Sale 3.92 1,000 3,920 Aug 29 04:17 PM Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Jul 25 '24 Sale 5.42 11,886 64,370 73,136 Jul 26 05:02 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Jul 19 '24 Sale 5.21 6,619 34,456 134,413 Jul 22 05:01 PM O'Neill Gilmore Neil CEO Jun 04 '24 Sale 5.50 12,191 66,997 315,279 Jun 06 04:17 PM Mei Baisong EVP, CHIEF MEDICAL OFFICER Jun 04 '24 Sale 5.50 511 2,808 141,032 Jun 06 04:16 PM Lucera Erick EVP, CHIEF FINANCIAL OFFICER May 20 '24 Sale 5.61 22,337 125,404 116,829 May 22 04:30 PM Hopfield Jessica Director May 13 '24 Buy 5.64 45,000 253,868 67,700 May 14 04:17 PM O'Neill Gilmore Neil CEO Mar 05 '24 Sale 9.42 77,824 732,884 327,470 Mar 05 08:00 PM Mei Baisong SVP, CHIEF MEDICAL OFFICER Mar 04 '24 Sale 9.42 20,327 191,425 141,543 Mar 05 07:54 PM Eaton Bruce EVP, CBO AND CTO Dec 05 '23 Sale 10.90 103 1,122 74,791 Dec 07 04:30 PM Eaton Bruce EVP, CBO AND CTO Nov 14 '23 Sale 8.21 695 5,706 74,894 Nov 16 04:30 PM Eaton Bruce EVP, CBO AND CTO Nov 07 '23 Sale 8.40 139 1,168 75,589 Nov 09 04:31 PM
Index RUT
P/E -
EPS (ttm) -5.27
Insider Own 9.86%
Shs Outstand 49.42M
Perf Week -4.33%
Market Cap 567.34M
Forward P/E -
EPS next Y -1.08
Insider Trans -2.77%
Shs Float 44.55M
Perf Month -4.65%
Income -241.08M
PEG -
EPS next Q -1.12
Inst Own 89.90%
Short Float 12.86%
Perf Quarter -16.57%
Sales 89.04M
P/S 6.37
EPS this Y 24.86%
Inst Trans -3.00%
Short Ratio 9.97
Perf Half Y -50.58%
Book/sh 7.06
P/B 1.63
EPS next Y 76.16%
ROA -38.52%
Short Interest 5.73M
Perf Year -35.03%
Cash/sh 5.88
P/C 1.95
EPS next 5Y 13.60%
ROE -63.94%
52W Range 10.49 - 28.80
Perf YTD -36.04%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -51.56%
52W High -60.14%
Beta 1.22
Dividend TTM -
Quick Ratio 3.53
Sales past 5Y 72.63%
Gross Margin 37.75%
52W Low 9.44%
ATR (14) 0.71
Dividend Ex-Date -
Current Ratio 3.53
EPS Y/Y TTM 16.62%
Oper. Margin -277.01%
RSI (14) 42.73
Volatility 5.77% 5.16%
Employees 344
Debt/Eq 0.46
Sales Y/Y TTM -8.18%
Profit Margin -270.74%
Recom 1.22
Target Price 39.44
Option/Short Yes / Yes
LT Debt/Eq 0.34
EPS Q/Q 36.74%
Payout -
Rel Volume 0.64
Prev Close 11.38
Sales Surprise -2.95%
EPS Surprise 18.70%
Sales Q/Q 11.60%
Earnings Aug 01 AMC
Avg Volume 574.81K
Price 11.48
SMA20 -3.72%
SMA50 -6.60%
SMA200 -28.42%
Trades
Volume 365,010
Change 0.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-07-24 Initiated
Goldman
Buy
$38
Mar-11-24 Initiated
H.C. Wainwright
Buy
$36
Mar-08-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$20 → $35
Mar-06-24 Upgrade
Leerink Partners
Market Perform → Outperform
$37
Feb-21-24 Resumed
Raymond James
Outperform
$45
Nov-01-23 Initiated
Stifel
Buy
$35
Jun-02-23 Initiated
Robert W. Baird
Outperform
$42
Jun-23-22 Initiated
Berenberg
Buy
$61
Dec-15-21 Initiated
Wedbush
Neutral
$29
Oct-19-21 Resumed
Morgan Stanley
Overweight
$62 → $50
Jan-06-21 Upgrade
Raymond James
Outperform → Strong Buy
$60
Dec-16-20 Initiated
UBS
Buy
$57
Jun-25-20 Resumed
BofA/Merrill
Buy
$9
Jun-25-20 Resumed
BofA/Merrill
Buy
$60
May-13-20 Initiated
RBC Capital Mkts
Sector Perform
$42
Aug-20-19 Upgrade
SVB Leerink
Underperform → Mkt Perform
$38 → $37
Jun-18-19 Reiterated
Chardan Capital Markets
Buy
$145 → $150
Jun-14-19 Resumed
Raymond James
Outperform
Jun-05-19 Reiterated
Chardan Capital Markets
Buy
$127.50 → $145
Feb-25-19 Upgrade
Evercore ISI
In-line → Outperform
Show Previous Ratings
Sep-04-24 09:15AM
Sep-03-24 01:33PM
(Pharmaceutical Technology) -7.20%
08:04AM
Aug-29-24 04:05PM
Aug-27-24 07:05AM
07:05AM
Loading…
Aug-08-24 07:05AM
06:00AM
Aug-06-24 09:55AM
Aug-01-24 05:45PM
04:46PM
(Associated Press Finance)
04:05PM
07:03AM
Jul-30-24 07:01PM
Jul-28-24 09:09AM
Jul-25-24 07:05AM
09:59AM
Loading…
Jul-12-24 09:59AM
Jun-27-24 10:05AM
Jun-26-24 04:36PM
Jun-25-24 04:32AM
Jun-24-24 12:56PM
07:05AM
Jun-21-24 04:28PM
(Investor's Business Daily)
06:40AM
(Investor's Business Daily)
Jun-18-24 07:05AM
07:02AM
Jun-12-24 08:00AM
07:05AM
Jun-05-24 07:05AM
May-15-24 11:38AM
May-10-24 02:30PM
07:05AM
Loading…
07:05AM
May-09-24 03:53PM
11:11AM
07:11AM
(Thomson Reuters StreetEvents)
03:46AM
May-08-24 09:56PM
05:40PM
04:44PM
(Associated Press Finance)
04:05PM
May-01-24 07:05AM
Apr-24-24 07:05AM
Mar-28-24 01:09PM
07:05AM
Mar-27-24 04:05PM
Mar-18-24 07:00PM
Mar-13-24 08:00AM
Mar-11-24 07:05AM
Mar-08-24 01:29AM
Mar-06-24 11:20PM
04:10PM
11:33AM
03:01AM
Mar-05-24 07:05AM
Feb-29-24 04:57PM
(PR Newswire) -12.36%
+21.50%
Feb-28-24 11:05AM
(Thomson Reuters StreetEvents)
09:36AM
Feb-27-24 05:35PM
04:41PM
04:32PM
(Associated Press Finance)
04:05PM
Feb-21-24 07:05AM
Feb-17-24 12:07AM
Feb-08-24 09:36AM
04:50AM
Feb-07-24 11:40AM
07:05AM
Jan-31-24 07:05AM
Jan-18-24 09:01PM
Jan-16-24 02:47PM
Jan-10-24 07:05AM
Jan-09-24 06:20PM
Jan-08-24 07:05AM
Dec-22-23 09:01AM
Nov-29-23 07:05AM
Nov-16-23 09:55AM
Nov-09-23 04:46PM
06:37AM
Nov-08-23 04:42PM
(Associated Press Finance)
04:05PM
Nov-07-23 07:05AM
Nov-03-23 06:53PM
Nov-01-23 07:05AM
Oct-30-23 07:05AM
Oct-05-23 07:05AM
Oct-03-23 04:05PM
Sep-26-23 07:05AM
Sep-05-23 07:05AM
Aug-30-23 07:05AM
Aug-23-23 04:05PM
Aug-02-23 05:55PM
04:41PM
04:05PM
Aug-01-23 04:05PM
Jul-26-23 07:05AM
Jul-24-23 04:05PM
Jul-11-23 07:05AM
Jul-01-23 10:09AM
Jun-27-23 07:05AM
Jun-21-23 08:00PM
Jun-20-23 08:00AM
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KARABELAS ARGERIS N Director Sep 03 '24 Option Exercise 3.76 10,000 37,600 21,286 Sep 04 08:20 PM KARABELAS ARGERIS N Director Sep 03 '24 Sale 11.56 10,000 115,588 11,286 Sep 04 08:20 PM Mills Kenneth T. Director Aug 08 '24 Option Exercise 0.85 36,316 30,869 444,351 Aug 12 04:58 PM KARABELAS ARGERIS N Director Aug 01 '24 Option Exercise 3.85 10,100 38,874 21,386 Aug 05 06:39 PM KARABELAS ARGERIS N Director Aug 01 '24 Sale 13.51 10,100 136,454 11,286 Aug 05 06:39 PM Simpson Curran Chief Executive Officer Aug 01 '24 Sale 15.00 100 1,500 170,037 Aug 05 06:39 PM ARGERIS N KARABELAS Director Aug 01 '24 Proposed Sale 14.25 31,000 441,750 Aug 01 04:34 PM KARABELAS ARGERIS N Director Jul 29 '24 Option Exercise 12.74 11,000 140,140 22,286 Jul 30 05:01 PM KARABELAS ARGERIS N Director Jul 29 '24 Sale 15.04 11,000 165,495 11,286 Jul 30 05:01 PM Simpson Curran Chief Executive Officer Jul 29 '24 Sale 15.04 9,648 145,106 170,137 Jul 30 05:01 PM CURRAN M SIMPSON Director Jul 29 '24 Proposed Sale 14.33 25,106 359,769 Jul 29 04:13 PM Mills Kenneth T. Director Jul 25 '24 Option Exercise 3.76 15,369 57,787 423,404 Jul 26 05:00 PM Mills Kenneth T. Director Jul 24 '24 Option Exercise 3.76 12,221 45,951 420,256 Jul 26 05:00 PM Mills Kenneth T. Director Jul 25 '24 Sale 13.96 15,369 214,501 408,035 Jul 26 05:00 PM Mills Kenneth T. Director Jul 24 '24 Sale 13.78 12,221 168,433 408,035 Jul 26 05:00 PM Mills Kenneth T. Director Jul 17 '24 Option Exercise 3.76 2,210 8,310 410,245 Jul 18 05:05 PM Mills Kenneth T. Director Jul 16 '24 Option Exercise 3.76 200 752 408,235 Jul 18 05:05 PM Mills Kenneth T. Director Jul 17 '24 Sale 13.77 2,210 30,440 408,035 Jul 18 05:05 PM Mills Kenneth T. Director Jul 16 '24 Sale 13.76 200 2,752 408,035 Jul 18 05:05 PM KARABELAS ARGERIS N Director Jul 01 '24 Option Exercise 3.76 10,000 37,600 21,286 Jul 03 07:55 AM KARABELAS ARGERIS N Director Jul 01 '24 Sale 11.27 10,000 112,691 11,286 Jul 03 07:55 AM Mills Kenneth T. President and CEO May 14 '24 Option Exercise 3.76 15,000 56,400 423,035 May 16 05:06 PM Mills Kenneth T. President and CEO May 14 '24 Sale 15.81 15,000 237,222 408,035 May 16 05:06 PM Mills Kenneth T. President and CEO Apr 15 '24 Option Exercise 3.76 15,000 56,400 423,035 Apr 17 05:05 PM Mills Kenneth T. President and CEO Apr 15 '24 Sale 18.19 15,000 272,871 408,035 Apr 17 05:05 PM Vasista Vittal Chief Financial Officer Mar 19 '24 Option Exercise 3.76 20,041 75,354 246,534 Mar 21 05:20 PM Mills Kenneth T. President and CEO Mar 14 '24 Option Exercise 3.76 15,000 56,400 423,035 Mar 18 05:03 PM Mills Kenneth T. President and CEO Mar 14 '24 Sale 21.86 15,000 327,942 408,035 Mar 18 05:03 PM PAKOLA STEVE Chief Medical Officer Mar 05 '24 Option Exercise 22.25 12,878 286,536 120,070 Mar 07 06:05 PM PAKOLA STEVE Chief Medical Officer Mar 05 '24 Sale 28.36 12,878 365,220 107,192 Mar 07 06:05 PM Mills Kenneth T. President and CEO Feb 14 '24 Option Exercise 3.76 15,000 56,400 423,035 Feb 16 06:28 PM Mills Kenneth T. President and CEO Feb 14 '24 Sale 16.76 15,000 251,349 408,035 Feb 16 06:28 PM Mills Kenneth T. President and CEO Jan 16 '24 Option Exercise 3.76 45,000 169,200 453,035 Jan 18 06:39 PM Mills Kenneth T. President and CEO Jan 16 '24 Sale 15.18 45,000 682,992 408,035 Jan 18 06:39 PM PAKOLA STEVE Chief Medical Officer Jan 03 '24 Sale 17.39 17,237 299,789 107,192 Jan 04 04:23 PM Mills Kenneth T. President and CEO Dec 19 '23 Option Exercise 3.66 45,000 164,835 400,289 Dec 21 01:38 PM Mills Kenneth T. President and CEO Dec 19 '23 Sale 19.68 45,000 885,825 355,289 Dec 21 01:38 PM
Index RUT
P/E -
EPS (ttm) -1.92
Insider Own 57.71%
Shs Outstand 145.58M
Perf Week 9.85%
Market Cap 4.98B
Forward P/E -
EPS next Y -2.32
Insider Trans -0.23%
Shs Float 61.90M
Perf Month 26.13%
Income -272.55M
PEG -
EPS next Q -0.59
Inst Own 50.55%
Short Float 19.76%
Perf Quarter 33.82%
Sales 0.00M
P/S -
EPS this Y -31.34%
Inst Trans 5.01%
Short Ratio 12.23
Perf Half Y 4.90%
Book/sh 3.73
P/B 9.13
EPS next Y 6.24%
ROA -57.93%
Short Interest 12.23M
Perf Year 47.83%
Cash/sh 3.83
P/C 8.89
EPS next 5Y 3.69%
ROE -64.54%
52W Range 19.50 - 45.58
Perf YTD -19.23%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -50.04%
52W High -25.34%
Beta 0.70
Dividend TTM -
Quick Ratio 13.08
Sales past 5Y 0.00%
Gross Margin -
52W Low 74.51%
ATR (14) 1.35
Dividend Ex-Date -
Current Ratio 13.08
EPS Y/Y TTM 0.52%
Oper. Margin 0.00%
RSI (14) 67.89
Volatility 4.83% 4.17%
Employees 207
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 48.43
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -5.29%
Payout -
Rel Volume 1.55
Prev Close 33.62
Sales Surprise -
EPS Surprise -0.53%
Sales Q/Q -
Earnings Aug 06 AMC
Avg Volume 1.00M
Price 34.03
SMA20 10.03%
SMA50 16.02%
SMA200 4.02%
Trades
Volume 1,549,499
Change 1.22%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated
Oppenheimer
Outperform
$50
Mar-13-24 Initiated
Goldman
Buy
$50
Feb-20-24 Initiated
JP Morgan
Overweight
$51
Feb-15-24 Initiated
Wolfe Research
Outperform
$55
Dec-12-23 Initiated
Deutsche Bank
Buy
$50
Oct-13-23 Upgrade
UBS
Neutral → Buy
$18 → $55
Sep-26-23 Upgrade
Raymond James
Mkt Perform → Outperform
$40
May-01-23 Initiated
BofA Securities
Buy
$26
Apr-25-23 Initiated
Citigroup
Buy
$28
Mar-31-23 Initiated
Piper Sandler
Overweight
$28
Mar-30-23 Initiated
Stifel
Buy
$28
Feb-15-23 Initiated
Cantor Fitzgerald
Overweight
$30
Feb-13-23 Upgrade
Guggenheim
Neutral → Buy
$30
Jan-03-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$10 → $27
Sep-26-22 Downgrade
UBS
Buy → Neutral
$7 → $5
Dec-08-21 Initiated
Wells Fargo
Equal Weight
$9
Aug-03-21 Downgrade
Robert W. Baird
Outperform → Neutral
$20 → $10
Aug-02-21 Downgrade
Credit Suisse
Neutral → Underperform
$12 → $7
Jun-01-21 Downgrade
Stifel
Buy → Hold
$28 → $9
Jun-01-21 Downgrade
Guggenheim
Buy → Neutral
Show Previous Ratings
Sep-05-24 11:31AM
06:30AM
Aug-09-24 12:20AM
(Thomson Reuters StreetEvents)
Aug-06-24 04:05PM
Jun-28-24 11:30AM
08:04AM
Loading…
May-31-24 08:04AM
02:26AM
(Thomson Reuters StreetEvents)
May-30-24 04:02PM
(Investor's Business Daily) -10.69%
11:29AM
07:22AM
05:53AM
May-29-24 09:53PM
04:06PM
(Investor's Business Daily)
04:01PM
10:17AM
(Investor's Business Daily)
06:28PM
Loading…
May-27-24 06:28PM
May-13-24 09:55AM
May-08-24 02:43AM
Apr-24-24 11:33AM
07:39AM
Apr-22-24 11:53AM
Apr-17-24 12:00PM
Mar-25-24 03:00PM
Mar-21-24 04:45PM
(Investor's Business Daily)
11:31AM
Mar-17-24 05:20PM
Mar-14-24 07:04AM
Mar-13-24 11:30AM
Mar-12-24 07:30AM
Mar-08-24 09:35AM
03:04PM
Loading…
Feb-26-24 03:04PM
Feb-23-24 11:22PM
Feb-14-24 04:35AM
12:29AM
(Thomson Reuters StreetEvents)
Feb-13-24 07:26AM
Feb-12-24 07:00AM
Feb-06-24 02:38PM
Jan-22-24 06:07AM
Jan-19-24 04:39PM
Jan-13-24 03:02AM
Jan-03-24 08:00AM
Dec-26-23 10:01AM
Dec-21-23 04:09PM
(Investor's Business Daily) +8.07%
+6.09%
11:00AM
10:57AM
06:49AM
Dec-20-23 04:30PM
04:30PM
Dec-19-23 10:16AM
Dec-01-23 01:01AM
Nov-29-23 10:22AM
Nov-28-23 07:00AM
07:00AM
Nov-25-23 11:03AM
Nov-14-23 12:30AM
(Thomson Reuters StreetEvents) +6.62%
Nov-13-23 08:00AM
Nov-10-23 07:19AM
Nov-09-23 08:17AM
07:00AM
Oct-27-23 11:02PM
Oct-13-23 09:50AM
Oct-11-23 11:01PM
Oct-07-23 01:00AM
Oct-05-23 03:01AM
Oct-02-23 04:52PM
Sep-28-23 09:58AM
Sep-27-23 11:41PM
04:09PM
(Investor's Business Daily)
04:06PM
(Investor's Business Daily)
12:25PM
(Investor's Business Daily)
12:21PM
09:25AM
Sep-26-23 05:00PM
04:13PM
(Investor's Business Daily)
04:06PM
03:23PM
02:26PM
10:01AM
(Investor's Business Daily)
09:10AM
06:00AM
Sep-25-23 11:01PM
Aug-17-23 09:31AM
Aug-12-23 08:25AM
Aug-11-23 11:20AM
Aug-10-23 07:00AM
Aug-09-23 06:26AM
Aug-01-23 10:00AM
Jul-03-23 09:00AM
Jul-01-23 09:00AM
Jun-29-23 01:42AM
(Thomson Reuters StreetEvents)
Jun-21-23 11:30AM
May-23-23 09:48AM
06:05AM
May-22-23 07:00AM
Apr-05-23 01:45PM
Feb-15-23 01:14PM
Feb-03-23 07:00AM
Dec-29-22 11:04AM
Dec-19-22 07:53AM
Dec-16-22 08:06AM
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Levine Mark S. Chief Legal Officer Aug 21 '24 Sale 31.86 3,295 104,976 330,099 Aug 23 04:15 PM Macias William L. Chief Medical Officer Aug 21 '24 Sale 31.86 3,027 96,437 368,332 Aug 23 04:14 PM Barnett Eva Renee Chief Financial Officer Aug 21 '24 Sale 31.86 3,768 120,045 343,776 Aug 23 04:11 PM Butchko Julia G. Chief Development Officer Aug 21 '24 Sale 31.86 3,027 96,437 440,959 Aug 23 04:10 PM Salzmann Peter Chief Executive Officer Aug 21 '24 Sale 31.86 15,068 480,052 1,008,344 Aug 23 04:07 PM Stout Jay S Chief Technology Officer Jul 24 '24 Sale 27.76 2,813 78,089 144,926 Jul 26 04:20 PM Geffner Michael Chief Medical Officer Jul 24 '24 Sale 27.76 3,456 95,939 138,160 Jul 26 04:19 PM Levine Mark S. Chief Legal Officer Jul 24 '24 Sale 27.76 4,015 111,456 333,394 Jul 26 04:17 PM Levine Mark S. Chief Legal Officer Jul 17 '24 Sale 29.69 2,505 74,382 337,409 Jul 19 05:42 PM Macias William L. Chief Medical Officer Jul 17 '24 Sale 29.69 3,044 90,386 371,359 Jul 19 05:41 PM Barnett Eva Renee Chief Financial Officer Jul 17 '24 Sale 29.69 3,123 92,733 347,544 Jul 19 05:39 PM Butchko Julia G. Chief Development Officer Jul 17 '24 Sale 29.69 2,867 85,132 443,986 Jul 19 05:38 PM Salzmann Peter Chief Executive Officer Jul 17 '24 Sale 29.69 8,685 257,887 1,023,412 Jul 19 05:36 PM Barnett Eva Renee Chief Financial Officer Jul 09 '24 Sale 28.06 4,747 133,201 350,667 Jul 10 05:07 PM Butchko Julia G. Chief Development Officer Jul 09 '24 Sale 28.06 1,527 42,848 446,853 Jul 10 05:06 PM Salzmann Peter Chief Executive Officer Jul 09 '24 Sale 28.06 4,619 129,609 1,032,097 Jul 10 05:04 PM Barnett Eva Renee Chief Financial Officer May 22 '24 Sale 29.65 4,042 119,845 355,414 May 24 04:18 PM Salzmann Peter Chief Executive Officer May 22 '24 Sale 29.65 16,163 479,233 1,036,716 May 24 04:15 PM Butchko Julia G. Chief Development Officer May 22 '24 Sale 29.65 3,247 96,274 448,380 May 24 04:14 PM Macias William L. Chief Medical Officer May 22 '24 Sale 29.65 3,247 96,274 374,403 May 24 04:13 PM Levine Mark S. Chief Legal Officer May 22 '24 Sale 29.65 3,242 96,125 339,914 May 24 04:10 PM Geffner Michael Chief Medical Officer Apr 24 '24 Sale 28.90 3,261 94,243 141,616 Apr 26 05:22 PM Stout Jay S Chief Technology Officer Apr 24 '24 Sale 28.90 7,239 209,207 147,739 Apr 26 05:20 PM Levine Mark S. Chief Legal Officer Apr 24 '24 Sale 28.90 3,963 114,531 343,156 Apr 26 05:18 PM Levine Mark S. Chief Legal Officer Apr 17 '24 Sale 29.06 9,827 285,554 347,119 Apr 19 06:06 PM Macias William L. Chief Medical Officer Apr 17 '24 Sale 29.06 8,280 240,602 377,650 Apr 19 06:05 PM Barnett Eva Renee Chief Financial Officer Apr 17 '24 Sale 29.06 12,253 356,049 359,456 Apr 19 06:01 PM Butchko Julia G. Chief Development Officer Apr 17 '24 Sale 29.06 10,115 293,923 451,627 Apr 19 05:59 PM Salzmann Peter Chief Executive Officer Apr 17 '24 Sale 29.06 34,079 990,269 1,052,879 Apr 19 05:57 PM Barnett Eva Renee Chief Financial Officer Apr 09 '24 Sale 31.18 3,689 115,023 371,709 Apr 10 04:18 PM Butchko Julia G. Chief Development Officer Apr 09 '24 Sale 31.18 1,053 32,833 461,742 Apr 10 04:16 PM Salzmann Peter Chief Executive Officer Apr 09 '24 Sale 31.18 4,807 149,882 1,086,958 Apr 10 04:14 PM Barnett Eva Renee Chief Financial Officer Feb 22 '24 Sale 36.15 2,930 105,920 320,420 Feb 23 04:21 PM Levine Mark S. Chief Legal Officer Feb 22 '24 Sale 36.15 2,134 77,144 301,968 Feb 23 04:18 PM Macias William L. Chief Medical Officer Feb 22 '24 Sale 36.15 2,221 80,289 330,952 Feb 23 04:16 PM Butchko Julia G. Chief Development Officer Feb 22 '24 Sale 36.15 2,146 77,578 407,817 Feb 23 04:14 PM Salzmann Peter Chief Executive Officer Feb 22 '24 Sale 36.15 13,454 486,362 931,231 Feb 23 04:11 PM Levine Mark S. Chief Legal Officer Jan 26 '24 Sale 37.92 3,027 114,778 304,102 Jan 29 04:12 PM Geffner Michael Chief Medical Officer Jan 26 '24 Sale 37.92 10,101 383,012 89,899 Jan 29 04:11 PM Macias William L. Chief Medical Officer Jan 18 '24 Sale 41.03 424 17,397 333,173 Jan 19 04:04 PM Barnett Eva Renee Chief Financial Officer Jan 11 '24 Sale 41.83 3,515 147,023 323,350 Jan 12 04:34 PM Butchko Julia G. Chief Development Officer Jan 05 '24 Sale 38.59 1,297 50,051 409,963 Jan 09 04:20 PM Salzmann Peter Chief Executive Officer Jan 05 '24 Sale 38.59 3,824 147,568 944,685 Jan 09 04:18 PM Fromkin Andrew J. Director Dec 01 '23 Sale 39.73 12,350 490,697 88,658 Dec 05 04:30 PM Pande Atul Director Dec 01 '23 Sale 39.73 12,350 490,667 83,158 Dec 05 04:28 PM MIGAUSKY GEORGE V Director Dec 01 '23 Sale 39.73 12,700 504,567 109,808 Dec 05 04:25 PM Salzmann Peter Chief Executive Officer Nov 22 '23 Sale 32.78 16,217 531,581 948,509 Nov 24 02:55 PM Barnett Eva Renee Chief Financial Officer Nov 22 '23 Sale 32.78 4,055 132,920 326,865 Nov 24 02:51 PM Butchko Julia G. Chief Development Officer Nov 22 '23 Sale 32.78 3,265 107,024 411,260 Nov 24 02:47 PM Macias William L. Chief Medical Officer Nov 22 '23 Sale 32.78 3,265 107,024 333,597 Nov 24 02:45 PM Levine Mark S. Chief Legal Officer Nov 22 '23 Sale 32.78 3,252 106,598 307,129 Nov 24 02:41 PM Levine Mark S. Chief Legal Officer Oct 25 '23 Sale 34.66 4,107 142,349 310,381 Oct 27 04:04 PM Macias William L. Chief Medical Officer Oct 19 '23 Sale 36.80 530 19,504 336,862 Oct 20 04:06 PM Barnett Eva Renee Chief Financial Officer Oct 10 '23 Sale 36.92 4,557 168,244 330,920 Oct 11 04:11 PM Butchko Julia G. Chief Development Officer Oct 05 '23 Sale 36.24 1,735 62,885 414,525 Oct 06 05:15 PM Salzmann Peter Chief Executive Officer Oct 05 '23 Sale 36.24 5,239 189,887 964,726 Oct 06 05:10 PM Roivant Sciences Ltd. Director Oct 02 '23 Buy 38.00 1,526,316 58,000,008 79,805,331 Oct 04 05:15 PM
Index RUT
P/E -
EPS (ttm) -1.62
Insider Own 23.68%
Shs Outstand 226.26M
Perf Week -20.11%
Market Cap 1.67B
Forward P/E -
EPS next Y -1.72
Insider Trans -1.55%
Shs Float 215.41M
Perf Month -7.06%
Income -374.93M
PEG -
EPS next Q -0.33
Inst Own 77.36%
Short Float 25.14%
Perf Quarter -34.30%
Sales 49.63M
P/S 33.67
EPS this Y 1.11%
Inst Trans 3.80%
Short Ratio 9.49
Perf Half Y -46.91%
Book/sh 2.08
P/B 2.85
EPS next Y -10.01%
ROA -51.98%
Short Interest 54.15M
Perf Year -34.59%
Cash/sh 1.69
P/C 3.51
EPS next 5Y 12.00%
ROE -71.18%
52W Range 4.97 - 15.74
Perf YTD -39.96%
Dividend Est. -
P/FCF -
EPS past 5Y -43.41%
ROI -57.01%
52W High -62.39%
Beta 0.85
Dividend TTM -
Quick Ratio 6.07
Sales past 5Y 132.77%
Gross Margin -31.81%
52W Low 19.11%
ATR (14) 0.52
Dividend Ex-Date -
Current Ratio 6.07
EPS Y/Y TTM -17.59%
Oper. Margin -817.09%
RSI (14) 35.50
Volatility 7.43% 6.89%
Employees -
Debt/Eq 0.15
Sales Y/Y TTM -0.70%
Profit Margin -755.37%
Recom 2.50
Target Price 10.14
Option/Short Yes / Yes
LT Debt/Eq 0.13
EPS Q/Q -5.72%
Payout -
Rel Volume 0.80
Prev Close 6.17
Sales Surprise 20.46%
EPS Surprise -4.09%
Sales Q/Q 30.86%
Earnings Aug 08 BMO
Avg Volume 5.70M
Price 5.92
SMA20 -14.33%
SMA50 -19.90%
SMA200 -34.73%
Trades
Volume 4,561,976
Change -4.05%
Date
Action
Analyst
Rating Change
Price Target Change
May-22-23 Initiated
Morgan Stanley
Equal-Weight
$8
Mar-16-23 Initiated
Needham
Buy
$17
Sep-16-22 Initiated
KeyBanc Capital Markets
Overweight
$20
Apr-18-22 Downgrade
BofA Securities
Buy → Neutral
$10
Mar-04-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$10
Sep-21-21 Initiated
Berenberg
Buy
$37
May-11-21 Initiated
SVB Leerink
Outperform
$33
May-11-21 Initiated
KeyBanc Capital Markets
Overweight
$36
May-11-21 Initiated
JP Morgan
Neutral
$32
May-11-21 Initiated
Goldman
Neutral
$34
May-11-21 Initiated
BofA Securities
Buy
$31
Show Previous Ratings
Sep-03-24 08:00AM
07:11AM
Aug-30-24 04:10AM
Aug-28-24 07:04PM
Aug-18-24 12:34PM
09:53AM
Loading…
Aug-17-24 09:53AM
Aug-16-24 06:36PM
Aug-14-24 09:45AM
Aug-13-24 07:05AM
Aug-12-24 09:15AM
Aug-11-24 04:59AM
Aug-08-24 05:37PM
02:41PM
08:45AM
07:45AM
(Associated Press Finance)
07:39AM
Loading…
07:39AM
07:30AM
07:07AM
01:32AM
Aug-06-24 06:00AM
Aug-05-24 04:01PM
Jul-31-24 05:06AM
Jul-29-24 05:50PM
Jul-27-24 05:41AM
Jul-26-24 09:55AM
Jul-18-24 06:10AM
Jul-14-24 06:25AM
Jul-13-24 09:29AM
06:26AM
Jul-12-24 05:50AM
07:09PM
Loading…
Jul-08-24 07:09PM
Jul-03-24 09:12AM
Jun-28-24 10:28AM
03:48AM
Jun-27-24 08:15AM
07:34AM
Jun-26-24 10:07PM
04:06PM
Jun-25-24 05:50PM
Jun-24-24 09:00AM
08:00AM
Jun-13-24 02:40PM
Jun-08-24 11:37AM
Jun-07-24 09:00AM
Jun-05-24 06:26AM
Jun-03-24 09:00AM
06:15AM
Jun-02-24 03:40AM
May-31-24 02:46AM
May-30-24 04:46AM
04:32AM
May-29-24 03:27PM
May-24-24 04:30PM
06:30AM
May-23-24 09:00AM
May-17-24 02:36AM
May-15-24 08:45AM
May-13-24 09:59AM
05:00AM
May-12-24 08:15AM
May-10-24 08:05PM
01:26PM
12:36PM
May-09-24 08:59PM
06:04PM
05:25PM
04:32PM
(Associated Press Finance)
04:01PM
May-06-24 11:41AM
May-03-24 05:50PM
May-02-24 09:00AM
08:00AM
May-01-24 08:01AM
Apr-30-24 08:00AM
07:29AM
Apr-27-24 08:58AM
07:00AM
Apr-25-24 05:50PM
10:30AM
08:01AM
Apr-17-24 05:50PM
07:00AM
Apr-16-24 08:00AM
Apr-15-24 12:54PM
08:00AM
Apr-10-24 05:50AM
Apr-08-24 09:00AM
Apr-04-24 08:45AM
01:31AM
Apr-03-24 09:35AM
Apr-02-24 08:00AM
Apr-01-24 12:00PM
Mar-26-24 08:00AM
Mar-22-24 01:29AM
Mar-18-24 01:00PM
Mar-15-24 04:54PM
01:49AM
Mar-11-24 04:00AM
Mar-07-24 10:28AM
Mar-01-24 02:58PM
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gibson Christopher Chief Executive Officer Sep 05 '24 Sale 6.14 20,000 122,800 762,656 Sep 06 04:57 PM Gibson Christopher Chief Executive Officer Sep 04 '24 Sale 6.04 20,000 120,800 762,656 Sep 06 04:57 PM Borgeson Blake Director Sep 03 '24 Sale 6.27 11,447 71,718 7,121,322 Sep 05 05:25 PM Gibson Christopher Officer Sep 05 '24 Proposed Sale 6.14 20,000 122,800 Sep 05 11:43 AM Gibson Christopher Officer Sep 04 '24 Proposed Sale 6.04 20,000 120,800 Sep 04 01:16 PM Marriott Tina President and COO Aug 29 '24 Option Exercise 1.06 6,000 6,360 527,138 Sep 03 04:48 PM Marriott Tina President and COO Aug 29 '24 Sale 7.56 6,000 45,376 521,138 Sep 03 04:48 PM Borgeson Blake Director Sep 03 '24 Proposed Sale 6.27 11,447 71,717 Sep 03 04:27 PM Gibson Christopher Chief Executive Officer Aug 30 '24 Option Exercise 2.48 5,000 12,400 762,656 Aug 30 04:26 PM Marriott Tina Officer Aug 29 '24 Proposed Sale 7.56 6,000 45,376 Aug 29 04:53 PM Gibson Christopher Chief Executive Officer Aug 29 '24 Option Exercise 2.48 5,000 12,400 757,656 Aug 29 04:22 PM Gibson Christopher Chief Executive Officer Aug 28 '24 Option Exercise 2.48 5,000 12,400 752,656 Aug 28 04:12 PM Gibson Christopher Chief Executive Officer Aug 27 '24 Option Exercise 2.48 5,000 12,400 747,656 Aug 27 04:10 PM Gibson Christopher Chief Executive Officer Aug 26 '24 Option Exercise 2.48 5,000 12,400 742,656 Aug 26 04:42 PM Gibson Christopher Chief Executive Officer Aug 23 '24 Option Exercise 2.48 5,000 12,400 737,656 Aug 23 05:25 PM Borgeson Blake Director Aug 20 '24 Sale 7.12 11,447 81,532 7,132,769 Aug 22 06:48 PM Borgeson Blake Director Aug 20 '24 Proposed Sale 7.12 11,447 81,533 Aug 20 04:25 PM Secora Michael Chief Financial Officer Aug 13 '24 Option Exercise 2.22 39,375 87,413 1,355,968 Aug 15 05:24 PM Secora Michael Chief Financial Officer Aug 14 '24 Option Exercise 2.22 39,375 87,413 1,380,343 Aug 15 05:24 PM Secora Michael Chief Financial Officer Aug 14 '24 Sale 6.35 15,000 95,252 1,365,343 Aug 15 05:24 PM Secora Michael Chief Financial Officer Aug 13 '24 Sale 6.35 15,000 95,182 1,340,968 Aug 15 05:24 PM Secora Michael Officer Aug 14 '24 Proposed Sale 6.35 15,000 95,251 Aug 14 04:35 PM Secora Michael Officer Aug 13 '24 Proposed Sale 6.35 15,000 95,183 Aug 13 04:22 PM Gibson Christopher Chief Executive Officer Aug 07 '24 Sale 7.10 30,000 213,000 758,738 Aug 09 04:56 PM Gibson Christopher Chief Executive Officer Aug 08 '24 Sale 6.50 20,000 130,000 758,738 Aug 09 04:56 PM Borgeson Blake Director Aug 06 '24 Sale 6.82 11,447 78,083 7,144,216 Aug 08 05:23 PM Gibson Christopher Officer Aug 08 '24 Proposed Sale 6.50 20,000 130,000 Aug 08 12:56 PM Gibson Christopher Officer Aug 07 '24 Proposed Sale 7.10 30,000 213,000 Aug 07 01:34 PM Borgeson Blake Director Aug 06 '24 Proposed Sale 6.82 11,447 78,083 Aug 06 04:50 PM Marriott Tina President and COO Jul 25 '24 Option Exercise 1.06 6,000 6,360 541,457 Jul 29 06:16 PM Marriott Tina President and COO Jul 25 '24 Sale 8.13 6,000 48,809 535,457 Jul 29 06:16 PM Borgeson Blake Director Jul 23 '24 Sale 8.48 11,447 97,041 7,155,663 Jul 25 06:15 PM Gibson Christopher Chief Executive Officer Jul 10 '24 Sale 7.48 50,000 374,000 758,738 Jul 12 06:54 PM Gibson Christopher Chief Executive Officer Jul 11 '24 Sale 7.47 50,000 373,500 758,738 Jul 12 06:54 PM Secora Michael Chief Financial Officer Jul 09 '24 Option Exercise 2.22 39,375 87,413 1,307,218 Jul 11 04:51 PM Secora Michael Chief Financial Officer Jul 10 '24 Option Exercise 2.22 39,375 87,413 1,331,593 Jul 11 04:51 PM Secora Michael Chief Financial Officer Jul 09 '24 Sale 7.32 15,000 109,778 1,292,218 Jul 11 04:51 PM Secora Michael Chief Financial Officer Jul 10 '24 Sale 7.24 15,000 108,576 1,316,593 Jul 11 04:51 PM Borgeson Blake Director Jul 09 '24 Sale 7.32 11,447 83,735 7,167,110 Jul 11 04:51 PM Marriott Tina President and COO Jun 27 '24 Option Exercise 1.06 6,000 6,360 541,457 Jun 28 05:14 PM Marriott Tina President and COO Jun 27 '24 Sale 7.21 6,000 43,290 535,457 Jun 28 05:14 PM Borgeson Blake Director Jun 25 '24 Sale 9.51 11,447 108,806 7,177,116 Jun 27 07:13 PM Secora Michael Chief Financial Officer Jun 13 '24 Option Exercise 2.22 39,375 87,413 1,258,468 Jun 17 05:46 PM Secora Michael Chief Financial Officer Jun 14 '24 Option Exercise 2.22 39,375 87,413 1,282,843 Jun 17 05:46 PM Secora Michael Chief Financial Officer Jun 13 '24 Sale 9.32 15,000 139,798 1,243,468 Jun 17 05:46 PM Secora Michael Chief Financial Officer Jun 14 '24 Sale 9.27 15,000 139,082 1,267,843 Jun 17 05:46 PM Borgeson Blake Director Jun 11 '24 Sale 8.45 11,447 96,763 7,188,563 Jun 13 05:36 PM Gibson Christopher Chief Executive Officer Jun 06 '24 Sale 9.00 50,000 450,000 708,738 Jun 07 04:01 PM Gibson Christopher Chief Executive Officer Jun 05 '24 Sale 8.42 50,000 421,000 758,738 Jun 07 04:01 PM Marriott Tina President and COO May 30 '24 Option Exercise 1.06 3,000 3,180 538,457 Jun 03 06:31 PM Marriott Tina President and COO May 30 '24 Sale 8.78 3,000 26,325 535,457 Jun 03 06:31 PM Borgeson Blake Director May 28 '24 Sale 9.17 11,447 104,943 7,186,913 May 30 06:41 PM Borgeson Blake Director May 14 '24 Sale 10.12 20,054 202,934 7,198,360 May 16 04:35 PM Gibson Christopher Chief Executive Officer May 02 '24 Sale 8.47 50,000 423,500 834,820 May 03 06:24 PM Gibson Christopher Chief Executive Officer May 01 '24 Sale 7.73 50,000 386,500 863,524 May 03 06:24 PM Borgeson Blake Director Apr 30 '24 Sale 7.95 11,447 90,964 7,218,414 May 02 05:41 PM Marriott Tina President and COO Apr 25 '24 Option Exercise 1.06 3,000 3,180 546,231 Apr 29 06:41 PM Marriott Tina President and COO Apr 25 '24 Sale 7.67 3,000 23,020 543,231 Apr 29 06:41 PM Borgeson Blake Director Apr 16 '24 Sale 7.66 11,447 87,725 7,229,861 Apr 18 05:12 PM Secora Michael Chief Financial Officer Apr 16 '24 Option Exercise 2.22 37,500 83,250 1,241,679 Apr 18 05:12 PM Secora Michael Chief Financial Officer Apr 17 '24 Option Exercise 2.22 37,500 83,250 1,254,179 Apr 18 05:12 PM Secora Michael Chief Financial Officer Apr 16 '24 Sale 7.67 25,000 191,658 1,216,679 Apr 18 05:12 PM Secora Michael Chief Financial Officer Apr 17 '24 Sale 7.58 23,124 175,349 1,231,055 Apr 18 05:12 PM Gibson Christopher Chief Executive Officer Apr 04 '24 Sale 9.02 40,000 360,800 938,524 Apr 05 05:44 PM Gibson Christopher Chief Executive Officer Apr 03 '24 Sale 8.84 40,000 353,600 978,524 Apr 05 05:44 PM Gibson Christopher Chief Executive Officer Apr 04 '24 Sale 9.02 25,000 225,500 0 Apr 05 05:44 PM Gibson Christopher Chief Executive Officer Apr 03 '24 Sale 8.84 25,000 221,000 0 Apr 05 05:44 PM Borgeson Blake Director Apr 02 '24 Sale 8.82 11,447 100,942 7,241,308 Apr 03 05:42 PM Gibson Christopher Chief Executive Officer Mar 28 '24 Sale 10.10 40,000 404,000 1,043,524 Apr 01 06:40 PM Gibson Christopher Chief Executive Officer Mar 28 '24 Sale 10.10 25,000 252,500 0 Apr 01 06:40 PM Marriott Tina President and COO Mar 21 '24 Option Exercise 1.06 8,000 8,480 647,982 Mar 25 06:39 PM Marriott Tina President and COO Mar 21 '24 Sale 10.75 8,000 85,980 639,982 Mar 25 06:39 PM Borgeson Blake Director Mar 19 '24 Sale 10.79 20,054 216,423 7,252,755 Mar 21 05:38 PM Secora Michael Chief Financial Officer Mar 12 '24 Option Exercise 2.22 37,500 83,250 1,216,679 Mar 14 07:28 PM Secora Michael Chief Financial Officer Mar 13 '24 Option Exercise 2.22 37,500 83,250 1,229,179 Mar 14 07:28 PM Secora Michael Chief Financial Officer Mar 13 '24 Sale 11.03 25,000 275,815 1,204,179 Mar 14 07:28 PM Secora Michael Chief Financial Officer Mar 12 '24 Sale 10.46 25,000 261,375 1,191,679 Mar 14 07:28 PM Gibson Christopher Chief Executive Officer Mar 06 '24 Option Exercise 4.42 39,924 176,384 1,144,843 Mar 08 07:08 PM Gibson Christopher Chief Executive Officer Mar 06 '24 Sale 11.86 36,319 430,682 1,108,524 Mar 08 07:08 PM Gibson Christopher Chief Executive Officer Mar 06 '24 Sale 11.55 25,000 288,823 0 Mar 08 07:08 PM Borgeson Blake Director Mar 05 '24 Sale 12.06 20,054 241,805 7,272,809 Mar 07 06:53 PM Marriott Tina President and COO Feb 22 '24 Option Exercise 1.06 8,000 8,480 647,982 Feb 23 07:22 PM Marriott Tina President and COO Feb 22 '24 Sale 14.89 8,000 119,160 639,982 Feb 23 07:22 PM Borgeson Blake Director Feb 20 '24 Sale 12.32 20,054 247,125 7,292,863 Feb 21 05:37 PM Secora Michael Chief Financial Officer Feb 13 '24 Option Exercise 2.22 37,500 83,250 1,198,851 Feb 15 06:00 PM Secora Michael Chief Financial Officer Feb 14 '24 Option Exercise 2.22 37,500 83,250 1,211,351 Feb 15 06:00 PM Secora Michael Chief Financial Officer Feb 14 '24 Sale 10.46 25,000 261,425 1,186,351 Feb 15 06:00 PM Secora Michael Chief Financial Officer Feb 13 '24 Sale 9.86 25,000 246,560 1,173,851 Feb 15 06:00 PM Gibson Christopher Chief Executive Officer Feb 07 '24 Option Exercise 2.48 31,250 77,500 822,975 Feb 09 05:34 PM Gibson Christopher Chief Executive Officer Feb 07 '24 Sale 9.22 48,272 444,981 774,703 Feb 09 05:34 PM Borgeson Blake Director Feb 06 '24 Sale 9.30 11,447 106,489 7,312,917 Feb 08 06:54 PM Larson Tina Marriott President and COO Jan 25 '24 Option Exercise 1.06 8,000 8,480 422,584 Jan 29 06:52 PM Larson Tina Marriott President and COO Jan 25 '24 Sale 10.35 8,000 82,762 414,548 Jan 29 06:52 PM Borgeson Blake Director Jan 23 '24 Sale 10.58 20,054 212,083 7,324,364 Jan 25 06:13 PM Virani Shafique Chief Business Officer Jan 16 '24 Option Exercise 2.22 18,000 39,960 154,748 Jan 18 06:39 PM Virani Shafique Chief Business Officer Jan 16 '24 Sale 10.93 18,000 196,740 136,748 Jan 18 06:39 PM Secora Michael Chief Financial Officer Jan 16 '24 Option Exercise 2.22 37,500 83,250 993,514 Jan 18 06:37 PM Secora Michael Chief Financial Officer Jan 17 '24 Option Exercise 2.22 37,500 83,250 1,006,014 Jan 18 06:37 PM Secora Michael Chief Financial Officer Jan 16 '24 Sale 10.45 25,000 261,160 968,514 Jan 18 06:37 PM Secora Michael Chief Financial Officer Jan 17 '24 Sale 10.25 25,000 256,348 981,014 Jan 18 06:37 PM
Index RUT
P/E -
EPS (ttm) -2.04
Insider Own 61.74%
Shs Outstand 60.34M
Perf Week -15.61%
Market Cap 123.69M
Forward P/E -
EPS next Y -1.86
Insider Trans -0.16%
Shs Float 32.41M
Perf Month -15.61%
Income -131.39M
PEG -
EPS next Q -0.45
Inst Own 26.49%
Short Float 6.90%
Perf Quarter -51.66%
Sales 2.04M
P/S 60.63
EPS this Y 23.48%
Inst Trans -1.45%
Short Ratio 6.66
Perf Half Y -72.53%
Book/sh 2.63
P/B 0.56
EPS next Y -5.59%
ROA -31.52%
Short Interest 2.23M
Perf Year -40.16%
Cash/sh 2.32
P/C 0.63
EPS next 5Y -
ROE -55.95%
52W Range 1.28 - 5.51
Perf YTD -56.02%
Dividend Est. -
P/FCF -
EPS past 5Y 15.24%
ROI -47.81%
52W High -73.50%
Beta 1.40
Dividend TTM -
Quick Ratio 10.62
Sales past 5Y -14.25%
Gross Margin -488.98%
52W Low 14.06%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 10.62
EPS Y/Y TTM 5.99%
Oper. Margin -6321.69%
RSI (14) 36.05
Volatility 11.62% 11.94%
Employees 165
Debt/Eq 0.25
Sales Y/Y TTM -55.26%
Profit Margin -6434.23%
Recom 1.33
Target Price 9.00
Option/Short Yes / Yes
LT Debt/Eq 0.24
EPS Q/Q 32.34%
Payout -
Rel Volume 0.89
Prev Close 1.44
Sales Surprise 79.30%
EPS Surprise 16.45%
Sales Q/Q 678.79%
Earnings Aug 08 BMO
Avg Volume 335.70K
Price 1.46
SMA20 -14.27%
SMA50 -31.08%
SMA200 -52.73%
Trades
Volume 300,198
Change 1.39%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-24 Initiated
Rodman & Renshaw
Buy
$6
Aug-28-23 Downgrade
JP Morgan
Overweight → Neutral
$28 → $5
Dec-27-22 Initiated
Chardan Capital Markets
Buy
$19
Oct-31-22 Initiated
Guggenheim
Buy
$15
Oct-10-22 Initiated
Canaccord Genuity
Buy
$28
May-23-22 Initiated
H.C. Wainwright
Buy
$27
May-12-22 Initiated
William Blair
Mkt Perform
Jul-13-21 Initiated
Piper Sandler
Overweight
$38
Jul-13-21 Initiated
JP Morgan
Overweight
$40
Jul-13-21 Initiated
BofA Securities
Buy
$34
Aug-08-24 08:50AM
07:30AM
Jul-09-24 12:00PM
Jun-03-24 07:00AM
May-10-24 03:35PM
07:00AM
Loading…
07:00AM
May-09-24 01:54PM
08:40AM
07:30AM
Apr-23-24 07:00AM
Apr-11-24 08:25AM
07:00AM
Apr-08-24 04:05PM
Mar-25-24 07:00AM
Mar-19-24 07:00AM
01:52PM
Loading…
Mar-14-24 01:52PM
07:30AM
Mar-08-24 11:55PM
Mar-07-24 09:55AM
Mar-05-24 06:03PM
Feb-01-24 07:00AM
Dec-09-23 12:00PM
Dec-07-23 11:01AM
Dec-06-23 07:30AM
07:30AM
Dec-05-23 08:55AM
Nov-21-23 07:00AM
Nov-14-23 03:58PM
Nov-09-23 08:29AM
07:01AM
07:00AM
Loading…
07:00AM
07:00AM
Nov-02-23 09:00AM
Sep-26-23 07:00AM
Aug-09-23 08:50AM
07:30AM
Aug-01-23 06:48AM
May-12-23 06:11AM
May-11-23 08:55AM
07:30AM
Apr-17-23 07:00AM
Apr-12-23 08:30AM
Mar-16-23 08:55AM
07:30AM
Mar-15-23 04:01PM
Feb-21-23 07:00AM
Feb-08-23 07:30AM
Feb-01-23 07:00AM
Jan-17-23 09:35AM
Jan-09-23 10:46AM
(American City Business Journals)
Jan-06-23 08:23AM
Jan-05-23 04:01PM
Jan-04-23 07:00AM
Dec-08-22 10:02AM
Nov-22-22 07:00AM
Nov-11-22 07:00AM
Nov-10-22 08:45AM
07:30AM
Nov-02-22 07:05AM
Oct-05-22 04:05PM
Oct-03-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 07:00AM
Aug-25-22 07:30AM
Aug-11-22 08:45AM
07:30AM
Jul-07-22 01:43PM
(American City Business Journals)
Jul-01-22 09:18AM
Jun-24-22 04:30PM
(GlobeNewswire) -6.39%
-8.37%
Jun-21-22 04:30PM
Jun-06-22 07:30AM
May-20-22 03:04PM
(American City Business Journals)
May-16-22 07:30AM
May-03-22 04:30PM
May-02-22 04:30PM
Apr-18-22 04:30PM
Apr-06-22 04:30PM
Mar-23-22 04:30PM
Mar-17-22 07:30AM
Feb-09-22 04:05PM
Jan-22-22 11:29AM
Jan-14-22 06:50AM
(American City Business Journals)
Jan-10-22 12:27PM
(American City Business Journals) +14.52%
11:12AM
08:08AM
06:59AM
Jan-04-22 04:30PM
Dec-17-21 07:00AM
Dec-16-21 06:30AM
Nov-22-21 08:00AM
Nov-10-21 07:30AM
Nov-04-21 09:00AM
Oct-07-21 07:30AM
Sep-17-21 04:01PM
(GlobeNewswire) -15.35%
-12.24%
Aug-12-21 08:00AM
Jun-22-21 04:01PM
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Farid Adrienne Chief Operations Officer Aug 05 '24 Sale 1.83 1,073 1,960 136,163 Aug 07 04:06 PM Carr Douglas SVP Finance & Operations Aug 05 '24 Sale 1.83 289 528 334,041 Aug 07 04:06 PM Farid Adrienne Officer Aug 05 '24 Proposed Sale 1.83 1,073 1,960 Aug 05 03:06 PM Russotti Gregory See Remarks Jul 26 '24 Sale 2.50 586 1,465 274,933 Jul 31 09:08 AM Russotti Gregory Officer Jul 26 '24 Proposed Sale 2.50 586 1,465 Jul 26 05:03 PM Russotti Gregory See Remarks Jul 24 '24 Sale 2.52 1,600 4,029 275,519 Jul 25 05:04 PM Russotti Gregory See Remarks Jul 23 '24 Sale 2.50 200 500 277,119 Jul 25 05:04 PM Russotti Gregory See Remarks Jun 20 '24 Sale 2.84 5,000 14,178 277,319 Jun 24 04:49 PM Russotti Gregory See Remarks Jun 05 '24 Sale 3.00 5,000 14,989 282,319 Jun 06 04:53 PM Russotti Gregory See Remarks May 20 '24 Sale 3.00 5,000 14,978 287,319 May 21 04:09 PM Russotti Gregory See Remarks May 06 '24 Sale 3.12 5,000 15,619 292,319 May 07 05:13 PM Carr Douglas SVP Finance & Operations May 03 '24 Sale 3.11 257 798 317,323 May 07 05:13 PM Farid Adrienne Chief Operations Officer May 03 '24 Sale 3.11 913 2,836 137,236 May 07 05:13 PM Russotti Gregory See Remarks Apr 22 '24 Sale 3.10 5,000 15,490 297,319 Apr 24 04:17 PM Farid Adrienne Chief Operations Officer Mar 06 '24 Option Exercise 1.03 30,684 31,605 144,833 Mar 08 06:29 PM Farid Adrienne Chief Operations Officer Mar 07 '24 Option Exercise 1.03 22,831 23,516 136,980 Mar 08 06:29 PM Farid Adrienne Chief Operations Officer Mar 06 '24 Sale 4.96 30,684 152,340 114,149 Mar 08 06:29 PM Farid Adrienne Chief Operations Officer Mar 07 '24 Sale 5.14 22,831 117,342 114,149 Mar 08 06:29 PM Farid Adrienne Chief Operations Officer Feb 16 '24 Option Exercise 1.03 485 500 114,634 Feb 21 04:10 PM Farid Adrienne Chief Operations Officer Feb 16 '24 Sale 4.86 485 2,358 114,149 Feb 21 04:10 PM Carr Douglas SVP Finance & Operations Feb 06 '24 Sale 4.49 557 2,499 303,580 Feb 07 05:21 PM Carr Douglas SVP Finance & Operations Feb 05 '24 Sale 3.84 643 2,470 304,137 Feb 07 05:21 PM Farid Adrienne Chief Operations Officer Feb 06 '24 Sale 4.49 1,784 8,005 114,149 Feb 07 05:21 PM Farid Adrienne Chief Operations Officer Feb 05 '24 Sale 3.84 2,035 7,816 115,933 Feb 07 05:21 PM
Index RUT
P/E -
EPS (ttm) -3.81
Insider Own 4.30%
Shs Outstand 57.56M
Perf Week -18.22%
Market Cap 2.15B
Forward P/E -
EPS next Y -2.39
Insider Trans -1.61%
Shs Float 56.07M
Perf Month -17.58%
Income -220.31M
PEG -
EPS next Q -0.70
Inst Own 106.35%
Short Float 16.43%
Perf Quarter -30.72%
Sales 295.21M
P/S 7.29
EPS this Y 4.32%
Inst Trans 2.41%
Short Ratio 9.16
Perf Half Y -3.34%
Book/sh 8.39
P/B 4.38
EPS next Y 30.61%
ROA -30.42%
Short Interest 9.21M
Perf Year 49.33%
Cash/sh 4.94
P/C 7.43
EPS next 5Y -
ROE -38.36%
52W Range 14.42 - 60.90
Perf YTD -0.38%
Dividend Est. -
P/FCF -
EPS past 5Y -6.09%
ROI -39.08%
52W High -39.70%
Beta 1.77
Dividend TTM -
Quick Ratio 4.52
Sales past 5Y 60.13%
Gross Margin 40.53%
52W Low 154.65%
ATR (14) 2.65
Dividend Ex-Date -
Current Ratio 4.91
EPS Y/Y TTM -3.16%
Oper. Margin -63.17%
RSI (14) 31.69
Volatility 6.38% 5.00%
Employees 919
Debt/Eq 0.18
Sales Y/Y TTM 25.37%
Profit Margin -74.63%
Recom 1.83
Target Price 51.80
Option/Short Yes / Yes
LT Debt/Eq 0.15
EPS Q/Q -46.26%
Payout -
Rel Volume 1.18
Prev Close 40.02
Sales Surprise 5.25%
EPS Surprise -92.43%
Sales Q/Q 27.81%
Earnings Aug 02 BMO
Avg Volume 1.01M
Price 36.72
SMA20 -15.32%
SMA50 -24.32%
SMA200 -7.22%
Trades
Volume 1,185,330
Change -8.25%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-04-24 Initiated
Guggenheim
Buy
$53
Jan-17-24 Upgrade
Goldman
Neutral → Buy
$25 → $45
Sep-27-23 Initiated
Berenberg
Buy
$27
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$33
Jan-03-23 Upgrade
Evercore ISI
In-line → Outperform
$28 → $36
Mar-02-22 Resumed
Cowen
Outperform
Oct-15-21 Resumed
Cowen
Outperform
Jun-29-21 Initiated
William Blair
Outperform
Jun-04-21 Initiated
Goldman
Neutral
$110
Apr-12-21 Initiated
Piper Sandler
Overweight
$150
Feb-05-21 Downgrade
JP Morgan
Neutral → Underweight
$100
Jan-04-21 Downgrade
Evercore ISI
Outperform → In-line
Oct-20-20 Initiated
SVB Leerink
Mkt Perform
$90
May-31-19 Initiated
Evercore ISI
Outperform
Nov-26-18 Initiated
JP Morgan
Neutral
$27
Show Previous Ratings
Aug-27-24 08:00AM
Aug-14-24 09:45AM
Aug-08-24 08:00AM
Aug-07-24 06:47AM
Aug-06-24 08:00AM
11:20AM
Loading…
Aug-05-24 11:20AM
08:00AM
Aug-02-24 08:40AM
07:37AM
(Associated Press Finance)
07:30AM
Jul-30-24 02:17AM
Jul-26-24 10:00AM
Jul-18-24 08:00AM
Jul-11-24 08:00AM
Jul-10-24 08:00AM
08:00AM
Loading…
Jul-09-24 08:00AM
Jul-01-24 07:08PM
02:31PM
Jun-06-24 08:00AM
Jun-04-24 08:00AM
May-24-24 04:58PM
(Investor's Business Daily)
May-23-24 08:00AM
May-22-24 12:00PM
May-13-24 08:00AM
May-10-24 06:00AM
May-08-24 08:00AM
May-03-24 03:55PM
01:58PM
01:22PM
10:02AM
06:47AM
Loading…
06:47AM
(Thomson Reuters StreetEvents)
04:05AM
May-02-24 09:00PM
05:35PM
04:33PM
(Associated Press Finance)
04:05PM
Apr-30-24 03:20PM
Apr-25-24 11:31AM
Apr-18-24 08:00AM
Mar-28-24 08:00AM
Mar-05-24 08:00AM
Feb-22-24 08:00AM
Feb-13-24 01:59PM
Feb-10-24 05:28AM
Feb-07-24 08:00AM
Feb-06-24 08:05AM
08:00AM
Feb-05-24 08:09AM
08:00AM
Feb-02-24 11:42PM
(Thomson Reuters StreetEvents) +10.01%
07:55AM
07:36AM
(Associated Press Finance)
07:30AM
Jan-24-24 08:00AM
Jan-16-24 08:00AM
Jan-08-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 12:44PM
Dec-18-23 08:00AM
Dec-15-23 08:11AM
Nov-20-23 08:55AM
Nov-18-23 01:29AM
(Thomson Reuters StreetEvents)
Nov-17-23 04:03PM
(Investor's Business Daily) +25.90%
08:40AM
08:28AM
07:47AM
(Associated Press Finance)
07:30AM
Nov-14-23 08:00AM
Nov-13-23 08:00AM
Nov-08-23 08:00AM
Nov-02-23 04:05PM
(Business Wire) +10.82%
+7.80%
Oct-31-23 08:00AM
Oct-16-23 10:43AM
Oct-06-23 12:08PM
11:44AM
Oct-05-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 08:00AM
Sep-26-23 01:02PM
12:40PM
Sep-20-23 12:11PM
Sep-14-23 12:56PM
12:31PM
Sep-05-23 08:00AM
Aug-31-23 03:10AM
03:00AM
Aug-22-23 08:00AM
Aug-11-23 01:39PM
Aug-07-23 09:53AM
08:00AM
Aug-04-23 01:21PM
08:45AM
07:37AM
07:30AM
Jul-20-23 08:00AM
Jul-18-23 09:50AM
08:00AM
Jun-26-23 08:10AM
Jun-20-23 08:00AM
Jun-04-23 09:46AM
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WERNER ROBERT F. Officer Sep 06 '24 Proposed Sale 39.16 240 9,399 Sep 06 03:27 PM Green Paula Officer Sep 06 '24 Proposed Sale 39.16 912 35,715 Sep 06 03:26 PM Cho Dennis Officer Sep 06 '24 Proposed Sale 39.16 275 10,769 Sep 06 03:19 PM Leproust Emily M. Officer Sep 06 '24 Proposed Sale 39.16 2,340 91,636 Sep 06 03:16 PM WERNER ROBERT F. Chief Accounting Officer Aug 23 '24 Sale 43.14 813 35,074 38,964 Aug 27 04:05 PM WERNER ROBERT F. Officer Aug 23 '24 Proposed Sale 43.14 813 35,075 Aug 23 03:21 PM Cho Dennis See Remarks Aug 05 '24 Sale 39.93 709 28,308 78,996 Aug 07 04:05 PM Finn Patrick John President and COO Aug 05 '24 Sale 39.93 2,885 115,187 168,327 Aug 07 04:05 PM Leproust Emily M. Chief Executive Officer Aug 05 '24 Sale 39.93 5,139 205,180 499,593 Aug 07 04:05 PM Green Paula SVP of Human Resources Aug 05 '24 Sale 39.93 1,137 45,396 88,837 Aug 07 04:05 PM WERNER ROBERT F. Chief Accounting Officer Aug 05 '24 Sale 39.93 168 6,708 39,777 Aug 07 04:05 PM Banyai William Officer Aug 06 '24 Proposed Sale 45.30 1,176 53,273 Aug 06 10:13 AM WERNER ROBERT F. Officer Aug 05 '24 Proposed Sale 39.93 168 6,708 Aug 05 03:47 PM Cho Dennis Officer Aug 05 '24 Proposed Sale 39.93 709 28,307 Aug 05 03:35 PM Leproust Emily M. Officer Aug 05 '24 Proposed Sale 39.93 5,139 205,179 Aug 05 03:25 PM Green Paula Officer Aug 05 '24 Proposed Sale 39.93 1,137 45,396 Aug 05 03:23 PM Finn Patrick John Officer Aug 05 '24 Proposed Sale 39.93 2,885 115,186 Aug 05 03:14 PM Banyai William Officer Aug 05 '24 Proposed Sale 39.93 1,415 56,495 Aug 05 03:10 PM Banyai William Officer Aug 01 '24 Proposed Sale 55.34 18,777 1,039,119 Aug 01 10:39 AM Finn Patrick John President and COO Jul 23 '24 Sale 56.62 2,207 124,971 171,212 Jul 25 04:05 PM Laponis Adam Chief Financial Officer Jul 09 '24 Sale 48.91 842 41,185 73,602 Jul 11 04:05 PM Cho Dennis See Remarks Jul 02 '24 Sale 48.00 126 6,048 79,705 Jul 05 04:05 PM Leproust Emily M. Chief Executive Officer Jul 02 '24 Sale 48.00 1,114 53,474 504,732 Jul 05 04:05 PM Green Paula SVP of Human Resources Jul 02 '24 Sale 48.00 322 15,457 89,974 Jul 05 04:05 PM Finn Patrick John President and COO Jul 02 '24 Sale 48.00 476 22,849 173,419 Jul 05 04:05 PM Leproust Emily M. Chief Executive Officer Jun 20 '24 Sale 49.41 1,732 85,578 505,846 Jun 24 04:05 PM Green Paula SVP of Human Resources Jun 20 '24 Sale 49.41 297 14,675 90,296 Jun 24 04:05 PM Cho Dennis See Remarks Jun 20 '24 Sale 49.41 234 11,562 79,831 Jun 24 04:05 PM Cho Dennis See Remarks Jun 14 '24 Sale 51.04 95 4,848 80,065 Jun 18 04:05 PM Cho Dennis See Remarks Jun 06 '24 Sale 51.33 276 14,167 80,160 Jun 10 04:05 PM Green Paula SVP of Human Resources Jun 06 '24 Sale 51.33 918 47,120 90,593 Jun 10 04:05 PM WERNER ROBERT F. Chief Accounting Officer Jun 06 '24 Sale 51.33 242 12,422 39,945 Jun 10 04:05 PM Leproust Emily M. Chief Executive Officer Jun 06 '24 Sale 51.33 2,408 123,600 507,578 Jun 10 04:05 PM Banyai William See Remark May 03 '24 Sale 37.13 798 29,633 345,188 May 07 04:05 PM Cho Dennis See Remarks May 03 '24 Sale 37.13 568 21,092 80,436 May 07 04:05 PM Green Paula SVP of Human Resources May 03 '24 Sale 37.13 910 33,792 91,511 May 07 04:05 PM Leproust Emily M. Chief Executive Officer May 03 '24 Sale 37.13 4,163 154,589 509,986 May 07 04:05 PM WERNER ROBERT F. Chief Accounting Officer May 03 '24 Sale 37.13 132 4,902 43,548 May 07 04:05 PM Finn Patrick John President and COO May 03 '24 Sale 37.13 2,311 85,817 173,895 May 07 04:05 PM Finn Patrick John President and COO Apr 23 '24 Sale 30.12 2,174 65,483 176,206 Apr 25 04:05 PM Laponis Adam Chief Financial Officer Apr 09 '24 Sale 33.16 556 18,434 74,444 Apr 11 04:05 PM Finn Patrick John President and COO Apr 02 '24 Sale 32.74 492 16,106 178,380 Apr 04 04:05 PM Banyai William See Remark Apr 02 '24 Sale 32.74 327 10,705 345,986 Apr 04 04:05 PM Leproust Emily M. Chief Executive Officer Apr 02 '24 Sale 32.74 1,132 37,057 514,149 Apr 04 04:05 PM Cho Dennis See Remarks Apr 02 '24 Sale 32.74 129 4,223 81,004 Apr 04 04:05 PM Green Paula SVP of Human Resources Apr 02 '24 Sale 32.74 229 7,497 92,421 Apr 04 04:05 PM Cho Dennis See Remarks Mar 20 '24 Sale 33.52 230 7,709 81,133 Mar 22 04:05 PM Banyai William See Remark Mar 20 '24 Sale 33.52 442 14,814 346,313 Mar 22 04:05 PM Leproust Emily M. Chief Executive Officer Mar 20 '24 Sale 33.52 1,128 37,806 515,281 Mar 22 04:05 PM Green Paula SVP of Human Resources Mar 20 '24 Sale 33.52 200 6,703 92,650 Mar 22 04:05 PM Cho Dennis See Remarks Mar 14 '24 Sale 34.60 93 3,218 81,363 Mar 18 04:05 PM Cho Dennis See Remarks Mar 06 '24 Sale 37.43 272 10,181 81,456 Mar 08 04:05 PM WERNER ROBERT F. Chief Accounting Officer Mar 06 '24 Sale 37.43 181 6,775 43,680 Mar 08 04:05 PM Leproust Emily M. Chief Executive Officer Mar 06 '24 Sale 37.43 1,487 55,658 516,409 Mar 08 04:05 PM Green Paula SVP of Human Resources Mar 06 '24 Sale 37.43 600 22,458 92,850 Mar 08 04:05 PM Banyai William See Remark Mar 06 '24 Sale 37.43 549 20,549 346,755 Mar 08 04:05 PM CHESS ROBERT Director Feb 08 '24 Sale 34.98 4,110 143,784 64,169 Feb 09 04:10 PM
Index RUT
P/E 22.95
EPS (ttm) 2.58
Insider Own 1.08%
Shs Outstand 126.77M
Perf Week -7.11%
Market Cap 7.50B
Forward P/E 12.36
EPS next Y 4.79
Insider Trans -14.12%
Shs Float 125.31M
Perf Month 9.41%
Income 337.29M
PEG 0.82
EPS next Q 1.00
Inst Own 97.25%
Short Float 7.72%
Perf Quarter 15.10%
Sales 873.30M
P/S 8.59
EPS this Y 43.05%
Inst Trans 3.82%
Short Ratio 6.90
Perf Half Y 41.96%
Book/sh 2.29
P/B 25.89
EPS next Y 20.92%
ROA 17.85%
Short Interest 9.67M
Perf Year 44.34%
Cash/sh 4.18
P/C 14.18
EPS next 5Y 28.00%
ROE 153.16%
52W Range 32.83 - 65.53
Perf YTD 60.20%
Dividend Est. -
P/FCF 18.37
EPS past 5Y -
ROI 18.82%
52W High -9.65%
Beta 1.28
Dividend TTM -
Quick Ratio 6.21
Sales past 5Y 41.16%
Gross Margin 71.52%
52W Low 80.35%
ATR (14) 1.85
Dividend Ex-Date -
Current Ratio 7.41
EPS Y/Y TTM 50.71%
Oper. Margin 46.04%
RSI (14) 48.88
Volatility 3.51% 3.01%
Employees 373
Debt/Eq 5.30
Sales Y/Y TTM 12.88%
Profit Margin 38.62%
Recom 1.73
Target Price 59.10
Option/Short Yes / Yes
LT Debt/Eq 5.19
EPS Q/Q 28.90%
Payout 0.00%
Rel Volume 0.76
Prev Close 61.05
Sales Surprise 12.89%
EPS Surprise 23.17%
Sales Q/Q 4.67%
Earnings Aug 06 AMC
Avg Volume 1.40M
Price 59.21
SMA20 -2.02%
SMA50 5.08%
SMA200 33.87%
Trades
Volume 1,061,676
Change -3.01%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-07-24 Downgrade
Piper Sandler
Overweight → Neutral
$48 → $51
Feb-29-24 Initiated
TD Cowen
Outperform
$54
Jul-24-23 Initiated
H.C. Wainwright
Buy
$61
Jul-24-23 Downgrade
Goldman
Buy → Neutral
$43 → $45
May-10-23 Upgrade
Piper Sandler
Neutral → Overweight
$46
Mar-27-23 Resumed
Berenberg
Buy
$58
Mar-16-23 Downgrade
SVB Securities
Outperform → Market Perform
$42
Dec-21-22 Resumed
Morgan Stanley
Overweight
$53 → $65
Nov-28-22 Initiated
Wells Fargo
Overweight
$65
Sep-09-22 Initiated
Morgan Stanley
Overweight
$50
May-23-22 Initiated
SVB Leerink
Outperform
$52
Jun-14-21 Initiated
Evercore ISI
Outperform
May-17-21 Initiated
SVB Leerink
Outperform
$56
May-11-21 Downgrade
Piper Sandler
Overweight → Neutral
$50 → $48
Jan-21-21 Reiterated
The Benchmark Company
Buy
$46 → $59
Dec-17-20 Initiated
Berenberg
Buy
$50
Sep-14-20 Resumed
JP Morgan
Overweight
$28
Jul-01-20 Initiated
The Benchmark Company
Buy
$39
Feb-05-20 Upgrade
Piper Sandler
Neutral → Overweight
$18 → $27
Jan-09-20 Upgrade
BMO Capital Markets
Market Perform → Outperform
$17 → $24
Show Previous Ratings
Sep-05-24 11:31AM
Sep-02-24 09:50AM
Aug-28-24 08:30AM
Aug-27-24 09:40AM
Aug-23-24 03:03PM
07:01PM
Loading…
Aug-14-24 07:01PM
Aug-12-24 04:37PM
Aug-07-24 04:11PM
(Investor's Business Daily)
10:39AM
Aug-06-24 06:30PM
05:50PM
04:45PM
(Associated Press Finance)
04:19PM
(Investor's Business Daily)
04:01PM
Aug-05-24 09:16AM
01:33PM
Loading…
Aug-04-24 01:33PM
Jul-26-24 09:45AM
Jul-23-24 09:40AM
08:30AM
Jul-18-24 07:00AM
Jul-16-24 05:11PM
Jul-15-24 09:04PM
Jul-09-24 12:45PM
Jul-08-24 12:42PM
Jul-05-24 06:20AM
Jul-03-24 08:00AM
(Investor's Business Daily)
Jul-01-24 10:02AM
Jun-25-24 01:15AM
Jun-21-24 05:15PM
Jun-17-24 09:40AM
04:00PM
Loading…
Jun-15-24 04:00PM
Jun-13-24 07:00PM
Jun-11-24 01:13PM
09:50AM
09:06AM
Jun-07-24 01:52PM
(Investor's Business Daily)
08:59AM
Jun-06-24 11:31AM
09:31AM
08:30AM
Jun-05-24 04:05PM
Jun-04-24 04:30PM
May-31-24 09:40AM
May-21-24 07:15AM
May-20-24 09:50AM
May-16-24 02:55PM
(Investor's Business Daily)
09:45AM
May-10-24 12:39PM
(Investor's Business Daily)
May-09-24 10:26AM
06:15AM
May-08-24 03:10PM
10:34AM
08:30AM
07:05AM
(Thomson Reuters StreetEvents)
03:52AM
May-07-24 09:00PM
06:00PM
05:49PM
05:48PM
05:25PM
04:23PM
(Associated Press Finance)
04:01PM
May-06-24 09:16AM
May-03-24 04:17AM
Apr-30-24 10:01AM
Apr-25-24 04:45PM
06:00AM
Apr-24-24 09:45AM
Apr-23-24 08:30AM
Apr-19-24 12:13PM
Apr-18-24 12:45PM
12:00PM
Apr-04-24 09:40AM
Mar-29-24 06:40AM
Mar-21-24 11:30AM
Mar-19-24 09:40AM
Mar-14-24 01:24AM
Mar-13-24 02:25PM
Mar-12-24 02:05AM
Mar-09-24 01:07PM
Feb-29-24 03:15AM
Feb-27-24 08:30AM
Feb-21-24 11:26AM
09:00AM
06:56AM
(Thomson Reuters StreetEvents)
Feb-20-24 05:30PM
05:10PM
04:36PM
04:15PM
(Associated Press Finance)
04:01PM
Feb-14-24 09:15AM
06:49AM
Feb-13-24 10:00AM
Feb-08-24 04:30PM
Jan-29-24 04:15PM
Jan-26-24 09:45AM
Jan-25-24 05:29PM
Jan-24-24 12:10PM
Jan-22-24 09:40AM
Jan-18-24 05:01PM
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 27 '24 Option Exercise 18.41 5,580 102,728 173,756 Aug 27 07:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 20 '24 Option Exercise 16.65 10,000 166,500 178,176 Aug 21 06:03 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 21 '24 Option Exercise 16.65 10,000 166,500 178,176 Aug 21 06:03 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 21 '24 Sale 61.75 10,000 617,470 168,176 Aug 21 06:03 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Aug 20 '24 Sale 61.05 10,000 610,550 168,176 Aug 21 06:03 PM MICHAEL LABARRE Officer Aug 21 '24 Proposed Sale 61.75 10,000 617,474 Aug 21 04:11 PM MICHAEL LABARRE Officer Aug 20 '24 Proposed Sale 61.06 10,000 610,553 Aug 20 04:16 PM Torley Helen PRESIDENT AND CEO Aug 13 '24 Option Exercise 13.87 10,000 138,700 686,744 Aug 15 04:59 PM Torley Helen PRESIDENT AND CEO Aug 14 '24 Option Exercise 13.87 10,000 138,700 686,744 Aug 15 04:59 PM Torley Helen PRESIDENT AND CEO Aug 15 '24 Option Exercise 13.87 10,000 138,700 686,744 Aug 15 04:59 PM Torley Helen PRESIDENT AND CEO Aug 15 '24 Sale 57.95 10,000 579,490 676,744 Aug 15 04:59 PM Torley Helen PRESIDENT AND CEO Aug 14 '24 Sale 57.25 10,000 572,471 676,744 Aug 15 04:59 PM Torley Helen PRESIDENT AND CEO Aug 13 '24 Sale 56.25 10,000 562,490 676,744 Aug 15 04:59 PM HELEN TORLEY Officer Aug 15 '24 Proposed Sale 57.95 10,000 579,488 Aug 15 04:31 PM Posard Matthew L. Director Aug 14 '24 Sale 57.70 9,881 570,134 69,874 Aug 14 04:57 PM Posard Matthew L. Director Aug 13 '24 Sale 56.19 10,000 561,930 79,755 Aug 14 04:57 PM Posard Matthew L. Director Aug 12 '24 Sale 55.72 10,000 557,230 89,755 Aug 14 04:57 PM HELEN TORLEY Officer Aug 14 '24 Proposed Sale 57.25 10,000 572,472 Aug 14 04:08 PM HELEN TORLEY Officer Aug 13 '24 Proposed Sale 56.25 10,000 562,496 Aug 13 04:19 PM Posard Matthew L. affiliate Aug 13 '24 Proposed Sale 54.15 30,000 1,624,500 Aug 07 04:41 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jul 24 '24 Option Exercise 15.19 10,000 151,854 178,176 Jul 24 05:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jul 23 '24 Option Exercise 8.11 10,000 81,100 178,176 Jul 24 05:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jul 24 '24 Sale 55.12 10,000 551,150 168,176 Jul 24 05:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jul 23 '24 Sale 54.89 10,000 548,873 168,176 Jul 24 05:48 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jul 22 '24 Option Exercise 22.50 5,000 112,500 19,488 Jul 23 04:37 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jul 22 '24 Sale 53.93 5,000 269,662 15,480 Jul 23 04:37 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jun 26 '24 Option Exercise 22.50 10,000 225,000 25,480 Jun 28 04:06 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jun 27 '24 Option Exercise 22.50 10,000 225,000 25,480 Jun 28 04:06 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jun 28 '24 Option Exercise 22.50 10,000 225,000 25,480 Jun 28 04:06 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jun 28 '24 Sale 52.04 10,000 520,400 15,480 Jun 28 04:06 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jun 27 '24 Sale 51.93 10,000 519,340 15,480 Jun 28 04:06 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Jun 26 '24 Sale 51.82 10,000 518,200 15,480 Jun 28 04:06 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jun 18 '24 Option Exercise 8.11 10,000 81,100 178,176 Jun 20 04:17 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jun 18 '24 Sale 49.43 10,000 494,260 168,176 Jun 20 04:17 PM Posard Matthew L. Director Jun 12 '24 Sale 50.62 10,000 506,190 99,755 Jun 13 04:15 PM Posard Matthew L. Director Jun 11 '24 Sale 50.01 10,000 500,110 109,755 Jun 13 04:15 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 22 '24 Option Exercise 8.11 10,000 81,100 178,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 21 '24 Option Exercise 8.11 10,000 81,100 178,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 22 '24 Sale 45.38 10,000 453,840 168,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER May 21 '24 Sale 45.16 10,000 451,640 168,176 May 22 05:24 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 16 '24 Option Exercise 8.11 10,000 81,100 178,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 17 '24 Option Exercise 8.11 10,000 81,100 178,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 17 '24 Sale 38.49 10,000 384,890 168,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Apr 16 '24 Sale 38.35 10,000 383,500 168,176 Apr 17 07:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 26 '24 Option Exercise 11.20 11,618 130,160 168,176 Mar 26 07:38 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 12 '24 Option Exercise 12.07 10,000 120,700 166,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 13 '24 Option Exercise 10.66 10,000 106,638 166,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 13 '24 Sale 42.27 10,000 422,730 156,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Mar 12 '24 Sale 41.64 10,000 416,370 156,558 Mar 13 05:22 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 28 '24 Option Exercise 8.11 7,471 60,590 164,029 Feb 28 06:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 27 '24 Sale 39.95 10,000 399,460 159,087 Feb 28 06:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 28 '24 Sale 39.55 10,000 395,463 156,558 Feb 28 06:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 16 '24 Option Exercise 0.00 10,376 0 171,247 Feb 20 06:59 PM Snyder Mark Howard SVP, GENERAL COUNSEL Feb 16 '24 Option Exercise 0.00 4,796 0 14,257 Feb 20 06:55 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Feb 16 '24 Option Exercise 0.00 10,422 0 18,344 Feb 20 06:53 PM Torley Helen PRESIDENT AND CEO Feb 16 '24 Option Exercise 0.00 37,884 0 685,814 Feb 20 06:49 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 15 '24 Option Exercise 0.00 3,386 0 160,529 Feb 16 05:47 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Feb 15 '24 Option Exercise 0.00 1,254 0 11,345 Feb 16 05:41 PM Torley Helen PRESIDENT AND CEO Feb 15 '24 Option Exercise 0.00 13,092 0 651,096 Feb 16 05:39 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Feb 10 '24 Option Exercise 0.00 8,133 0 160,044 Feb 13 04:18 PM LaBrosse Nicole SVP, CHIEF FINANCIAL OFFICER Feb 10 '24 Option Exercise 0.00 2,502 0 11,568 Feb 13 04:15 PM Torley Helen PRESIDENT AND CEO Feb 10 '24 Option Exercise 0.00 31,281 0 654,947 Feb 13 04:12 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 16 '24 Option Exercise 12.07 10,000 120,700 161,911 Jan 18 04:07 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 17 '24 Option Exercise 12.07 10,000 120,700 161,911 Jan 18 04:07 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 17 '24 Sale 36.00 10,000 360,000 151,911 Jan 18 04:07 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Jan 16 '24 Sale 36.00 10,000 360,000 151,911 Jan 18 04:07 PM Snyder Mark Howard SVP, GENERAL COUNSEL Jan 03 '24 Option Exercise 0.00 7,611 0 12,418 Jan 05 04:04 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 12 '23 Option Exercise 13.55 10,000 135,547 161,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 13 '23 Option Exercise 12.07 10,000 120,700 161,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 13 '23 Sale 40.39 10,000 403,940 151,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Dec 12 '23 Sale 39.63 10,000 396,322 151,911 Dec 13 07:48 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 14 '23 Option Exercise 14.32 10,000 143,173 160,203 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 15 '23 Option Exercise 13.81 10,000 138,100 161,911 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 15 '23 Sale 39.79 10,000 397,880 151,911 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Nov 14 '23 Sale 39.08 10,000 390,790 151,911 Nov 16 04:18 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Oct 17 '23 Option Exercise 19.98 10,000 199,800 161,911 Oct 17 07:28 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Oct 17 '23 Sale 36.52 10,000 365,200 151,911 Oct 17 07:28 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Sep 19 '23 Option Exercise 19.98 10,000 199,800 161,911 Sep 19 04:09 PM LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER Sep 19 '23 Sale 39.10 10,000 390,980 151,911 Sep 19 04:09 PM
Index RUT
P/E -
EPS (ttm) -4.76
Insider Own 4.26%
Shs Outstand 111.61M
Perf Week 40.74%
Market Cap 12.45B
Forward P/E -
EPS next Y -4.95
Insider Trans -4.41%
Shs Float 106.86M
Perf Month 58.22%
Income -497.19M
PEG -
EPS next Q -1.12
Inst Own 106.93%
Short Float 10.52%
Perf Quarter 53.88%
Sales 0.00M
P/S -
EPS this Y -4.84%
Inst Trans 5.42%
Short Ratio 12.32
Perf Half Y 55.49%
Book/sh 17.96
P/B 6.21
EPS next Y -14.12%
ROA -27.70%
Short Interest 11.24M
Perf Year 119.65%
Cash/sh 13.02
P/C 8.57
EPS next 5Y -
ROE -29.08%
52W Range 44.20 - 119.27
Perf YTD 77.68%
Dividend Est. -
P/FCF -
EPS past 5Y -46.98%
ROI -24.80%
52W High -6.45%
Beta 0.84
Dividend TTM -
Quick Ratio 17.88
Sales past 5Y 0.00%
Gross Margin -
52W Low 152.44%
ATR (14) 5.27
Dividend Ex-Date -
Current Ratio 17.88
EPS Y/Y TTM -41.53%
Oper. Margin 0.00%
RSI (14) 83.72
Volatility 6.30% 3.64%
Employees 254
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 137.86
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -57.50%
Payout -
Rel Volume 2.56
Prev Close 112.10
Sales Surprise -
EPS Surprise -12.75%
Sales Q/Q -
Earnings Aug 06 AMC
Avg Volume 912.56K
Price 111.58
SMA20 34.06%
SMA50 37.73%
SMA200 59.77%
Trades
Volume 2,332,437
Change -0.46%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-07-23 Initiated
Mizuho
Buy
$69
Apr-18-23 Initiated
TD Cowen
Outperform
Jan-03-23 Reiterated
Needham
Buy
$52 → $58
Dec-15-22 Initiated
Guggenheim
Buy
$66
Nov-17-22 Initiated
BTIG Research
Buy
$69
Dec-29-21 Resumed
Jefferies
Buy
$50
Jun-24-21 Resumed
Jefferies
Buy
$50
Jul-07-20 Initiated
Needham
Buy
$40
Jul-07-20 Initiated
Cantor Fitzgerald
Overweight
$55
Jul-07-20 Initiated
BofA Securities
Buy
$37
Sep-06-24 04:05PM
07:00AM
Sep-04-24 11:58PM
Sep-03-24 06:06PM
04:09PM
(Investor's Business Daily)
04:01PM
Loading…
04:01PM
01:22PM
(The Wall Street Journal)
11:43AM
10:48AM
09:40AM
09:07AM
(Investor's Business Daily)
08:10AM
07:07AM
Sep-02-24 06:40PM
Aug-06-24 04:05PM
07:02PM
Loading…
Aug-05-24 07:02PM
Jul-31-24 09:55AM
Jul-29-24 12:00PM
Jul-02-24 07:01PM
08:30AM
May-10-24 12:32PM
May-08-24 10:55PM
04:05PM
May-04-24 02:31AM
Apr-22-24 04:46PM
Apr-02-24 04:05PM
Mar-26-24 09:02PM
Mar-20-24 07:01PM
Mar-17-24 08:50AM
Mar-04-24 08:30AM
12:08PM
Loading…
Feb-28-24 12:08PM
(Thomson Reuters StreetEvents) -7.33%
12:00PM
09:57AM
Feb-27-24 04:01PM
Feb-26-24 08:32AM
Feb-25-24 11:05AM
Feb-22-24 11:28PM
Feb-15-24 04:05PM
Feb-02-24 11:12PM
06:39PM
Feb-01-24 11:02PM
04:05PM
Jan-30-24 11:37PM
04:01PM
Jan-29-24 08:30AM
Jan-19-24 08:28PM
Jan-16-24 04:01PM
Jan-04-24 04:01PM
Dec-21-23 05:01PM
Dec-04-23 06:35PM
Nov-28-23 08:30AM
Nov-27-23 04:00PM
Nov-23-23 11:04AM
Nov-09-23 08:30AM
Nov-06-23 05:19PM
04:03PM
Nov-03-23 11:54PM
Oct-31-23 04:05PM
Oct-20-23 09:55PM
Oct-19-23 08:30AM
Oct-16-23 08:00AM
Oct-04-23 11:00PM
Sep-19-23 04:05PM
Sep-11-23 08:21AM
Sep-08-23 04:44PM
(American City Business Journals)
Aug-08-23 04:03PM
Jul-11-23 08:30AM
Jul-01-23 09:05AM
Jun-13-23 09:30AM
Jun-01-23 04:05PM
May-29-23 09:55AM
May-12-23 09:55AM
May-08-23 04:03PM
May-03-23 04:05PM
Apr-21-23 05:25PM
Apr-19-23 11:36AM
12:26AM
Apr-18-23 12:56PM
Apr-17-23 04:05PM
06:30AM
Apr-16-23 05:00PM
Mar-30-23 08:30AM
Mar-12-23 11:55PM
Feb-27-23 04:01PM
Feb-21-23 08:30AM
Feb-16-23 04:05PM
Feb-07-23 04:05PM
Jan-22-23 07:39AM
Jan-05-23 08:30AM
Jan-03-23 12:34PM
Dec-20-22 04:05PM
Dec-11-22 07:21PM
Nov-07-22 04:10PM
Nov-03-22 08:30AM
Oct-31-22 02:58PM
(The Wall Street Journal)
Oct-30-22 09:13AM
Oct-29-22 11:03AM
Oct-28-22 04:01PM
Oct-26-22 02:13PM
10:55AM
(American City Business Journals)
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wassil Jim CHIEF OPERATING OFFICER Sep 03 '24 Option Exercise 2.42 10,000 24,200 217,503 Sep 05 05:19 PM Wassil Jim CHIEF OPERATING OFFICER Sep 03 '24 Sale 111.93 10,000 1,119,252 207,503 Sep 05 05:19 PM Cowan Elvia SVP, FINANCE Sep 03 '24 Option Exercise 25.92 5,000 129,600 17,723 Sep 05 05:15 PM Cowan Elvia SVP, FINANCE Sep 03 '24 Sale 107.67 5,000 538,350 12,723 Sep 05 05:15 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Sep 03 '24 Option Exercise 21.41 1,667 35,690 32,493 Sep 05 05:13 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Sep 03 '24 Sale 112.11 1,667 186,880 30,826 Sep 05 05:13 PM Cowan Elvia Officer Sep 03 '24 Proposed Sale 107.67 5,000 538,350 Sep 03 04:08 PM Wassil Jim Officer Sep 03 '24 Proposed Sale 107.67 10,000 1,076,700 Sep 03 04:07 PM Eydelman Mikhail Officer Sep 03 '24 Proposed Sale 107.67 1,667 179,485 Sep 03 04:04 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Aug 23 '24 Option Exercise 2.03 15,000 30,450 493,888 Aug 26 04:58 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Aug 23 '24 Sale 78.98 15,000 1,184,767 478,888 Aug 26 04:58 PM PICKERING GRANT Officer Aug 23 '24 Proposed Sale 78.89 15,000 1,183,350 Aug 23 04:03 PM GUGGENHIME ANDREW PRESIDENT AND CFO Aug 19 '24 Option Exercise 5.35 8,000 42,800 104,720 Aug 20 04:49 PM GUGGENHIME ANDREW PRESIDENT AND CFO Aug 19 '24 Sale 78.58 8,000 628,650 96,720 Aug 20 04:49 PM GUGGENHIME ANDREW Officer Aug 19 '24 Proposed Sale 78.91 8,000 631,280 Aug 19 04:05 PM Wassil Jim CHIEF OPERATING OFFICER Aug 01 '24 Sale 78.84 3,000 236,527 207,503 Aug 05 04:10 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Aug 01 '24 Sale 78.79 2,616 206,122 142,130 Aug 05 04:08 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Aug 01 '24 Option Exercise 21.41 1,667 35,690 32,493 Aug 05 04:06 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Aug 01 '24 Sale 78.85 1,667 131,449 30,826 Aug 05 04:06 PM PICKERING GRANT Officer Aug 01 '24 Proposed Sale 78.80 2,616 206,141 Aug 01 04:04 PM Wassil Jim Officer Aug 01 '24 Proposed Sale 78.80 3,000 236,400 Aug 01 04:02 PM Eydelman Mikhail Officer Aug 01 '24 Proposed Sale 78.80 1,667 131,360 Aug 01 04:01 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jul 23 '24 Option Exercise 2.03 15,000 30,450 493,888 Jul 24 05:44 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jul 23 '24 Sale 84.26 15,000 1,263,912 478,888 Jul 24 05:44 PM GUGGENHIME ANDREW PRESIDENT AND CFO Jul 18 '24 Option Exercise 5.35 8,000 42,800 104,720 Jul 22 04:03 PM GUGGENHIME ANDREW PRESIDENT AND CFO Jul 18 '24 Sale 81.17 8,000 649,325 96,720 Jul 22 04:03 PM Cowan Elvia SVP, FINANCE Jul 16 '24 Option Exercise 25.92 5,000 129,600 17,723 Jul 17 04:03 PM Cowan Elvia SVP, FINANCE Jul 16 '24 Sale 85.00 5,000 425,000 12,723 Jul 17 04:03 PM Cowan Elvia SVP, FINANCE Jul 08 '24 Option Exercise 25.92 5,000 129,600 17,723 Jul 09 05:15 PM Cowan Elvia SVP, FINANCE Jul 08 '24 Sale 80.00 5,000 400,000 12,723 Jul 09 05:15 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Jul 01 '24 Option Exercise 21.41 1,667 35,690 32,493 Jul 02 04:17 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Jul 01 '24 Sale 76.37 1,667 127,304 30,826 Jul 02 04:17 PM Wassil Jim CHIEF OPERATING OFFICER Jul 01 '24 Sale 76.34 3,000 229,013 210,503 Jul 02 04:16 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jul 01 '24 Sale 76.33 2,616 199,690 143,438 Jul 02 04:12 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jun 24 '24 Option Exercise 2.03 15,000 30,450 493,888 Jun 25 04:43 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jun 24 '24 Sale 75.64 15,000 1,134,579 478,888 Jun 25 04:43 PM GUGGENHIME ANDREW PRESIDENT AND CFO Jun 18 '24 Option Exercise 5.35 8,000 42,800 104,720 Jun 20 08:30 PM GUGGENHIME ANDREW PRESIDENT AND CFO Jun 18 '24 Sale 71.92 8,000 575,375 96,720 Jun 20 08:30 PM Gilbert Halley E Director Jun 03 '24 Option Exercise 5.35 18,200 97,370 23,825 Jun 05 04:59 PM Gilbert Halley E Director Jun 03 '24 Sale 73.00 18,200 1,328,600 5,625 Jun 05 04:59 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Jun 03 '24 Option Exercise 21.41 1,667 35,690 32,828 Jun 05 04:58 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Jun 03 '24 Sale 72.06 1,667 120,127 31,161 Jun 05 04:58 PM Wassil Jim CHIEF OPERATING OFFICER Jun 03 '24 Sale 71.99 3,000 215,961 213,503 Jun 05 04:57 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jun 03 '24 Sale 72.06 2,616 188,512 144,746 Jun 05 04:56 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER May 23 '24 Option Exercise 2.03 15,000 30,450 492,847 May 28 04:22 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER May 23 '24 Sale 69.43 15,000 1,041,408 477,847 May 28 04:22 PM GUGGENHIME ANDREW PRESIDENT AND CFO May 20 '24 Option Exercise 5.35 8,000 42,800 103,679 May 22 05:03 PM GUGGENHIME ANDREW PRESIDENT AND CFO May 20 '24 Sale 74.99 8,000 599,909 95,679 May 22 05:03 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC May 01 '24 Option Exercise 21.41 1,667 35,690 32,264 May 03 04:20 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC May 01 '24 Sale 61.74 1,667 102,921 30,597 May 03 04:20 PM Wassil Jim CHIEF OPERATING OFFICER May 01 '24 Sale 61.65 3,000 184,942 215,462 May 03 04:19 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER May 01 '24 Sale 61.70 2,616 161,419 146,054 May 03 04:18 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Apr 23 '24 Option Exercise 1.79 15,000 26,850 492,847 Apr 25 04:52 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Apr 23 '24 Sale 61.92 15,000 928,845 477,847 Apr 25 04:52 PM GUGGENHIME ANDREW PRESIDENT AND CFO Apr 18 '24 Option Exercise 5.35 8,000 42,800 103,679 Apr 22 04:42 PM GUGGENHIME ANDREW PRESIDENT AND CFO Apr 18 '24 Sale 61.27 8,000 490,199 95,679 Apr 22 04:42 PM Wassil Jim CHIEF OPERATING OFFICER Apr 17 '24 Option Exercise 5.35 3,551 18,998 221,840 Apr 19 04:31 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Apr 01 '24 Option Exercise 21.41 1,667 35,690 32,264 Apr 03 04:22 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Apr 01 '24 Sale 66.73 1,667 111,234 30,597 Apr 03 04:22 PM Wassil Jim CHIEF OPERATING OFFICER Apr 01 '24 Sale 66.69 3,000 200,066 218,289 Apr 03 04:22 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Apr 01 '24 Sale 66.71 2,616 174,502 147,362 Apr 03 04:21 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Mar 25 '24 Option Exercise 1.79 15,000 26,850 492,847 Mar 27 04:44 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Mar 25 '24 Sale 66.93 15,000 1,003,978 477,847 Mar 27 04:44 PM GUGGENHIME ANDREW PRESIDENT AND CFO Mar 18 '24 Option Exercise 5.35 8,000 42,800 103,679 Mar 20 04:29 PM GUGGENHIME ANDREW PRESIDENT AND CFO Mar 18 '24 Sale 69.02 8,000 552,144 95,679 Mar 20 04:29 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Mar 11 '24 Option Exercise 2.03 65,000 131,950 477,847 Mar 13 04:22 PM Wassil Jim CHIEF OPERATING OFFICER Mar 01 '24 Sale 73.71 3,000 221,134 220,852 Mar 04 09:23 PM Cowan Elvia SVP, FINANCE Mar 01 '24 Option Exercise 25.92 11,000 285,120 24,158 Mar 04 09:22 PM Cowan Elvia SVP, FINANCE Mar 01 '24 Sale 74.08 11,678 865,070 12,480 Mar 04 09:22 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Mar 01 '24 Option Exercise 21.41 1,667 35,690 32,877 Mar 04 09:21 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Mar 01 '24 Sale 73.73 1,667 122,907 31,210 Mar 04 09:21 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Mar 01 '24 Sale 73.70 2,616 192,799 148,670 Mar 04 09:19 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Feb 26 '24 Option Exercise 1.79 30,000 53,700 405,814 Feb 27 04:17 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Feb 23 '24 Option Exercise 1.79 15,000 26,850 390,814 Feb 27 04:17 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Feb 26 '24 Sale 79.03 30,000 2,370,900 375,814 Feb 27 04:17 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Feb 23 '24 Sale 76.21 15,000 1,143,206 375,814 Feb 27 04:17 PM GUGGENHIME ANDREW PRESIDENT AND CFO Feb 20 '24 Option Exercise 5.35 8,000 42,800 87,474 Feb 22 04:30 PM GUGGENHIME ANDREW PRESIDENT AND CFO Feb 20 '24 Sale 74.53 8,000 596,232 79,474 Feb 22 04:30 PM Wassil Jim CHIEF OPERATING OFFICER Feb 15 '24 Option Exercise 2.42 27,917 67,559 203,852 Feb 20 04:22 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Feb 01 '24 Option Exercise 21.41 1,667 35,690 22,377 Feb 05 05:39 PM Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC Feb 01 '24 Sale 73.87 1,667 123,144 20,710 Feb 05 05:39 PM Wassil Jim CHIEF OPERATING OFFICER Feb 01 '24 Option Exercise 2.42 3,000 7,260 178,935 Feb 05 05:37 PM Wassil Jim CHIEF OPERATING OFFICER Feb 01 '24 Sale 73.88 3,000 221,626 175,935 Feb 05 05:37 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Feb 01 '24 Sale 73.91 2,616 193,353 149,978 Feb 05 05:33 PM Lukatch Heath Director Jan 31 '24 Option Exercise 16.00 5,000 80,000 10,625 Feb 02 04:40 PM Lukatch Heath Director Jan 31 '24 Sale 71.50 5,000 357,500 5,625 Feb 02 04:40 PM Lukatch Heath Director Jan 29 '24 Option Exercise 16.00 4,000 64,000 9,625 Jan 31 04:12 PM Lukatch Heath Director Jan 29 '24 Sale 67.50 4,000 270,000 5,625 Jan 31 04:12 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jan 29 '24 Option Exercise 1.79 30,000 53,700 405,814 Jan 31 04:11 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jan 29 '24 Sale 66.03 30,000 1,980,900 375,814 Jan 31 04:11 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jan 23 '24 Option Exercise 1.44 15,000 21,600 390,814 Jan 25 05:50 PM PICKERING GRANT CHIEF EXECUTIVE OFFICER Jan 23 '24 Sale 63.92 15,000 958,783 375,814 Jan 25 05:50 PM GUGGENHIME ANDREW PRESIDENT AND CFO Jan 18 '24 Option Exercise 5.35 8,000 42,800 87,474 Jan 19 04:17 PM GUGGENHIME ANDREW PRESIDENT AND CFO Jan 18 '24 Sale 60.73 8,000 485,879 79,474 Jan 19 04:17 PM Lukatch Heath Director Jan 02 '24 Option Exercise 16.00 13,000 208,000 18,625 Jan 04 04:26 PM Lukatch Heath Director Jan 02 '24 Sale 63.76 13,000 828,915 5,625 Jan 04 04:26 PM Eydelman Mikhail SVP, Gen Counsel & Corp Sec Jan 02 '24 Option Exercise 21.41 1,667 35,690 22,377 Jan 04 04:26 PM Eydelman Mikhail SVP, Gen Counsel & Corp Sec Jan 02 '24 Sale 63.93 1,667 106,579 20,710 Jan 04 04:26 PM Wassil Jim Chief Operating Officer Jan 02 '24 Option Exercise 2.42 3,000 7,260 178,935 Jan 04 04:25 PM Wassil Jim Chief Operating Officer Jan 02 '24 Sale 63.91 3,000 191,741 175,935 Jan 04 04:25 PM
Index -
P/E -
EPS (ttm) -0.91
Insider Own 2.87%
Shs Outstand 75.80M
Perf Week -0.53%
Market Cap 142.50M
Forward P/E -
EPS next Y -0.78
Insider Trans 9.02%
Shs Float 73.62M
Perf Month 5.62%
Income -57.90M
PEG -
EPS next Q -0.22
Inst Own 63.45%
Short Float 0.47%
Perf Quarter 1.08%
Sales 0.59M
P/S 241.53
EPS this Y 6.21%
Inst Trans 0.55%
Short Ratio 0.91
Perf Half Y 13.25%
Book/sh 1.08
P/B 1.75
EPS next Y 11.34%
ROA -48.51%
Short Interest 0.35M
Perf Year 13.94%
Cash/sh 1.04
P/C 1.82
EPS next 5Y 13.00%
ROE -61.64%
52W Range 1.08 - 2.50
Perf YTD 33.33%
Dividend Est. -
P/FCF -
EPS past 5Y 43.36%
ROI -61.41%
52W High -24.80%
Beta 1.22
Dividend TTM -
Quick Ratio 7.63
Sales past 5Y 436.18%
Gross Margin -334.18%
52W Low 74.06%
ATR (14) 0.13
Dividend Ex-Date -
Current Ratio 7.63
EPS Y/Y TTM 26.39%
Oper. Margin -10633.50%
RSI (14) 52.34
Volatility 7.16% 6.47%
Employees 59
Debt/Eq 0.17
Sales Y/Y TTM -94.34%
Profit Margin -9846.43%
Recom 1.00
Target Price 22.00
Option/Short Yes / Yes
LT Debt/Eq 0.16
EPS Q/Q -0.85%
Payout -
Rel Volume 2.02
Prev Close 1.75
Sales Surprise -100.00%
EPS Surprise 9.20%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 381.62K
Price 1.88
SMA20 1.38%
SMA50 4.47%
SMA200 11.21%
Trades
Volume 772,336
Change 7.43%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-05-24 Initiated
Jefferies
Buy
$9
Jul-05-23 Downgrade
Oppenheimer
Outperform → Perform
Oct-12-21 Initiated
RBC Capital Mkts
Outperform
$22
Sep-21-21 Initiated
Piper Sandler
Overweight
$19
May-10-21 Initiated
Laidlaw
Buy
$18
Aug-17-20 Upgrade
H.C. Wainwright
Neutral → Buy
$13
Mar-04-20 Initiated
ROTH Capital
Buy
$15
Mar-02-20 Initiated
Oppenheimer
Outperform
$8
Feb-14-18 Downgrade
JP Morgan
Neutral → Underweight
Sep-07-17 Initiated
Piper Jaffray
Overweight
$7
Dec-13-16 Downgrade
JP Morgan
Overweight → Neutral
Dec-16-15 Initiated
Citigroup
Neutral
Jun-01-15 Initiated
JP Morgan
Overweight
$44
Jun-01-15 Initiated
Citigroup
Buy
$32
Show Previous Ratings
Aug-21-24 08:00AM
Aug-13-24 04:00PM
Aug-06-24 08:00AM
Jul-30-24 08:00AM
Jul-22-24 08:00AM
09:40AM
Loading…
Jun-18-24 09:40AM
Jun-10-24 10:52AM
Jun-05-24 03:17PM
Jun-03-24 08:00AM
May-24-24 04:00PM
May-15-24 07:00AM
May-14-24 08:00AM
May-06-24 08:00AM
May-02-24 09:58PM
04:15PM
(Associated Press Finance)
04:00PM
Loading…
04:00PM
Apr-01-24 08:00AM
Mar-26-24 02:19PM
Mar-15-24 01:33PM
11:30AM
(Thomson Reuters StreetEvents)
11:01AM
Mar-14-24 08:56PM
04:16PM
(Associated Press Finance)
04:00PM
Feb-28-24 08:00AM
Feb-21-24 08:00AM
Jan-29-24 08:00AM
Jan-18-24 08:00AM
Nov-13-23 08:00AM
Nov-09-23 04:07PM
(Associated Press Finance) -5.74%
04:00PM
Loading…
04:00PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Sep-11-23 08:00AM
Aug-30-23 09:35AM
Aug-24-23 08:00AM
Aug-09-23 05:30PM
04:29PM
(Associated Press Finance)
04:00PM
Jul-20-23 07:30AM
Jun-28-23 07:00AM
Jun-22-23 08:00AM
Jun-20-23 08:00AM
Jun-09-23 04:00PM
Jun-06-23 08:00AM
May-25-23 08:00AM
May-22-23 08:00AM
07:33AM
May-13-23 08:06AM
May-11-23 04:00PM
May-10-23 06:11AM
May-09-23 05:15PM
04:12PM
04:00PM
May-07-23 04:00AM
May-05-23 02:24PM
Apr-17-23 08:00AM
Mar-30-23 08:00AM
Mar-28-23 10:45AM
Mar-23-23 07:10AM
Mar-21-23 08:00AM
Mar-20-23 08:00AM
Mar-09-23 05:15PM
04:00PM
Mar-08-23 08:00AM
Mar-02-23 08:00AM
Mar-01-23 08:00AM
Feb-17-23 12:00PM
Feb-10-23 05:21AM
Feb-09-23 08:00AM
Feb-08-23 04:11PM
Feb-06-23 08:00AM
Jan-31-23 08:00AM
Jan-19-23 08:00AM
Jan-18-23 08:00AM
Dec-29-22 06:59PM
Dec-15-22 08:00AM
Nov-18-22 04:00PM
Nov-10-22 05:15PM
04:00PM
08:00AM
Nov-09-22 08:00AM
Nov-03-22 08:02AM
Oct-25-22 08:00AM
Oct-11-22 08:00AM
Oct-04-22 08:00AM
Sep-29-22 08:00AM
Sep-27-22 08:00AM
Sep-16-22 08:35AM
Sep-13-22 08:00AM
Sep-12-22 08:35AM
Sep-09-22 11:52AM
08:00AM
Sep-06-22 08:00AM
Sep-01-22 08:00AM
Aug-15-22 04:00PM
Aug-12-22 04:05PM
Aug-11-22 08:03AM
Aug-04-22 08:00AM
Jun-24-22 02:22PM
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SCHIMMEL PAUL Director Jul 24 '24 Buy 1.93 52,300 101,038 413,023 Jul 24 05:29 PM SCHIMMEL PAUL Director Jul 22 '24 Buy 1.74 41,052 71,500 354,075 Jul 24 05:29 PM SCHIMMEL PAUL Director Jul 23 '24 Buy 1.82 6,648 12,075 360,723 Jul 24 05:29 PM DENYES NANCY General Counsel Jun 05 '24 Buy 1.86 5,000 9,276 22,267 Jun 06 08:26 AM COUGHLIN TIMOTHY Director May 30 '24 Buy 1.75 50,000 87,500 56,000 Jun 03 04:21 PM Broadfoot Jill Marie Chief Financial Officer May 31 '24 Buy 1.79 5,000 8,950 27,960 Jun 03 08:38 AM Shukla Sanjay President and CEO May 31 '24 Buy 1.81 20,000 36,140 136,548 Jun 03 08:34 AM Broadfoot Jill Marie Chief Financial Officer Feb 06 '24 Sale 1.69 1,590 2,687 20,821 Feb 06 08:18 PM Shukla Sanjay President and CEO Dec 12 '23 Buy 1.18 12,000 14,136 106,173 Dec 12 06:50 PM Shukla Sanjay President and CEO Dec 11 '23 Buy 1.17 3,000 3,510 94,173 Dec 12 06:50 PM Shukla Sanjay President and CEO Nov 13 '23 Buy 1.11 13,578 15,085 91,173 Nov 13 04:11 PM Shukla Sanjay President and CEO Nov 10 '23 Buy 1.14 1,422 1,618 77,595 Nov 13 04:11 PM
Index -
P/E -
EPS (ttm) -
Insider Own 50.80%
Shs Outstand 17.58M
Perf Week 6.37%
Market Cap 291.97M
Forward P/E -
EPS next Y -
Insider Trans 111.43%
Shs Float 11.95M
Perf Month 6.37%
Income -
PEG -
EPS next Q -0.83
Inst Own 41.37%
Short Float 0.47%
Perf Quarter -
Sales -
P/S -
EPS this Y -
Inst Trans -
Short Ratio 0.45
Perf Half Y -
Book/sh -234.70
P/B -
EPS next Y -
ROA -
Short Interest 0.06M
Perf Year -
Cash/sh 1.92
P/C 6.27
EPS next 5Y -
ROE -
52W Range 9.71 - 16.00
Perf YTD 0.17%
Dividend Est. -
P/FCF -
EPS past 5Y -63.82%
ROI -
52W High -24.87%
Beta -
Dividend TTM -
Quick Ratio 4.59
Sales past 5Y 181.38%
Gross Margin -
52W Low 23.79%
ATR (14) 0.75
Dividend Ex-Date -
Current Ratio 4.59
EPS Y/Y TTM -
Oper. Margin -
RSI (14) 59.68
Volatility 8.64% 6.18%
Employees 77
Debt/Eq 0.62
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 21.25
Option/Short No / Yes
LT Debt/Eq 0.47
EPS Q/Q -3282.42%
Payout -
Rel Volume 0.52
Prev Close 11.91
Sales Surprise -100.00%
EPS Surprise -1579.39%
Sales Q/Q -100.00%
Earnings Aug 29 AMC
Avg Volume 127.03K
Price 12.02
SMA20 9.63%
SMA50 6.73%
SMA200 6.73%
Trades
Volume 65,745
Change 0.92%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Initiated
Wedbush
Outperform
$18
Aug-13-24 Initiated
TD Cowen
Buy
Aug-13-24 Initiated
Needham
Buy
$23
Aug-13-24 Initiated
Jefferies
Buy
$21
Aug-13-24 Initiated
Cantor Fitzgerald
Overweight
$23
Aug-29-24 04:05PM
Jul-18-24 07:08PM
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Jul 22 '24 Buy 12.00 8,333,333 99,999,996 8,693,579 Jul 24 04:27 PM 5AM Partners VI, LLC 10% Owner Jul 22 '24 Buy 12.00 833,333 9,999,996 1,182,054 Jul 24 04:15 PM venBio Global Strategic Fund I 10% Owner Jul 22 '24 Buy 12.00 416,666 4,999,992 1,936,637 Jul 22 08:26 PM GC Corp. 10% Owner Jul 22 '24 Buy 12.00 1,666,666 19,999,992 3,306,900 Jul 22 08:25 PM GC Corp. 10% Owner Jul 22 '24 Buy 12.00 416,666 4,999,992 1,260,512 Jul 22 08:25 PM Huh Yong-Jun Director Jul 22 '24 Buy 12.00 2,083,332 24,999,984 3,306,900 Jul 22 08:22 PM
Index -
P/E -
EPS (ttm) -0.23
Insider Own 9.15%
Shs Outstand 79.73M
Perf Week -19.15%
Market Cap 20.53M
Forward P/E -
EPS next Y -0.17
Insider Trans -0.86%
Shs Float 72.43M
Perf Month -6.33%
Income -12.75M
PEG -
EPS next Q -0.04
Inst Own 15.32%
Short Float 2.23%
Perf Quarter -37.67%
Sales 0.00M
P/S -
EPS this Y 62.50%
Inst Trans -0.71%
Short Ratio 2.96
Perf Half Y -25.98%
Book/sh -0.04
P/B -
EPS next Y -10.00%
ROA -223.03%
Short Interest 1.62M
Perf Year -83.81%
Cash/sh 0.04
P/C 5.92
EPS next 5Y -
ROE -1121.89%
52W Range 0.13 - 1.65
Perf YTD -5.68%
Dividend Est. -
P/FCF -
EPS past 5Y 10.57%
ROI -
52W High -84.39%
Beta 0.36
Dividend TTM -
Quick Ratio 0.50
Sales past 5Y 0.00%
Gross Margin -
52W Low 92.16%
ATR (14) 0.03
Dividend Ex-Date -
Current Ratio 0.50
EPS Y/Y TTM 62.05%
Oper. Margin 0.00%
RSI (14) 33.95
Volatility 9.94% 12.77%
Employees 29
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 2.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 73.40%
Payout -
Rel Volume 0.88
Prev Close 0.28
Sales Surprise -
EPS Surprise 214.29%
Sales Q/Q -
Earnings Aug 14 BMO
Avg Volume 545.99K
Price 0.26
SMA20 -18.12%
SMA50 -23.86%
SMA200 -32.64%
Trades
Volume 480,292
Change -7.04%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-04-21 Upgrade
Maxim Group
Hold → Buy
$12
Nov-17-20 Downgrade
Maxim Group
Buy → Hold
Dec-19-16 Reiterated
Maxim Group
Buy
$5 → $6
Dec-22-15 Reiterated
Maxim Group
Buy
$14 → $5
Aug-14-24 07:05AM
Aug-07-24 06:00AM
Jul-24-24 08:30AM
Jul-01-24 06:00AM
Jun-27-24 09:15AM
08:00AM
Loading…
Jun-26-24 08:00AM
Jun-20-24 06:00AM
Jun-14-24 12:01PM
May-20-24 06:00AM
May-14-24 10:53PM
04:30PM
May-01-24 07:31AM
Apr-16-24 06:30PM
Apr-11-24 06:00AM
Apr-10-24 06:00AM
06:00AM
Loading…
Apr-09-24 06:00AM
Apr-08-24 06:00AM
Apr-01-24 08:05AM
Feb-27-24 06:30AM
Feb-23-24 06:00AM
Feb-13-24 06:30AM
Dec-27-23 09:30AM
Dec-26-23 07:30AM
Dec-20-23 09:00AM
Dec-07-23 08:40AM
Nov-20-23 08:10AM
Nov-17-23 07:00AM
Nov-15-23 01:53PM
03:29AM
(Thomson Reuters StreetEvents)
Nov-14-23 07:05AM
08:00AM
Loading…
Nov-08-23 08:00AM
Nov-07-23 06:00AM
Oct-24-23 07:00AM
Oct-23-23 10:05AM
Oct-18-23 08:01AM
06:00AM
Oct-02-23 07:00AM
Sep-27-23 10:48PM
06:15PM
(Associated Press Finance)
07:00AM
Sep-26-23 12:17PM
Sep-25-23 08:13AM
Aug-18-23 08:34AM
Aug-15-23 03:11AM
(Thomson Reuters StreetEvents) -6.59%
Aug-14-23 07:05AM
Aug-07-23 04:05PM
Jul-17-23 09:15AM
Jul-12-23 07:00AM
Jul-07-23 07:00AM
Jun-20-23 09:06AM
Jun-16-23 07:00AM
Jun-06-23 06:00AM
May-23-23 11:35AM
(Zacks Small Cap Research)
May-19-23 07:30AM
May-18-23 08:55AM
May-17-23 02:41PM
May-15-23 07:05AM
May-09-23 06:00AM
Apr-24-23 07:00AM
Apr-07-23 07:30AM
Apr-05-23 07:46PM
Apr-04-23 09:12AM
(Zacks Small Cap Research) -10.70%
Mar-30-23 07:05AM
Mar-27-23 09:15AM
(Zacks Small Cap Research)
06:00AM
Mar-21-23 08:18AM
Jan-10-23 07:00AM
Jan-05-23 07:30AM
Jan-04-23 07:30AM
Dec-27-22 06:00AM
Dec-12-22 07:00AM
Nov-17-22 06:56AM
06:15AM
(Zacks Small Cap Research)
Nov-16-22 11:28AM
Nov-14-22 07:05AM
Nov-10-22 11:01AM
08:30AM
Nov-07-22 04:10PM
06:00AM
Oct-20-22 06:00AM
Oct-07-22 12:00PM
Oct-04-22 06:00AM
(Zacks Small Cap Research)
Sep-15-22 06:00AM
Aug-30-22 08:20AM
Aug-17-22 10:16AM
(Zacks Small Cap Research) +11.92%
Aug-15-22 07:05AM
Aug-01-22 06:00AM
May-31-22 06:00AM
May-24-22 07:10AM
(Zacks Small Cap Research)
May-16-22 08:00AM
(Thomson Reuters StreetEvents)
07:05AM
May-12-22 08:02AM
May-04-22 06:00AM
May-03-22 06:00AM
May-02-22 06:00AM
Apr-04-22 06:20AM
(Zacks Small Cap Research)
Mar-28-22 09:00AM
07:05AM
Mar-23-22 12:56PM
Mar-14-22 06:00AM
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dagher Ibrahim B. Chief Medical Officer Jul 19 '24 Sale 0.35 63,000 22,069 0 Jul 24 04:05 PM
Index -
P/E -
EPS (ttm) -1.23
Insider Own 49.77%
Shs Outstand 113.97M
Perf Week -1.33%
Market Cap 88.16M
Forward P/E -
EPS next Y -0.29
Insider Trans -0.18%
Shs Float 57.95M
Perf Month 5.84%
Income -140.34M
PEG -
EPS next Q -0.10
Inst Own 40.51%
Short Float 9.57%
Perf Quarter -1.04%
Sales 0.00M
P/S -
EPS this Y 72.86%
Inst Trans 24.76%
Short Ratio 17.05
Perf Half Y 3.72%
Book/sh 1.04
P/B 0.73
EPS next Y 41.61%
ROA -67.85%
Short Interest 5.55M
Perf Year -74.78%
Cash/sh 1.12
P/C 0.68
EPS next 5Y 29.50%
ROE -80.33%
52W Range 0.58 - 3.13
Perf YTD 12.42%
Dividend Est. -
P/FCF -
EPS past 5Y -70.96%
ROI -109.11%
52W High -75.58%
Beta 0.76
Dividend TTM -
Quick Ratio 55.08
Sales past 5Y -37.09%
Gross Margin -
52W Low 31.76%
ATR (14) 0.03
Dividend Ex-Date -
Current Ratio 55.08
EPS Y/Y TTM 32.62%
Oper. Margin 0.00%
RSI (14) 51.29
Volatility 3.46% 4.29%
Employees 112
Debt/Eq 0.07
Sales Y/Y TTM -
Profit Margin -
Recom 4.00
Target Price 0.80
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 88.96%
Payout -
Rel Volume 0.09
Prev Close 0.76
Sales Surprise -
EPS Surprise 51.50%
Sales Q/Q -
Earnings Aug 01
Avg Volume 325.21K
Price 0.76
SMA20 1.41%
SMA50 0.85%
SMA200 -14.64%
Trades
Volume 27,670
Change 0.37%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-26-23 Downgrade
BofA Securities
Buy → Underperform
$17 → $1
Dec-22-23 Downgrade
Piper Sandler
Overweight → Neutral
Dec-22-23 Downgrade
Leerink Partners
Outperform → Market Perform
Dec-22-23 Downgrade
JP Morgan
Overweight → Underweight
Aug-18-23 Initiated
BofA Securities
Buy
$17
Oct-19-21 Resumed
Morgan Stanley
Overweight
$48
Aug-24-20 Initiated
SVB Leerink
Outperform
$41
Aug-24-20 Initiated
Morgan Stanley
Overweight
$49
Aug-24-20 Initiated
JP Morgan
Overweight
$50
Aug-09-24 02:52PM
May-14-24 08:53AM
Mar-18-24 03:53PM
Mar-13-24 11:53AM
10:00AM
05:50AM
Loading…
Mar-12-24 05:50AM
Mar-06-24 06:17PM
Mar-04-24 05:37PM
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
Feb-23-24 10:30AM
Jan-29-24 09:40AM
Jan-24-24 09:45AM
Jan-12-24 09:35AM
11:03AM
Loading…
Jan-05-24 11:03AM
08:37AM
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
07:17AM
Loading…
Jul-21-23 07:17AM
Jul-12-23 03:12AM
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
Sep-03-21 08:19AM
Aug-26-21 01:41PM
Aug-06-21 07:00AM
Jun-27-21 03:19AM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Brainard Diana Chief Executive Officer Aug 20 '24 Sale 0.74 5,390 3,996 753,923 Aug 22 04:15 PM Brainard Diana Officer Aug 20 '24 Proposed Sale 0.74 5,390 3,996 Aug 21 11:14 AM Miller Edward General Counsel Aug 19 '24 Sale 0.76 422 321 215,981 Aug 20 04:15 PM Sinha Vikas See Remarks Aug 19 '24 Sale 0.76 3,159 2,399 1,153,584 Aug 20 04:15 PM Hagen Brett R Chief Accounting Officer Aug 19 '24 Sale 0.76 544 413 71,981 Aug 20 04:15 PM Brainard Diana Chief Executive Officer Aug 19 '24 Sale 0.76 3,091 2,348 759,313 Aug 20 04:15 PM Sinha Vikas Owner Aug 19 '24 Proposed Sale 0.76 3,159 2,399 Aug 19 08:00 PM Brainard Diana Officer Aug 19 '24 Proposed Sale 0.76 3,091 2,348 Aug 19 08:00 PM Hagen Brett R Officer Aug 19 '24 Proposed Sale 0.76 544 413 Aug 19 08:00 PM Miller Edward Officer Aug 19 '24 Proposed Sale 0.76 422 321 Aug 19 08:00 PM Miller Edward General Counsel Aug 05 '24 Sale 0.73 2,323 1,707 216,403 Aug 07 04:15 PM Brainard Diana Chief Executive Officer Aug 05 '24 Sale 0.73 10,847 7,970 762,404 Aug 07 04:15 PM Sinha Vikas See Remarks Aug 05 '24 Sale 0.73 5,251 3,858 1,156,743 Aug 07 04:15 PM Hagen Brett R Chief Accounting Officer Aug 05 '24 Sale 0.73 1,692 1,243 72,525 Aug 07 04:15 PM Brainard Diana Officer Aug 05 '24 Proposed Sale 0.73 10,847 7,970 Aug 06 08:00 PM Sinha Vikas Owner Aug 05 '24 Proposed Sale 0.73 5,251 3,858 Aug 06 08:00 PM Hagen Brett R Officer Aug 05 '24 Proposed Sale 0.73 1,692 1,243 Aug 06 08:00 PM Miller Edward Officer Aug 05 '24 Proposed Sale 0.73 2,323 1,707 Aug 06 08:00 PM Hagen Brett R Chief Accounting Officer Jul 19 '24 Sale 0.75 479 359 74,698 Jul 23 04:28 PM Hagen Brett R Chief Accounting Officer Jul 22 '24 Sale 0.74 481 356 74,217 Jul 23 04:28 PM Brainard Diana Chief Executive Officer Jul 19 '24 Sale 0.75 9,731 7,299 773,251 Jul 23 04:28 PM Sinha Vikas See Remarks Jul 22 '24 Sale 0.74 1,858 1,373 1,161,994 Jul 23 04:27 PM Sinha Vikas See Remarks Jul 19 '24 Sale 0.75 1,542 1,157 1,163,852 Jul 23 04:27 PM Miller Edward General Counsel Jul 22 '24 Sale 0.74 757 560 218,726 Jul 23 04:25 PM Miller Edward General Counsel Jul 19 '24 Sale 0.75 634 476 219,483 Jul 23 04:25 PM Miller Edward General Counsel Jul 02 '24 Sale 0.72 379 273 220,117 Jul 03 04:14 PM Sinha Vikas See Remarks Jul 02 '24 Sale 0.72 939 676 1,165,394 Jul 03 04:14 PM Hagen Brett R Chief Accounting Officer Jul 02 '24 Sale 0.72 304 219 75,177 Jul 03 04:12 PM Brainard Diana Chief Executive Officer Jul 02 '24 Sale 0.72 1,489 1,072 782,982 Jul 03 04:11 PM Brainard Diana Chief Executive Officer May 21 '24 Sale 0.79 5,149 4,080 784,471 May 23 05:24 PM Hagen Brett R Chief Accounting Officer May 17 '24 Sale 0.75 541 405 75,481 May 21 04:35 PM Brainard Diana Chief Executive Officer May 17 '24 Sale 0.75 3,075 2,304 789,620 May 21 04:35 PM Sinha Vikas See Remarks May 17 '24 Sale 0.75 3,143 2,355 1,129,996 May 21 04:33 PM Miller Edward General Counsel May 17 '24 Sale 0.75 420 315 220,496 May 21 04:33 PM Brainard Diana Chief Executive Officer May 03 '24 Sale 0.80 10,240 8,151 792,695 May 07 04:15 PM Hagen Brett R Chief Accounting Officer May 03 '24 Sale 0.80 1,597 1,271 76,022 May 07 04:15 PM Sinha Vikas See Remarks May 03 '24 Sale 0.80 4,957 3,946 1,133,139 May 07 04:15 PM Miller Edward General Counsel May 03 '24 Sale 0.80 2,311 1,840 220,916 May 07 04:15 PM Hagen Brett R Chief Accounting Officer Apr 22 '24 Sale 0.75 480 360 77,619 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 19 '24 Sale 0.75 473 355 78,099 Apr 23 04:15 PM Miller Edward General Counsel Apr 22 '24 Sale 0.75 757 568 223,227 Apr 23 04:15 PM Miller Edward General Counsel Apr 19 '24 Sale 0.75 626 470 223,984 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 19 '24 Sale 0.75 9,601 7,207 802,935 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 22 '24 Sale 0.75 1,857 1,393 1,138,096 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 19 '24 Sale 0.75 1,521 1,142 1,139,953 Apr 23 04:15 PM Miller Edward General Counsel Apr 02 '24 Sale 0.77 368 284 224,610 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Apr 02 '24 Sale 0.77 1,533 1,183 812,536 Apr 04 04:15 PM Hagen Brett R Chief Accounting Officer Apr 02 '24 Sale 0.77 281 217 78,572 Apr 04 04:15 PM Sinha Vikas See Remarks Apr 02 '24 Sale 0.77 885 683 1,141,474 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Feb 21 '24 Sale 0.71 5,155 3,650 814,069 Feb 22 04:18 PM Brainard Diana Chief Executive Officer Feb 20 '24 Sale 0.70 3,097 2,153 819,224 Feb 22 04:18 PM Miller Edward General Counsel Feb 20 '24 Sale 0.70 385 268 224,978 Feb 22 04:16 PM Sinha Vikas See Remarks Feb 20 '24 Sale 0.70 2,893 2,011 1,142,359 Feb 22 04:15 PM Hagen Brett R Chief Accounting Officer Feb 20 '24 Sale 0.70 494 343 78,853 Feb 22 04:15 PM Hagen Brett R Chief Accounting Officer Feb 08 '24 Sale 0.67 11,150 7,494 79,347 Feb 09 08:01 PM Sinha Vikas See Remarks Feb 05 '24 Sale 0.67 18,331 12,282 1,145,252 Feb 06 04:46 PM Miller Edward General Counsel Feb 05 '24 Sale 0.67 8,869 5,942 225,363 Feb 06 04:40 PM Hagen Brett R Chief Accounting Officer Feb 05 '24 Sale 0.67 5,792 3,881 90,497 Feb 06 04:39 PM Brainard Diana Chief Executive Officer Feb 05 '24 Sale 0.67 41,421 27,752 822,321 Feb 06 04:38 PM Sinha Vikas See Remarks Jan 23 '24 Sale 0.67 3,205 2,150 1,163,583 Jan 25 04:15 PM Brainard Diana Chief Executive Officer Jan 23 '24 Sale 0.67 9,500 6,369 863,742 Jan 25 04:15 PM Hagen Brett R Chief Accounting Officer Jan 23 '24 Sale 0.67 901 604 96,289 Jan 25 04:15 PM Miller Edward General Counsel Jan 23 '24 Sale 0.67 1,302 873 234,232 Jan 25 04:15 PM Hagen Brett R Chief Accounting Officer Jan 04 '24 Sale 0.64 310 198 97,190 Jan 08 04:15 PM Miller Edward General Counsel Jan 04 '24 Sale 0.64 424 271 235,534 Jan 08 04:15 PM Sinha Vikas See Remarks Jan 04 '24 Sale 0.64 961 614 1,166,788 Jan 08 04:15 PM Brainard Diana Chief Executive Officer Jan 04 '24 Sale 0.64 1,664 1,063 873,242 Jan 08 04:15 PM Hagen Brett R Chief Accounting Officer Dec 27 '23 Sale 0.74 28,335 20,838 97,500 Jan 02 07:36 PM Sinha Vikas See Remarks Nov 17 '23 Sale 1.63 2,490 4,061 1,167,749 Nov 21 05:00 PM Brainard Diana Chief Executive Officer Nov 20 '23 Sale 1.69 4,382 7,408 874,906 Nov 21 05:00 PM Brainard Diana Chief Executive Officer Nov 17 '23 Sale 1.63 2,689 4,386 879,288 Nov 21 05:00 PM Hagen Brett R Chief Accounting Officer Nov 17 '23 Sale 1.63 403 657 125,835 Nov 21 05:00 PM Hagen Brett R Chief Accounting Officer Oct 19 '23 Sale 1.58 358 566 126,595 Oct 23 05:00 PM Hagen Brett R Chief Accounting Officer Oct 20 '23 Sale 1.54 357 550 126,238 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 19 '23 Sale 1.58 8,581 13,558 881,977 Oct 23 05:00 PM Sinha Vikas See Remarks Oct 20 '23 Sale 1.54 1,475 2,273 1,170,239 Oct 23 05:00 PM Sinha Vikas See Remarks Oct 19 '23 Sale 1.58 1,232 1,947 1,171,714 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 03 '23 Sale 1.98 1,325 2,619 890,558 Oct 05 05:00 PM Sinha Vikas See Remarks Oct 03 '23 Sale 1.98 755 1,492 1,172,946 Oct 05 05:00 PM Hagen Brett R Chief Accounting Officer Oct 03 '23 Sale 1.98 222 439 126,953 Oct 05 05:00 PM
Index RUT
P/E 11305.00
EPS (ttm) 0.00
Insider Own 0.89%
Shs Outstand 49.03M
Perf Week -12.28%
Market Cap 2.22B
Forward P/E 84.49
EPS next Y 0.54
Insider Trans -40.62%
Shs Float 48.59M
Perf Month -0.20%
Income 0.79M
PEG -
EPS next Q -0.05
Inst Own 103.55%
Short Float 6.47%
Perf Quarter -1.29%
Sales 214.52M
P/S 10.34
EPS this Y 238.18%
Inst Trans -2.06%
Short Ratio 8.82
Perf Half Y 0.89%
Book/sh 4.97
P/B 9.09
EPS next Y 453.31%
ROA 0.23%
Short Interest 3.14M
Perf Year 34.86%
Cash/sh 2.61
P/C 17.31
EPS next 5Y -
ROE 0.36%
52W Range 30.18 - 54.10
Perf YTD 26.99%
Dividend Est. -
P/FCF -
EPS past 5Y 19.85%
ROI 0.24%
52W High -16.41%
Beta 1.70
Dividend TTM -
Quick Ratio 4.16
Sales past 5Y 17.25%
Gross Margin 70.42%
52W Low 49.83%
ATR (14) 2.02
Dividend Ex-Date -
Current Ratio 4.50
EPS Y/Y TTM 106.81%
Oper. Margin -1.78%
RSI (14) 39.00
Volatility 4.28% 3.74%
Employees 314
Debt/Eq 0.39
Sales Y/Y TTM 20.39%
Profit Margin 0.37%
Recom 1.00
Target Price 57.25
Option/Short Yes / Yes
LT Debt/Eq 0.37
EPS Q/Q 8.82%
Payout -
Rel Volume 0.53
Prev Close 47.10
Sales Surprise 0.14%
EPS Surprise -7.64%
Sales Q/Q 14.68%
Earnings Aug 01 BMO
Avg Volume 356.44K
Price 45.22
SMA20 -6.15%
SMA50 -6.67%
SMA200 1.01%
Trades
Volume 189,152
Change -3.99%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-09-24 Initiated
Canaccord Genuity
Buy
$57
Jun-20-24 Initiated
TD Cowen
Buy
$55
Jan-25-24 Upgrade
Truist
Hold → Buy
$39 → $51
Aug-08-23 Upgrade
BTIG Research
Neutral → Buy
$39
Nov-10-22 Downgrade
BTIG Research
Buy → Neutral
Nov-09-22 Downgrade
Truist
Buy → Hold
Oct-14-22 Resumed
Stephens
Overweight
$40
Jan-11-21 Downgrade
Oppenheimer
Outperform → Perform
Dec-18-20 Initiated
Stephens
Overweight
$31
Sep-17-20 Initiated
Truist
Buy
$24
Oct-09-19 Initiated
H.C. Wainwright
Buy
$19
Feb-28-19 Downgrade
Needham
Buy → Hold
Aug-08-18 Reiterated
Needham
Buy
$15 → $14
Jul-16-18 Upgrade
Ladenburg Thalmann
Neutral → Buy
Apr-04-18 Initiated
Leerink Partners
Outperform
$15
Mar-06-18 Reiterated
Needham
Buy
$5 → $15
Mar-06-18 Downgrade
Ladenburg Thalmann
Buy → Neutral
Mar-05-18 Reiterated
BTIG Research
Buy
$8 → $13
Jun-21-17 Initiated
BTIG Research
Buy
$6
Mar-13-17 Reiterated
Needham
Buy
$9 → $6
Show Previous Ratings
Aug-29-24 09:17AM
Aug-26-24 07:45AM
Aug-16-24 10:33AM
Aug-15-24 04:05PM
Aug-07-24 08:30AM
12:00PM
Loading…
Aug-05-24 12:00PM
Aug-01-24 09:05AM
07:55AM
Jul-29-24 03:45PM
Jul-22-24 08:30AM
Jul-18-24 08:30AM
Jul-16-24 07:01PM
Jul-02-24 09:58AM
Jun-27-24 02:03PM
Jun-25-24 07:22AM
09:54AM
Loading…
Jun-20-24 09:54AM
Jun-11-24 08:30AM
May-22-24 08:30AM
May-21-24 06:42AM
May-09-24 03:28PM
03:08AM
May-08-24 11:24PM
(Thomson Reuters StreetEvents)
09:35AM
09:10AM
07:55AM
Apr-24-24 08:30AM
Mar-29-24 07:01PM
Mar-28-24 01:48PM
(Investor's Business Daily)
Mar-15-24 07:00PM
Mar-01-24 09:30AM
11:37PM
Loading…
Feb-29-24 11:37PM
(Thomson Reuters StreetEvents)
09:05AM
08:32AM
07:55AM
Feb-27-24 08:30AM
Feb-22-24 12:00PM
Feb-18-24 03:00AM
Feb-15-24 10:00AM
08:50AM
08:30AM
Feb-05-24 08:30AM
Jan-30-24 11:01PM
08:50AM
Jan-25-24 09:49AM
Jan-24-24 07:01PM
Jan-19-24 08:28PM
Jan-09-24 08:47AM
07:55AM
Jan-03-24 08:30AM
Dec-17-23 03:01AM
Dec-09-23 03:05AM
Dec-02-23 05:04AM
Nov-23-23 07:04AM
Nov-16-23 05:35PM
Nov-10-23 09:52PM
Nov-09-23 03:56PM
Nov-08-23 03:30PM
07:55AM
Nov-07-23 08:30AM
Nov-01-23 10:01AM
Oct-25-23 08:30AM
Oct-24-23 01:22AM
Oct-23-23 05:59PM
Oct-16-23 10:23AM
Sep-28-23 08:30AM
Sep-20-23 04:30PM
Sep-06-23 08:30AM
Aug-10-23 01:48AM
Aug-02-23 09:05AM
07:55AM
Jul-23-23 11:44AM
Jul-20-23 08:30AM
Jul-10-23 09:30AM
Jun-21-23 08:00PM
May-10-23 09:05AM
07:55AM
May-02-23 09:00AM
Apr-26-23 08:00PM
08:30AM
Apr-24-23 02:06AM
Apr-17-23 03:03PM
Feb-28-23 08:30AM
Feb-23-23 09:45AM
07:55AM
Feb-09-23 08:00AM
Jan-31-23 07:19AM
Jan-11-23 10:24PM
Jan-10-23 07:55AM
Jan-04-23 08:34AM
Dec-30-22 01:42PM
(American City Business Journals)
05:26AM
Dec-29-22 01:46PM
01:45PM
Nov-11-22 06:09AM
Nov-10-22 09:00AM
Nov-09-22 09:05AM
07:55AM
Oct-26-22 08:30AM
Oct-10-22 11:50AM
Sep-22-22 08:30AM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILMAN STEVEN C Director Sep 04 '24 Option Exercise 3.74 5,000 18,700 16,000 Sep 05 04:06 PM GILMAN STEVEN C Director Sep 04 '24 Sale 48.58 5,000 242,900 11,000 Sep 05 04:06 PM Hopper Jonathan Mark Chief Medical Officer Sep 03 '24 Option Exercise 10.95 10,000 109,500 68,229 Sep 05 04:05 PM Hopper Jonathan Mark Chief Medical Officer Sep 03 '24 Sale 49.83 10,000 498,300 58,229 Sep 05 04:05 PM GILMAN STEVEN C Director Sep 04 '24 Proposed Sale 48.99 5,000 244,950 Sep 04 10:25 AM Hopper Jonathan Mark Officer Sep 03 '24 Proposed Sale 51.22 10,000 512,200 Sep 03 01:27 PM Colangelo Dominick President and CEO Aug 14 '24 Option Exercise 3.02 17,500 52,850 238,437 Aug 16 04:05 PM Colangelo Dominick President and CEO Aug 15 '24 Option Exercise 3.02 17,500 52,850 238,437 Aug 16 04:05 PM Colangelo Dominick President and CEO Aug 15 '24 Sale 46.24 17,500 809,200 220,937 Aug 16 04:05 PM Colangelo Dominick President and CEO Aug 14 '24 Sale 45.17 17,500 790,475 220,937 Aug 16 04:05 PM Colangelo Dominick Officer Aug 15 '24 Proposed Sale 46.24 17,500 809,196 Aug 15 05:03 PM Colangelo Dominick Officer Aug 14 '24 Proposed Sale 45.17 17,500 790,400 Aug 14 04:17 PM MCLAUGHLIN KEVIN F Director Aug 07 '24 Option Exercise 3.74 7,000 26,180 16,900 Aug 09 04:05 PM MCLAUGHLIN KEVIN F Director Aug 07 '24 Sale 45.94 7,000 321,580 11,900 Aug 09 04:05 PM MCLAUGHLIN KEVIN F Director Aug 07 '24 Proposed Sale 45.94 7,000 321,596 Aug 07 04:11 PM Colangelo Dominick President and CEO Jul 17 '24 Option Exercise 3.02 17,500 52,850 238,437 Jul 19 04:05 PM Colangelo Dominick President and CEO Jul 18 '24 Option Exercise 3.02 17,500 52,850 238,437 Jul 19 04:05 PM Colangelo Dominick President and CEO Jul 17 '24 Sale 51.55 17,500 902,125 220,937 Jul 19 04:05 PM Colangelo Dominick President and CEO Jul 18 '24 Sale 51.40 17,500 899,500 220,937 Jul 19 04:05 PM Flynn Sean C. Chief Legal Officer Jul 16 '24 Option Exercise 16.25 15,000 243,750 15,707 Jul 18 04:05 PM Flynn Sean C. Chief Legal Officer Jul 16 '24 Sale 52.18 15,000 782,700 707 Jul 18 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Jul 12 '24 Sale 50.00 5,000 250,000 14,436 Jul 16 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Jul 05 '24 Sale 45.00 545 24,525 1,033 Jul 09 04:05 PM Flynn Sean C. Chief Legal Officer Jun 21 '24 Option Exercise 16.25 6,772 110,045 7,259 Jun 24 06:21 PM Flynn Sean C. Chief Legal Officer Jun 20 '24 Option Exercise 16.25 6,754 109,752 7,241 Jun 24 06:21 PM Flynn Sean C. Chief Legal Officer Jun 24 '24 Option Exercise 16.25 1,474 23,952 1,961 Jun 24 06:21 PM Flynn Sean C. Chief Legal Officer Jun 21 '24 Sale 45.02 6,772 304,875 487 Jun 24 06:21 PM Flynn Sean C. Chief Legal Officer Jun 20 '24 Sale 45.04 6,754 304,200 487 Jun 24 06:21 PM Flynn Sean C. Chief Legal Officer Jun 24 '24 Sale 45.84 1,474 67,568 487 Jun 24 06:21 PM Colangelo Dominick President and CEO Jun 12 '24 Option Exercise 3.02 17,500 52,850 238,252 Jun 14 04:05 PM Colangelo Dominick President and CEO Jun 13 '24 Option Exercise 3.02 17,500 52,850 238,252 Jun 14 04:05 PM Colangelo Dominick President and CEO Jun 12 '24 Sale 44.12 17,500 772,100 220,752 Jun 14 04:05 PM Colangelo Dominick President and CEO Jun 13 '24 Sale 43.10 17,500 754,250 220,752 Jun 14 04:05 PM Hopper Jonathan Mark Chief Medical Officer May 20 '24 Option Exercise 10.95 10,000 109,500 68,116 May 21 04:07 PM Hopper Jonathan Mark Chief Medical Officer May 20 '24 Sale 49.99 10,000 499,900 58,116 May 21 04:07 PM Halpin Michael Chief Operating Officer May 17 '24 Option Exercise 5.39 5,195 28,017 6,284 May 21 04:05 PM Colangelo Dominick President and CEO May 15 '24 Option Exercise 3.02 17,500 52,850 238,252 May 17 04:05 PM Colangelo Dominick President and CEO May 16 '24 Option Exercise 3.02 17,500 52,850 238,252 May 17 04:05 PM Colangelo Dominick President and CEO May 15 '24 Sale 49.67 17,500 869,225 220,752 May 17 04:05 PM Colangelo Dominick President and CEO May 16 '24 Sale 47.85 17,500 837,375 220,752 May 17 04:05 PM Colangelo Dominick President and CEO Apr 30 '24 Option Exercise 11.79 25,445 299,977 220,752 May 01 04:05 PM Colangelo Dominick President and CEO Apr 17 '24 Option Exercise 3.02 17,500 52,850 212,807 Apr 19 04:05 PM Colangelo Dominick President and CEO Apr 18 '24 Option Exercise 3.02 17,500 52,850 212,807 Apr 19 04:05 PM Colangelo Dominick President and CEO Apr 17 '24 Sale 46.47 17,500 813,225 195,307 Apr 19 04:05 PM Colangelo Dominick President and CEO Apr 18 '24 Sale 44.59 17,500 780,325 195,307 Apr 19 04:05 PM Rubino Alan L Director Apr 09 '24 Option Exercise 4.12 3,000 12,360 20,594 Apr 11 04:05 PM ZERBE ROBERT L MD Director Mar 27 '24 Option Exercise 3.74 3,278 12,260 26,673 Mar 29 04:05 PM ZERBE ROBERT L MD Director Mar 27 '24 Sale 51.57 3,278 169,046 23,395 Mar 29 04:05 PM Colangelo Dominick President and CEO Mar 13 '24 Option Exercise 3.02 17,500 52,850 212,370 Mar 15 04:07 PM Colangelo Dominick President and CEO Mar 14 '24 Option Exercise 3.02 17,500 52,850 212,370 Mar 15 04:07 PM Colangelo Dominick President and CEO Mar 13 '24 Sale 44.67 17,500 781,725 194,870 Mar 15 04:07 PM Colangelo Dominick President and CEO Mar 14 '24 Sale 44.02 17,500 770,350 194,870 Mar 15 04:07 PM Halpin Michael Chief Operating Officer Mar 11 '24 Sale 44.71 7,874 352,047 949 Mar 13 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Mar 07 '24 Sale 45.00 1,634 73,530 1,400 Mar 11 04:08 PM Flynn Sean C. SVP, General Counsel Mar 08 '24 Sale 45.33 8,115 367,853 167 Mar 11 04:07 PM ZERBE ROBERT L MD Director Feb 20 '24 Option Exercise 3.74 722 2,700 24,117 Feb 22 04:07 PM ZERBE ROBERT L MD Director Feb 20 '24 Sale 50.01 722 36,107 23,395 Feb 22 04:07 PM Halpin Michael Chief Operating Officer Feb 20 '24 Option Exercise 0.00 11,887 0 10,155 Feb 22 04:07 PM Flynn Sean C. SVP, General Counsel Feb 20 '24 Option Exercise 0.00 7,075 0 9,059 Feb 22 04:07 PM Colangelo Dominick President and CEO Feb 20 '24 Option Exercise 0.00 38,887 0 199,013 Feb 22 04:06 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 20 '24 Option Exercise 0.00 7,380 0 20,097 Feb 22 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Feb 20 '24 Option Exercise 0.00 2,920 0 3,900 Feb 22 04:06 PM Hopper Jonathan Mark Chief Medical Officer Feb 20 '24 Option Exercise 0.00 7,075 0 58,695 Feb 22 04:06 PM Colangelo Dominick President and CEO Feb 14 '24 Option Exercise 3.02 17,500 52,850 191,508 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 15 '24 Option Exercise 3.02 17,500 52,850 191,508 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 15 '24 Sale 48.85 17,500 854,875 174,008 Feb 16 04:05 PM Colangelo Dominick President and CEO Feb 14 '24 Sale 46.99 17,500 822,325 174,008 Feb 16 04:05 PM Hopper Jonathan Mark Chief Medical Officer Feb 12 '24 Option Exercise 0.00 1,625 0 54,759 Feb 13 04:06 PM Halpin Michael Chief Operating Officer Feb 12 '24 Option Exercise 0.00 3,500 0 4,449 Feb 13 04:05 PM Colangelo Dominick President and CEO Feb 12 '24 Option Exercise 0.00 7,500 0 177,485 Feb 13 04:05 PM ZERBE ROBERT L MD Director Jan 29 '24 Sale 44.22 2,300 101,706 23,395 Jan 30 04:05 PM ZERBE ROBERT L MD Director Jan 25 '24 Sale 44.02 200 8,804 25,695 Jan 29 04:05 PM ZERBE ROBERT L MD Director Jan 22 '24 Option Exercise 4.12 3,000 12,360 28,895 Jan 24 04:05 PM ZERBE ROBERT L MD Director Jan 22 '24 Sale 41.85 8,000 334,775 25,895 Jan 24 04:05 PM Colangelo Dominick President and CEO Jan 17 '24 Option Exercise 3.02 16,726 50,513 186,711 Jan 19 04:06 PM Colangelo Dominick President and CEO Jan 18 '24 Option Exercise 3.02 16,726 50,513 186,711 Jan 19 04:06 PM Colangelo Dominick President and CEO Jan 18 '24 Sale 38.58 16,726 645,289 169,985 Jan 19 04:06 PM Colangelo Dominick President and CEO Jan 17 '24 Sale 37.97 16,726 635,086 169,985 Jan 19 04:06 PM ZERBE ROBERT L MD Director Jan 12 '24 Sale 38.09 2,200 83,798 30,895 Jan 16 04:05 PM Flynn Sean C. SVP, General Counsel Dec 13 '23 Sale 34.20 1,432 48,974 4,573 Dec 15 04:07 PM Flynn Sean C. SVP, General Counsel Dec 14 '23 Sale 37.45 106 3,970 4,467 Dec 15 04:07 PM Wotton Paul K Director Dec 14 '23 Sale 37.31 5,000 186,550 26,802 Dec 15 04:07 PM Colangelo Dominick President and CEO Dec 13 '23 Option Exercise 3.57 12,000 42,840 181,985 Dec 15 04:05 PM Colangelo Dominick President and CEO Dec 14 '23 Option Exercise 3.57 12,000 42,840 181,985 Dec 15 04:05 PM Colangelo Dominick President and CEO Dec 14 '23 Sale 37.12 12,000 445,440 169,985 Dec 15 04:05 PM Colangelo Dominick President and CEO Dec 13 '23 Sale 34.03 12,000 408,360 169,985 Dec 15 04:05 PM Colangelo Dominick President and CEO Dec 06 '23 Option Exercise 3.57 12,397 44,257 189,139 Dec 08 04:05 PM Colangelo Dominick President and CEO Dec 07 '23 Option Exercise 3.57 12,000 42,840 188,742 Dec 08 04:05 PM Colangelo Dominick President and CEO Dec 06 '23 Sale 34.43 12,397 426,829 176,742 Dec 08 04:05 PM Colangelo Dominick President and CEO Dec 07 '23 Sale 33.84 12,000 406,080 176,742 Dec 08 04:05 PM Halpin Michael Chief Operating Officer Nov 30 '23 Option Exercise 7.20 17,447 125,618 18,274 Dec 01 04:05 PM Halpin Michael Chief Operating Officer Nov 30 '23 Sale 35.41 17,447 617,798 827 Dec 01 04:05 PM Hopper Jonathan Mark Chief Medical Officer Nov 20 '23 Option Exercise 10.95 5,000 54,750 58,007 Nov 22 04:05 PM Hopper Jonathan Mark Chief Medical Officer Nov 20 '23 Sale 36.40 5,000 182,000 53,007 Nov 22 04:05 PM ZERBE ROBERT L MD Director Nov 15 '23 Sale 38.02 300 11,406 33,095 Nov 17 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Nov 15 '23 Sale 37.70 662 24,954 1,305 Nov 17 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Oct 02 '23 Option Exercise 0.00 938 0 2,134 Oct 04 04:05 PM
Index RUT
P/E -
EPS (ttm) -1.70
Insider Own 42.79%
Shs Outstand 29.21M
Perf Week -3.76%
Market Cap 196.97M
Forward P/E -
EPS next Y -
Insider Trans -0.99%
Shs Float 18.36M
Perf Month 22.31%
Income -49.99M
PEG -
EPS next Q -
Inst Own 12.91%
Short Float 8.88%
Perf Quarter -13.76%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -0.70%
Short Ratio 4.11
Perf Half Y 301.31%
Book/sh -0.32
P/B -
EPS next Y -
ROA -117.35%
Short Interest 1.63M
Perf Year 438.60%
Cash/sh 0.67
P/C 9.18
EPS next 5Y -
ROE -480.68%
52W Range 0.66 - 14.30
Perf YTD 317.69%
Dividend Est. -
P/FCF -
EPS past 5Y -46.75%
ROI -
52W High -57.06%
Beta -0.87
Dividend TTM -
Quick Ratio 1.62
Sales past 5Y -25.00%
Gross Margin -3654.84%
52W Low 830.30%
ATR (14) 0.47
Dividend Ex-Date -
Current Ratio 1.62
EPS Y/Y TTM -52.74%
Oper. Margin 0.00%
RSI (14) 53.16
Volatility 8.88% 7.42%
Employees 42
Debt/Eq -
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 11.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -123.89%
Payout -
Rel Volume 0.36
Prev Close 6.31
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings Aug 13 BMO
Avg Volume 396.37K
Price 6.14
SMA20 6.67%
SMA50 3.55%
SMA200 40.79%
Trades
Volume 142,966
Change -2.69%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-02-22 Initiated
H.C. Wainwright
Buy
$11
Nov-19-21 Initiated
BMO Capital Markets
Outperform
$18
Aug-23-21 Initiated
UBS
Buy
$9
Aug-23-21 Initiated
Jefferies
Buy
$22
Aug-23-21 Initiated
Credit Suisse
Outperform
$15
Sep-04-24 08:00AM
Sep-03-24 08:00AM
Aug-13-24 08:00AM
Aug-12-24 04:37PM
Jun-18-24 08:00AM
08:30AM
Loading…
Jun-14-24 08:30AM
07:15AM
Jun-12-24 10:22AM
Jun-11-24 08:00AM
Jun-07-24 08:30AM
Jun-03-24 08:30AM
May-30-24 08:00AM
May-28-24 11:07AM
May-24-24 11:42AM
May-23-24 05:00PM
11:51AM
Loading…
11:51AM
May-22-24 08:00AM
May-20-24 08:00AM
May-15-24 11:14AM
May-14-24 01:53PM
08:00AM
May-09-24 10:26AM
Apr-25-24 08:00AM
Apr-12-24 10:00AM
Apr-11-24 09:00AM
Apr-09-24 08:00AM
Apr-05-24 12:10PM
Apr-04-24 12:24PM
08:00AM
Mar-28-24 04:05PM
01:53PM
Loading…
01:53PM
08:05AM
Mar-15-24 08:15AM
Mar-06-24 08:00AM
Mar-05-24 04:30PM
Feb-13-24 07:30AM
Feb-05-24 08:00AM
Dec-13-23 12:21PM
Dec-12-23 08:00AM
Nov-28-23 09:00AM
Nov-09-23 09:43AM
08:00AM
Nov-04-23 08:00AM
Nov-03-23 12:00PM
Oct-18-23 11:00AM
Sep-27-23 09:40AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Aug-10-23 08:00AM
Aug-02-23 08:00AM
Jun-13-23 08:00AM
Jun-08-23 08:00AM
Jun-05-23 08:00AM
May-22-23 08:26AM
May-19-23 01:51PM
09:00AM
May-11-23 08:00AM
May-02-23 08:00AM
Apr-17-23 08:00AM
Mar-30-23 08:00AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 08:00AM
06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 06:55AM
Jan-19-23 06:43AM
Jan-18-23 06:28AM
Jan-17-23 06:27AM
Jan-13-23 06:56AM
Jan-12-23 08:00AM
06:50AM
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Tyagarajan Seshu Chief Technology Officer Jul 17 '24 Sale 6.47 14,851 96,125 146,049 Jul 19 08:31 AM Tak Paul Peter Chief Executive Officer Jul 17 '24 Sale 6.47 22,528 145,815 330,735 Jul 19 08:29 AM Schoch Charles See Remarks Jul 17 '24 Sale 6.47 9,884 63,975 62,520 Jul 19 08:28 AM Nichols William Garrett Chief Medical Officer Jul 17 '24 Sale 6.47 10,875 70,390 114,482 Jul 19 08:26 AM Barone Francesca Chief Scientific Officer Jul 17 '24 Sale 6.47 14,051 90,947 159,961 Jul 19 08:24 AM Tyagarajan Seshu Chief Technology Officer Jul 11 '24 Sale 5.97 13,330 79,625 160,900 Jul 15 08:36 AM Tak Paul Peter Chief Executive Officer Jul 11 '24 Sale 5.97 20,293 121,218 353,263 Jul 15 08:35 AM Schoch Charles See Remarks Jul 11 '24 Sale 5.97 8,897 53,145 72,404 Jul 15 08:34 AM Nichols William Garrett Chief Medical Officer Jul 11 '24 Sale 5.97 9,769 58,354 125,357 Jul 15 08:32 AM Barone Francesca Chief Scientific Officer Jul 11 '24 Sale 5.97 12,645 75,534 174,012 Jul 15 08:30 AM
Index RUT
P/E -
EPS (ttm) -7.99
Insider Own 32.25%
Shs Outstand 20.80M
Perf Week -1.74%
Market Cap 140.61M
Forward P/E -
EPS next Y -5.08
Insider Trans 4.72%
Shs Float 14.09M
Perf Month 0.15%
Income -99.86M
PEG -
EPS next Q -1.36
Inst Own 56.62%
Short Float 10.62%
Perf Quarter -9.26%
Sales 0.00M
P/S -
EPS this Y 54.97%
Inst Trans 2.88%
Short Ratio 4.58
Perf Half Y -64.79%
Book/sh 8.08
P/B 0.84
EPS next Y 2.82%
ROA -40.33%
Short Interest 1.50M
Perf Year -61.59%
Cash/sh 8.36
P/C 0.81
EPS next 5Y -
ROE -66.76%
52W Range 6.38 - 29.70
Perf YTD -10.20%
Dividend Est. -
P/FCF -
EPS past 5Y 0.36%
ROI -43.17%
52W High -77.24%
Beta 1.03
Dividend TTM -
Quick Ratio 7.99
Sales past 5Y -56.90%
Gross Margin -249.44%
52W Low 5.96%
ATR (14) 0.45
Dividend Ex-Date -
Current Ratio 7.99
EPS Y/Y TTM 40.09%
Oper. Margin 0.00%
RSI (14) 43.95
Volatility 5.00% 6.07%
Employees 121
Debt/Eq 0.44
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.25
Target Price 30.00
Option/Short Yes / Yes
LT Debt/Eq 0.38
EPS Q/Q 71.67%
Payout -
Rel Volume 0.31
Prev Close 6.82
Sales Surprise -100.00%
EPS Surprise 39.36%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 326.53K
Price 6.76
SMA20 -2.06%
SMA50 -7.62%
SMA200 -35.63%
Trades
Volume 101,887
Change -0.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-25-24 Initiated
Oppenheimer
Outperform
$25
Apr-30-24 Initiated
H.C. Wainwright
Buy
$30
Jul-07-22 Upgrade
Truist
Hold → Buy
$4
Jul-23-21 Downgrade
Cantor Fitzgerald
Overweight → Neutral
May-03-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$5
Apr-29-21 Downgrade
Truist
Buy → Hold
$30 → $9
Apr-29-21 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$6
Apr-29-21 Downgrade
Chardan Capital Markets
Buy → Neutral
$5
Dec-16-20 Initiated
UBS
Neutral
$13
Nov-12-20 Upgrade
Raymond James
Underperform → Mkt Perform
Jun-26-20 Downgrade
Raymond James
Mkt Perform → Underperform
May-13-20 Initiated
RBC Capital Mkts
Outperform
$24
May-05-20 Upgrade
SunTrust
Hold → Buy
$13 → $21
Apr-28-20 Initiated
Goldman
Buy
$17
Mar-16-20 Initiated
SVB Leerink
Outperform
$17
Feb-10-20 Upgrade
Chardan Capital Markets
Neutral → Buy
$20
Feb-10-20 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$8 → $21
Oct-15-19 Reiterated
Chardan Capital Markets
Neutral
$6 → $10
Sep-13-19 Reiterated
Chardan Capital Markets
Neutral
$10 → $6
Jun-14-19 Resumed
Raymond James
Mkt Perform
Show Previous Ratings
Sep-05-24 07:30AM
Sep-04-24 04:05PM
Sep-03-24 09:55AM
Aug-12-24 04:35PM
(Associated Press Finance)
04:05PM
07:00AM
Loading…
Aug-02-24 07:00AM
Aug-01-24 08:00AM
Jul-18-24 09:40AM
Jul-17-24 02:45AM
Jul-16-24 09:55AM
Jul-10-24 08:00AM
Jun-18-24 08:00AM
Jun-11-24 08:00AM
08:00AM
May-10-24 03:36PM
09:35AM
Loading…
09:35AM
May-09-24 11:55PM
05:45PM
(Associated Press Finance)
04:05PM
May-03-24 08:00AM
May-02-24 10:01AM
Apr-30-24 07:39AM
Apr-29-24 08:33AM
Apr-25-24 04:05PM
Apr-23-24 09:40AM
Apr-19-24 09:35AM
Apr-04-24 09:40AM
08:34AM
Apr-03-24 09:35AM
Mar-27-24 09:35AM
07:52AM
Loading…
Mar-21-24 07:52AM
Mar-20-24 05:33AM
Mar-19-24 09:40AM
Mar-18-24 10:53PM
04:20PM
(Associated Press Finance)
04:05PM
Mar-06-24 03:07PM
Feb-28-24 04:05PM
Feb-27-24 06:10AM
Feb-22-24 06:15AM
Feb-12-24 08:00AM
Feb-08-24 07:00AM
Feb-05-24 07:45AM
Feb-01-24 05:30PM
(GlobeNewswire) +13.33%
+19.33%
Jan-29-24 08:00AM
Jan-04-24 08:27AM
Dec-07-23 04:05PM
(GlobeNewswire) +9.43%
-10.88%
Nov-28-23 04:05PM
Nov-09-23 04:51PM
(Associated Press Finance)
04:05PM
Nov-06-23 08:00AM
Nov-04-23 05:54PM
Oct-24-23 12:30PM
Sep-26-23 04:05PM
Sep-21-23 04:05PM
Sep-05-23 04:05PM
Aug-21-23 04:05PM
Aug-14-23 08:00AM
Aug-10-23 04:20PM
(Associated Press Finance)
04:05PM
Jun-12-23 08:00AM
Jun-02-23 08:00AM
May-25-23 06:30AM
May-18-23 09:00AM
09:00AM
May-11-23 04:47PM
04:05PM
May-10-23 04:05PM
May-02-23 04:30PM
Apr-23-23 01:00PM
Apr-21-23 06:03AM
Apr-18-23 08:00AM
Apr-17-23 04:05PM
Apr-04-23 09:40AM
Mar-30-23 04:05PM
Mar-02-23 10:23AM
Feb-27-23 04:05PM
Jan-18-23 04:05PM
Dec-06-22 04:05PM
Nov-10-22 04:05PM
Nov-04-22 12:08PM
Oct-27-22 04:05PM
Sep-30-22 04:45PM
Sep-27-22 04:05PM
Sep-23-22 04:05PM
11:06AM
08:00AM
Sep-15-22 05:19PM
Sep-14-22 08:00AM
Sep-08-22 04:05PM
Aug-26-22 04:05PM
Aug-11-22 04:05PM
Aug-10-22 04:05PM
Aug-01-22 04:05PM
(GlobeNewswire) -5.48%
-5.07%
Jul-25-22 07:16AM
Jul-15-22 09:52AM
08:32AM
Jul-08-22 08:00AM
Jul-07-22 05:14PM
(American City Business Journals) +13.82%
11:22AM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Leonard Braden Michael 10% Owner Jul 30 '24 Buy 7.15 85,800 613,470 2,268,064 Jul 31 04:19 PM Leonard Braden Michael 10% Owner Jul 17 '24 Buy 7.75 135,546 1,049,926 2,101,546 Jul 18 09:16 PM Leonard Braden Michael 10% Owner Jul 18 '24 Buy 9.11 80,718 735,736 2,182,264 Jul 18 09:16 PM Scopa James Paul Director Feb 07 '24 Buy 1.35 100,000 135,000 100,000 Feb 09 05:51 PM Lupher, Jr. Mark L. Director Feb 07 '24 Buy 1.35 130,000 175,500 130,000 Feb 09 05:50 PM Seyedkazemi Setareh Chief Development Officer Sep 15 '23 Sale 1.52 6,201 9,429 47,674 Sep 18 06:54 PM
Index RUT
P/E -
EPS (ttm) -2.73
Insider Own 15.93%
Shs Outstand 51.97M
Perf Week -1.18%
Market Cap 783.19M
Forward P/E -
EPS next Y -3.10
Insider Trans -0.66%
Shs Float 43.69M
Perf Month 2.45%
Income -95.93M
PEG -
EPS next Q -0.67
Inst Own 105.37%
Short Float 22.78%
Perf Quarter -33.23%
Sales 21.99M
P/S 35.62
EPS this Y -4.53%
Inst Trans 0.27%
Short Ratio 11.25
Perf Half Y -48.93%
Book/sh 11.33
P/B 1.33
EPS next Y -14.90%
ROA -29.90%
Short Interest 9.95M
Perf Year -4.92%
Cash/sh 10.43
P/C 1.45
EPS next 5Y -
ROE -33.00%
52W Range 9.44 - 36.25
Perf YTD -25.62%
Dividend Est. -
P/FCF -
EPS past 5Y -46.35%
ROI -16.02%
52W High -58.43%
Beta 2.75
Dividend TTM -
Quick Ratio 28.48
Sales past 5Y 111.29%
Gross Margin 74.42%
52W Low 59.64%
ATR (14) 1.03
Dividend Ex-Date -
Current Ratio 28.48
EPS Y/Y TTM 17.81%
Oper. Margin -477.24%
RSI (14) 43.68
Volatility 5.87% 5.58%
Employees 147
Debt/Eq 0.02
Sales Y/Y TTM 1014.45%
Profit Margin -436.30%
Recom 1.09
Target Price 50.30
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 27.86%
Payout -
Rel Volume 0.42
Prev Close 15.51
Sales Surprise -99.61%
EPS Surprise 7.92%
Sales Q/Q -98.32%
Earnings Aug 08 AMC
Avg Volume 885.02K
Price 15.07
SMA20 0.35%
SMA50 -15.29%
SMA200 -31.81%
Trades
Volume 370,185
Change -2.84%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-15-24 Initiated
Barclays
Overweight
$459
Apr-15-24 Initiated
Barclays
Overweight
$45
Feb-07-24 Resumed
Goldman
Buy
$81
Oct-26-23 Initiated
RBC Capital Mkts
Outperform
$25
Oct-24-23 Initiated
Cantor Fitzgerald
Overweight
$32
Oct-18-23 Upgrade
Leerink Partners
Market Perform → Outperform
$24
Jul-05-23 Initiated
Chardan Capital Markets
Buy
$30
Jan-30-23 Initiated
BMO Capital Markets
Outperform
$50
Nov-18-22 Initiated
H.C. Wainwright
Buy
$36
Nov-15-22 Upgrade
Goldman
Neutral → Buy
$12 → $68
Aug-12-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$12
Jun-22-22 Initiated
Jefferies
Buy
$22
Jan-04-22 Initiated
SVB Leerink
Outperform
$30
Jan-05-21 Initiated
Goldman
Neutral
$44
Jan-05-21 Initiated
Evercore ISI
Outperform
$70
Jan-05-21 Initiated
BofA Securities
Buy
$47
Show Previous Ratings
Sep-05-24 08:00AM
Sep-03-24 08:00AM
Aug-27-24 08:00AM
Aug-23-24 09:35AM
Aug-12-24 08:00AM
05:55PM
Loading…
Aug-08-24 05:55PM
04:05PM
Aug-05-24 08:00AM
Jul-17-24 05:00AM
Jul-12-24 09:40AM
Jul-08-24 05:52PM
12:30PM
Jun-24-24 08:00AM
Jun-18-24 08:00AM
Jun-08-24 04:30PM
07:30AM
Loading…
Jun-06-24 07:30AM
Jun-04-24 08:00AM
Jun-03-24 08:00AM
May-30-24 08:00AM
May-10-24 01:48PM
May-09-24 11:55PM
04:05PM
May-07-24 08:00AM
May-01-24 10:01AM
08:00AM
Apr-04-24 01:30AM
Mar-29-24 07:01PM
Mar-28-24 08:00AM
Mar-04-24 08:00AM
Mar-02-24 04:32AM
06:05PM
Loading…
Feb-29-24 06:05PM
04:05PM
Feb-12-24 08:00AM
Feb-08-24 03:05AM
Feb-06-24 11:27PM
Feb-05-24 04:05PM
02:50PM
12:36PM
Feb-03-24 05:00PM
Jan-29-24 08:00AM
Jan-25-24 10:04PM
Jan-23-24 08:00AM
Jan-19-24 12:00PM
Jan-11-24 10:00AM
Jan-09-24 05:02AM
Jan-06-24 05:02AM
05:02AM
Jan-04-24 08:00AM
Jan-03-24 08:01AM
Dec-21-23 08:00AM
Dec-04-23 08:00AM
Nov-15-23 08:00AM
Nov-09-23 04:19PM
Nov-01-23 04:00PM
Oct-30-23 08:00AM
Oct-26-23 09:56AM
Oct-25-23 08:00AM
Oct-23-23 08:00AM
Sep-12-23 04:05PM
Sep-07-23 04:05PM
08:00AM
Aug-09-23 06:15PM
04:05PM
08:22AM
Jul-29-23 12:00PM
Jul-17-23 04:05PM
Jul-10-23 07:30PM
Jun-08-23 09:53AM
Jun-07-23 04:10PM
Jun-01-23 08:00AM
May-24-23 08:00AM
May-13-23 08:27AM
May-12-23 06:02PM
06:02PM
May-11-23 08:00AM
May-10-23 05:55PM
04:05PM
May-09-23 04:05PM
08:25AM
May-08-23 04:05PM
06:27AM
May-04-23 09:04PM
(GlobeNewswire) -15.46%
+5.35%
04:08PM
Apr-27-23 04:29PM
(Benzinga) -19.79%
+9.15%
07:00AM
Apr-24-23 08:00AM
08:00AM
Apr-14-23 04:23AM
Apr-13-23 08:00AM
Apr-12-23 08:21AM
Mar-24-23 06:30AM
Mar-22-23 08:09AM
Mar-15-23 05:45PM
04:05PM
Mar-02-23 05:41AM
Feb-23-23 11:33AM
Feb-22-23 04:05PM
Feb-16-23 04:05PM
Feb-08-23 04:05PM
Feb-02-23 04:05PM
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bizily Scott Chief Legal Officer Aug 19 '24 Option Exercise 6.49 500 3,245 7,281 Aug 21 04:28 PM Bizily Scott Chief Legal Officer Aug 19 '24 Sale 15.00 500 7,500 6,781 Aug 21 04:28 PM Bizily Scott Chief Legal Officer Jul 16 '24 Option Exercise 7.60 1,750 13,295 8,531 Jul 18 08:22 PM Bizily Scott Chief Legal Officer Jul 16 '24 Sale 27.11 1,750 47,442 6,781 Jul 18 08:22 PM Bizily Scott Chief Legal Officer Jul 11 '24 Option Exercise 15.78 1,996 31,497 8,777 Jul 15 06:13 PM Bizily Scott Chief Legal Officer Jul 11 '24 Sale 25.00 1,996 49,900 6,781 Jul 15 06:13 PM Kirn David Chief Executive Officer Jul 10 '24 Option Exercise 14.55 12,923 188,077 1,072,076 Jul 12 05:46 PM Kirn David Chief Executive Officer Jul 10 '24 Sale 22.49 12,923 290,598 1,059,153 Jul 12 05:46 PM Bizily Scott Chief Legal Officer Jul 01 '24 Option Exercise 7.55 4,248 32,089 5,985 Jul 03 05:11 PM Bizily Scott Chief Legal Officer Jul 01 '24 Sale 21.36 4,248 90,758 1,737 Jul 03 05:11 PM Kirn David Chief Executive Officer Jun 24 '24 Option Exercise 14.42 12,930 186,451 1,072,083 Jun 26 05:07 PM Kirn David Chief Executive Officer Jun 24 '24 Sale 23.10 12,930 298,711 1,059,153 Jun 26 05:07 PM Bizily Scott Chief Legal Officer Jun 17 '24 Option Exercise 7.60 1,750 13,295 3,487 Jun 20 04:59 PM Bizily Scott Chief Legal Officer Jun 17 '24 Sale 23.71 1,750 41,494 1,737 Jun 20 04:59 PM Bizily Scott Chief Legal Officer May 16 '24 Option Exercise 7.60 1,750 13,295 3,487 May 20 08:35 PM Bizily Scott Chief Legal Officer May 16 '24 Sale 25.45 1,750 44,541 1,737 May 20 08:35 PM Bizily Scott Chief Legal Officer Apr 16 '24 Option Exercise 7.60 1,750 13,295 3,487 Apr 18 08:48 PM Bizily Scott Chief Legal Officer Apr 16 '24 Sale 25.74 1,750 45,045 1,737 Apr 18 08:48 PM Bizily Scott Chief Legal Officer Apr 01 '24 Option Exercise 12.54 8,153 102,224 9,890 Apr 03 07:18 PM Bizily Scott Chief Legal Officer Apr 01 '24 Sale 31.78 8,153 259,102 1,737 Apr 03 07:18 PM Bizily Scott Chief Legal Officer Mar 27 '24 Option Exercise 25.98 5,833 151,541 7,570 Mar 29 04:52 PM Bizily Scott Chief Legal Officer Mar 27 '24 Sale 35.04 5,833 204,410 1,737 Mar 29 04:52 PM Bizily Scott Chief Legal Officer Mar 18 '24 Option Exercise 7.60 1,750 13,295 3,487 Mar 20 04:40 PM Bizily Scott Chief Legal Officer Mar 18 '24 Sale 31.27 1,750 54,722 1,737 Mar 20 04:40 PM Bizily Scott Chief Legal Officer Feb 27 '24 Option Exercise 20.24 1,909 38,638 3,646 Feb 29 06:01 PM Bizily Scott Chief Legal Officer Feb 27 '24 Sale 30.00 1,909 57,270 1,737 Feb 29 06:01 PM Bizily Scott Chief Legal Officer Feb 16 '24 Option Exercise 7.60 1,750 13,295 3,487 Feb 21 05:41 PM Bizily Scott Chief Legal Officer Feb 16 '24 Sale 27.67 1,750 48,422 1,737 Feb 21 05:41 PM Bizily Scott Chief Legal Officer Feb 08 '24 Option Exercise 10.18 6,244 63,586 4,653 Feb 12 09:04 PM Bizily Scott Chief Legal Officer Feb 08 '24 Sale 27.50 6,244 171,710 1,737 Feb 12 09:04 PM Kirn David Chief Executive Officer Feb 08 '24 Sale 27.13 92,001 2,495,822 1,059,153 Feb 12 08:22 PM Kim Robert Young Chief Medical Officer Feb 05 '24 Option Exercise 15.29 24,000 366,840 13,595 Feb 07 08:32 PM Kim Robert Young Chief Medical Officer Feb 05 '24 Sale 30.05 24,552 737,788 1,043 Feb 07 08:32 PM Kirn David Chief Executive Officer Jan 23 '24 Sale 18.41 5,696 104,851 1,151,154 Jan 25 04:59 PM Kirn David Chief Executive Officer Jan 04 '24 Sale 20.31 40,732 827,202 1,185,087 Jan 08 04:19 PM Kirn David Chief Executive Officer Jan 05 '24 Sale 19.57 28,237 552,478 1,156,850 Jan 08 04:19 PM Kirn David Chief Executive Officer Dec 15 '23 Sale 17.27 28,632 494,432 1,230,521 Jan 08 04:19 PM Kirn David Chief Executive Officer Dec 18 '23 Sale 18.13 4,702 85,243 1,225,819 Jan 08 04:19 PM VIKING GLOBAL INVESTORS LP 10% Owner Jan 04 '24 Sale 19.53 540,000 10,546,200 4,247,914 Jan 05 05:44 PM
Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 25.04%
Shs Outstand 52.28M
Perf Week 5.59%
Market Cap 3.83B
Forward P/E -
EPS next Y -2.33
Insider Trans -5.55%
Shs Float 40.29M
Perf Month 39.95%
Income -53.89M
PEG -
EPS next Q -0.33
Inst Own 81.58%
Short Float 12.48%
Perf Quarter 38.78%
Sales 144.75M
P/S 26.46
EPS this Y 0.14%
Inst Trans 15.14%
Short Ratio 11.15
Perf Half Y 0.68%
Book/sh 9.08
P/B 7.84
EPS next Y -58.49%
ROA -7.94%
Short Interest 5.03M
Perf Year 92.83%
Cash/sh 9.61
P/C 7.41
EPS next 5Y -
ROE -13.80%
52W Range 30.88 - 75.10
Perf YTD 28.38%
Dividend Est. -
P/FCF -
EPS past 5Y -29.89%
ROI -10.07%
52W High -5.13%
Beta 0.25
Dividend TTM -
Quick Ratio 6.01
Sales past 5Y 0.00%
Gross Margin 97.77%
52W Low 130.73%
ATR (14) 3.29
Dividend Ex-Date -
Current Ratio 6.01
EPS Y/Y TTM 73.62%
Oper. Margin -55.73%
RSI (14) 63.32
Volatility 5.66% 4.90%
Employees 130
Debt/Eq 0.15
Sales Y/Y TTM 349.32%
Profit Margin -37.23%
Recom 1.12
Target Price 80.14
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -2.50%
Payout -
Rel Volume 1.24
Prev Close 70.37
Sales Surprise 24.27%
EPS Surprise 1.72%
Sales Q/Q 91.47%
Earnings Aug 08 AMC
Avg Volume 450.94K
Price 71.25
SMA20 9.01%
SMA50 16.20%
SMA200 21.33%
Trades
Volume 561,401
Change 1.25%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-03-24 Initiated
Cantor Fitzgerald
Overweight
May-31-24 Initiated
Piper Sandler
Overweight
$70
Mar-07-24 Initiated
Morgan Stanley
Overweight
$81
Jan-04-24 Reiterated
Needham
Buy
$65 → $71
Dec-19-23 Initiated
Scotiabank
Sector Outperform
$66
Oct-30-23 Initiated
TD Cowen
Outperform
Oct-17-23 Initiated
UBS
Buy
$52
May-18-23 Initiated
Truist
Buy
$60
Apr-14-23 Initiated
Robert W. Baird
Outperform
$39
Mar-14-23 Initiated
Stifel
Buy
$43
Feb-13-23 Initiated
H.C. Wainwright
Buy
$42
Dec-13-22 Resumed
BofA Securities
Buy
$29 → $37
Oct-31-22 Initiated
Guggenheim
Buy
$36
Oct-27-22 Initiated
Needham
Buy
$31
Jul-20-22 Initiated
Canaccord Genuity
Buy
$32
Mar-01-22 Initiated
SVB Leerink
Outperform
$47
Mar-01-22 Initiated
BofA Securities
Buy
$24
Show Previous Ratings
Aug-08-24 05:25PM
04:00PM
Aug-02-24 06:53AM
Jul-04-24 02:13PM
Jun-29-24 03:08AM
04:42PM
Loading…
Jun-21-24 04:42PM
(Investor's Business Daily)
May-27-24 12:32PM
May-25-24 03:11AM
May-17-24 08:06AM
May-15-24 07:21AM
May-14-24 08:00AM
May-10-24 01:13PM
04:21AM
May-09-24 10:57PM
05:10PM
04:05PM
Loading…
04:05PM
04:05PM
04:00PM
06:49AM
May-07-24 04:00PM
May-03-24 05:57PM
Apr-23-24 11:26AM
Apr-04-24 04:00PM
08:40AM
Mar-29-24 02:57PM
Mar-28-24 08:13AM
Mar-27-24 01:50AM
Mar-20-24 04:00PM
Feb-29-24 04:00PM
Feb-28-24 07:30PM
04:00PM
Loading…
04:00PM
Feb-15-24 11:57AM
Jan-16-24 01:51PM
Dec-22-23 01:30AM
Dec-15-23 05:04PM
Dec-08-23 04:00PM
Nov-30-23 09:37PM
Nov-21-23 08:00AM
(Investor's Business Daily)
Nov-16-23 10:10AM
Nov-15-23 04:05PM
(Investor's Business Daily) +5.31%
09:47AM
09:22AM
07:16AM
06:00AM
06:00AM
Nov-13-23 04:47PM
04:00PM
Nov-09-23 11:14AM
08:30AM
Nov-02-23 09:40AM
09:00AM
Oct-26-23 04:00PM
Oct-23-23 02:50AM
Oct-17-23 09:40AM
Sep-29-23 12:43PM
Sep-04-23 09:55AM
Sep-01-23 09:18AM
Aug-17-23 09:55AM
Aug-16-23 01:21PM
Aug-14-23 04:00PM
Jul-31-23 07:13AM
Jul-25-23 02:37AM
Jun-26-23 12:48PM
Jun-22-23 11:04AM
Jun-21-23 10:38AM
Jun-20-23 04:05PM
(Investor's Business Daily) -7.18%
Jun-19-23 07:46PM
May-11-23 10:45AM
May-10-23 06:11AM
May-08-23 05:15PM
04:00PM
May-04-23 04:59AM
May-03-23 06:44AM
Apr-28-23 03:34PM
Apr-25-23 12:00PM
Apr-21-23 12:00PM
Apr-13-23 04:01PM
Apr-11-23 10:00AM
Apr-05-23 09:55AM
Apr-04-23 12:20PM
Apr-03-23 08:34AM
Mar-29-23 05:25PM
04:01PM
Mar-16-23 12:18PM
Feb-21-23 04:00PM
Feb-02-23 04:00PM
Jan-30-23 09:00AM
Jan-04-23 11:45AM
Dec-14-22 10:24AM
Dec-12-22 10:55AM
Dec-09-22 04:08PM
(Investor's Business Daily) +29.24%
09:54AM
09:42AM
08:46AM
08:17AM
08:17AM
08:15AM
Nov-30-22 11:08AM
Nov-14-22 04:00PM
01:13PM
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Heery Christopher CHIEF MEDICAL OFFICER Sep 05 '24 Option Exercise 15.00 3,421 51,315 12,699 Sep 06 05:48 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 05 '24 Sale 70.02 3,421 239,526 9,278 Sep 06 05:48 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 03 '24 Option Exercise 13.27 27,451 364,232 36,729 Sep 03 09:33 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 03 '24 Sale 67.03 27,451 1,840,053 9,278 Sep 03 09:33 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 26 '24 Option Exercise 15.00 21,684 325,260 30,962 Aug 28 04:54 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 26 '24 Sale 71.12 21,684 1,542,274 9,278 Aug 28 04:54 PM CHRISTOPHER HEERY Officer Aug 26 '24 Proposed Sale 69.38 48,907 3,393,168 Aug 26 04:24 PM Patel Kavita Director Aug 20 '24 Option Exercise 6.66 1,500 9,990 1,500 Aug 22 04:01 PM Patel Kavita Director Aug 20 '24 Sale 65.88 1,500 98,820 0 Aug 22 04:01 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 16 '24 Option Exercise 6.28 5,450 34,226 14,728 Aug 19 04:39 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 16 '24 Sale 65.05 5,450 354,526 9,278 Aug 19 04:39 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 01 '24 Option Exercise 10.94 20,000 218,764 29,278 Aug 02 04:02 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 01 '24 Sale 60.42 20,000 1,208,435 9,278 Aug 02 04:02 PM Patel Kavita Director Jul 30 '24 Option Exercise 6.66 1,500 9,990 1,500 Aug 01 05:24 PM Patel Kavita Director Jul 30 '24 Sale 61.97 1,500 92,949 0 Aug 01 05:24 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 16 '24 Option Exercise 6.28 10,901 68,458 20,179 Jul 18 06:44 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 16 '24 Sale 65.30 10,901 711,854 9,278 Jul 18 06:44 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 11 '24 Option Exercise 6.28 3,671 23,054 12,949 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 12 '24 Option Exercise 6.28 1,780 11,178 11,058 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 11 '24 Sale 60.01 3,671 220,302 9,278 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 12 '24 Sale 60.21 1,780 107,175 9,278 Jul 12 06:39 PM Patel Kavita Director Jul 09 '24 Option Exercise 6.66 1,500 9,990 1,500 Jul 11 04:04 PM Patel Kavita Director Jul 09 '24 Sale 56.63 1,500 84,947 0 Jul 11 04:04 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 01 '24 Option Exercise 11.93 20,000 238,646 29,278 Jul 03 04:05 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 01 '24 Sale 55.39 20,000 1,107,763 9,278 Jul 03 04:05 PM Patel Kavita Director Jun 27 '24 Option Exercise 6.66 10,000 66,600 10,000 Jun 28 04:08 PM Patel Kavita Director Jun 27 '24 Sale 54.27 10,000 542,656 0 Jun 28 04:08 PM Gilson Michelle CHIEF FINANCIAL OFFICER Jun 26 '24 Sale 53.70 12,877 691,519 6,915 Jun 28 04:06 PM Heery Christopher CHIEF MEDICAL OFFICER Jun 12 '24 Option Exercise 11.53 20,000 230,554 29,278 Jun 14 04:31 PM Heery Christopher CHIEF MEDICAL OFFICER Jun 12 '24 Sale 55.13 20,000 1,102,668 9,278 Jun 14 04:31 PM Gilson Michelle CHIEF FINANCIAL OFFICER May 23 '24 Option Exercise 0.00 22,428 0 31,913 May 24 08:16 PM Gilson Michelle CHIEF FINANCIAL OFFICER May 24 '24 Sale 50.71 12,121 614,656 19,792 May 24 08:16 PM Heery Christopher CHIEF MEDICAL OFFICER May 01 '24 Option Exercise 6.28 18,168 114,095 27,106 May 03 05:50 PM Heery Christopher CHIEF MEDICAL OFFICER May 01 '24 Sale 51.33 18,168 932,557 8,938 May 03 05:50 PM Ware Olivia C Director Apr 16 '24 Option Exercise 7.61 9,402 71,549 9,402 Apr 18 04:01 PM Ware Olivia C Director Apr 16 '24 Sale 55.55 9,402 522,260 0 Apr 18 04:01 PM Elghandour Rami SEE REMARKS Apr 01 '24 Sale 67.09 23,086 1,548,887 69,253 Apr 03 04:44 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 22 '24 Option Exercise 6.28 20,000 125,600 50,303 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 26 '24 Option Exercise 6.28 5,450 34,226 14,388 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 22 '24 Sale 70.18 41,365 2,903,066 8,938 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 26 '24 Sale 69.11 5,450 376,648 8,938 Mar 26 08:52 PM Carroll Jill Director Mar 21 '24 Sale 70.55 504,263 35,575,755 1,479,148 Mar 25 05:30 PM Gilson Michelle CHIEF FINANCIAL OFFICER Mar 18 '24 Sale 69.34 6,825 473,255 9,485 Mar 18 08:49 PM Ware Olivia C Director Mar 15 '24 Option Exercise 7.61 9,000 68,490 9,000 Mar 18 06:38 PM Ware Olivia C Director Mar 15 '24 Sale 70.40 9,000 633,582 0 Mar 18 06:38 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 09 '24 Sale 63.40 3,688 233,811 33,270 Feb 12 07:46 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 08 '24 Sale 62.29 3,456 215,290 36,958 Feb 12 07:46 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 12 '24 Sale 64.46 2,967 191,251 30,303 Feb 12 07:46 PM Elghandour Rami SEE REMARKS Feb 09 '24 Sale 63.40 13,886 880,340 103,508 Feb 12 07:43 PM Elghandour Rami SEE REMARKS Feb 08 '24 Sale 62.29 13,010 810,451 117,394 Feb 12 07:43 PM Elghandour Rami SEE REMARKS Feb 12 '24 Sale 64.46 11,169 719,948 92,339 Feb 12 07:43 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 07 '24 Option Exercise 0.00 22,555 0 40,414 Feb 09 04:08 PM Elghandour Rami SEE REMARKS Feb 07 '24 Option Exercise 0.00 70,211 0 130,404 Feb 09 04:05 PM Heery Christopher Chief Medical Officer Jan 04 '24 Sale 55.27 7,598 419,926 17,859 Jan 08 04:06 PM Gilson Michelle Chief Financial Officer Jan 04 '24 Sale 55.27 8,514 470,551 16,310 Jan 08 04:04 PM Elghandour Rami See Remarks Jan 04 '24 Sale 55.27 29,073 1,606,804 60,193 Jan 08 04:02 PM Heery Christopher Chief Medical Officer Jan 03 '24 Option Exercise 0.00 16,519 0 25,457 Jan 04 07:32 PM Elghandour Rami See Remarks Jan 03 '24 Option Exercise 0.00 53,097 0 89,266 Jan 04 07:29 PM Heery Christopher Chief Medical Officer Dec 18 '23 Option Exercise 6.28 120,000 753,600 127,795 Dec 19 04:43 PM Heery Christopher Chief Medical Officer Dec 18 '23 Sale 50.17 120,000 6,020,281 7,795 Dec 19 04:43 PM Carroll Jill Director Dec 14 '23 Sale 49.13 504,263 24,774,441 1,983,411 Dec 18 04:47 PM
Index -
P/E 36.30
EPS (ttm) 3.31
Insider Own 2.23%
Shs Outstand 100.98M
Perf Week -6.43%
Market Cap 12.13B
Forward P/E 17.48
EPS next Y 6.88
Insider Trans -13.23%
Shs Float 98.77M
Perf Month -16.62%
Income 339.20M
PEG 1.11
EPS next Q 1.53
Inst Own 93.04%
Short Float 2.31%
Perf Quarter -9.69%
Sales 2.12B
P/S 5.73
EPS this Y 99.31%
Inst Trans -1.45%
Short Ratio 2.57
Perf Half Y -11.20%
Book/sh 24.87
P/B 4.83
EPS next Y 39.67%
ROA 11.46%
Short Interest 2.29M
Perf Year 9.08%
Cash/sh 10.29
P/C 11.68
EPS next 5Y 32.80%
ROE 15.55%
52W Range 103.63 - 157.98
Perf YTD -8.80%
Dividend Est. -
P/FCF 24.53
EPS past 5Y 62.04%
ROI 12.27%
52W High -23.93%
Beta 0.38
Dividend TTM -
Quick Ratio 4.08
Sales past 5Y 34.77%
Gross Margin 97.28%
52W Low 15.96%
ATR (14) 5.35
Dividend Ex-Date Dec 29, 1995
Current Ratio 4.19
EPS Y/Y TTM 87.53%
Oper. Margin 25.70%
RSI (14) 27.49
Volatility 3.53% 2.86%
Employees 1400
Debt/Eq 0.12
Sales Y/Y TTM 26.69%
Profit Margin 16.00%
Recom 1.46
Target Price 169.52
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -34.36%
Payout 0.00%
Rel Volume 0.98
Prev Close 121.21
Sales Surprise 8.10%
EPS Surprise -44.16%
Sales Q/Q 30.37%
Earnings Aug 01 BMO
Avg Volume 887.70K
Price 120.17
SMA20 -15.33%
SMA50 -16.06%
SMA200 -11.58%
Trades
Volume 868,949
Change -0.86%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-29-24 Upgrade
Piper Sandler
Neutral → Overweight
$131 → $159
Apr-24-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$140 → $170
Dec-13-23 Resumed
Citigroup
Neutral
$127
Dec-12-23 Initiated
Deutsche Bank
Buy
$136
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$135 → $140
Aug-21-23 Reiterated
Mizuho
Neutral
$112 → $113
Jul-24-23 Upgrade
SVB Securities
Market Perform → Outperform
$115 → $125
Jul-06-23 Upgrade
BMO Capital Markets
Underperform → Market Perform
$91 → $96
May-04-23 Upgrade
Guggenheim
Neutral → Buy
$145
Mar-30-23 Upgrade
Canaccord Genuity
Hold → Buy
$124 → $132
Mar-03-23 Upgrade
Evercore ISI
In-line → Outperform
$130
Feb-03-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$120 → $130
Nov-14-22 Downgrade
Evercore ISI
Outperform → In-line
$140 → $130
Oct-11-22 Initiated
UBS
Buy
$136
Sep-26-22 Initiated
Wells Fargo
Equal Weight
$110
Jun-06-22 Resumed
Jefferies
Buy
$126 → $112
Mar-03-22 Downgrade
Piper Sandler
Overweight → Neutral
$114 → $94
Feb-25-22 Upgrade
Goldman
Neutral → Buy
$115
Jan-18-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$122 → $90
Nov-19-21 Initiated
BMO Capital Markets
Underperform
$76
Show Previous Ratings
Sep-02-24 10:53AM
(Pharmaceutical Technology)
Aug-30-24 07:41AM
Aug-29-24 01:22PM
06:52AM
Aug-28-24 06:19PM
04:28PM
Loading…
04:28PM
(Investor's Business Daily)
04:05PM
11:16AM
09:56AM
(Investor's Business Daily)
08:17AM
(Investor's Business Daily)
08:15AM
07:07AM
07:00AM
Aug-16-24 07:01PM
Aug-07-24 04:01PM
12:45PM
Loading…
Aug-06-24 12:45PM
Aug-02-24 06:39AM
01:05AM
Aug-01-24 10:00AM
08:06AM
08:05AM
07:09AM
(Associated Press Finance)
07:00AM
Jul-31-24 09:15AM
Jul-25-24 10:02AM
Jul-18-24 08:30AM
Jul-12-24 08:38AM
Jul-11-24 04:01PM
Jul-02-24 06:33AM
(Pharmaceutical Technology)
Jul-01-24 07:30AM
04:37PM
Loading…
Jun-28-24 04:37PM
Jun-17-24 03:27PM
Jun-14-24 02:34PM
(Investor's Business Daily)
Jun-03-24 08:01AM
07:35AM
07:30AM
May-29-24 04:01PM
May-28-24 04:14PM
08:30AM
May-21-24 04:05PM
May-16-24 04:47PM
May-14-24 08:30AM
May-09-24 11:51AM
(Investor's Business Daily)
11:51AM
(Investor's Business Daily)
09:45AM
08:30AM
02:35AM
May-08-24 08:30AM
May-07-24 04:15PM
08:30AM
May-06-24 08:30AM
May-04-24 08:00AM
(Investor's Business Daily)
May-03-24 01:15PM
May-02-24 11:18AM
03:01AM
01:06AM
May-01-24 11:36PM
(Thomson Reuters StreetEvents)
09:01PM
04:18PM
(Investor's Business Daily)
11:54AM
09:30AM
09:04AM
(Investor's Business Daily)
08:31AM
08:15AM
07:18AM
(Associated Press Finance)
07:00AM
Apr-30-24 05:48PM
05:45PM
05:31PM
05:12PM
09:15AM
Apr-24-24 10:15AM
(Investor's Business Daily)
10:01AM
08:30AM
08:00AM
Apr-23-24 11:50AM
(Investor's Business Daily)
07:22AM
07:00AM
Apr-22-24 11:10AM
Apr-16-24 04:01PM
02:30AM
Apr-10-24 04:01PM
Apr-09-24 07:37AM
Apr-03-24 08:30AM
Mar-28-24 08:30AM
Mar-24-24 09:19AM
Mar-23-24 08:00AM
(Investor's Business Daily)
Mar-16-24 08:00AM
(Investor's Business Daily)
01:23AM
01:23AM
Mar-15-24 10:00AM
Mar-13-24 01:26AM
Mar-11-24 04:01PM
01:12PM
(Investor's Business Daily)
Mar-06-24 04:45PM
Mar-01-24 12:40AM
Feb-27-24 04:01PM
Feb-22-24 11:28PM
03:55AM
Feb-15-24 11:36PM
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RASTETTER WILLIAM H Director Aug 15 '24 Sale 146.69 14,250 2,090,332 37,491 Aug 16 05:00 PM LYONS GARY A Director Aug 13 '24 Option Exercise 42.76 11,570 494,733 130,617 Aug 15 05:21 PM LYONS GARY A Director Aug 13 '24 Sale 150.43 11,570 1,740,450 119,047 Aug 15 05:21 PM ABERNETHY MATT Chief Financial Officer Aug 13 '24 Option Exercise 73.60 14,100 1,037,760 45,628 Aug 15 05:12 PM ABERNETHY MATT Chief Financial Officer Aug 13 '24 Sale 150.38 14,100 2,120,347 31,528 Aug 15 05:12 PM Delaet Ingrid Chief Regulatory Officer Aug 13 '24 Option Exercise 103.52 3,043 315,011 9,650 Aug 15 05:06 PM Delaet Ingrid Chief Regulatory Officer Aug 13 '24 Sale 150.10 7,143 1,072,180 2,507 Aug 15 05:06 PM Delaet Ingrid Chief Regulatory Officer Aug 06 '24 Option Exercise 79.02 273 21,572 6,880 Aug 08 05:16 PM Delaet Ingrid Chief Regulatory Officer Aug 06 '24 Sale 147.70 273 40,322 6,607 Aug 08 05:16 PM Cooke Julie Chief Human Resources Officer Aug 01 '24 Option Exercise 61.82 12,632 780,910 30,834 Aug 05 05:40 PM Cooke Julie Chief Human Resources Officer Aug 01 '24 Sale 153.26 12,632 1,936,017 18,202 Aug 05 05:40 PM Lippoldt Darin Chief Legal Officer Aug 01 '24 Option Exercise 79.02 2,996 236,744 42,736 Aug 05 05:18 PM Lippoldt Darin Chief Legal Officer Aug 01 '24 Sale 154.01 2,996 461,423 39,740 Aug 05 05:18 PM Cooke Julie Chief Human Resources Officer Jul 16 '24 Option Exercise 61.82 900 55,638 19,102 Jul 18 05:12 PM Cooke Julie Chief Human Resources Officer Jul 16 '24 Sale 150.04 900 135,036 18,202 Jul 18 05:12 PM Delaet Ingrid Chief Regulatory Officer Jul 16 '24 Option Exercise 103.52 1,957 202,589 9,064 Jul 18 05:00 PM Delaet Ingrid Chief Regulatory Officer Jul 16 '24 Sale 150.03 2,857 428,627 6,607 Jul 18 05:00 PM LYONS GARY A Director Jul 16 '24 Option Exercise 42.76 930 39,767 119,977 Jul 18 04:54 PM LYONS GARY A Director Jul 16 '24 Sale 150.03 930 139,530 119,047 Jul 18 04:54 PM ABERNETHY MATT Chief Financial Officer Jul 16 '24 Option Exercise 73.60 900 66,240 32,428 Jul 18 04:45 PM ABERNETHY MATT Chief Financial Officer Jul 16 '24 Sale 150.04 900 135,037 31,528 Jul 18 04:45 PM Lippoldt Darin Chief Legal Officer Jul 16 '24 Option Exercise 79.02 7,004 553,456 46,744 Jul 18 04:41 PM Lippoldt Darin Chief Legal Officer Jul 16 '24 Sale 150.00 7,004 1,050,590 39,740 Jul 18 04:41 PM Cooke Julie Chief Human Resources Officer Jul 01 '24 Option Exercise 61.82 10,000 618,200 28,202 Jul 02 09:36 PM Cooke Julie Chief Human Resources Officer Jul 01 '24 Sale 140.19 10,000 1,401,864 18,202 Jul 02 09:36 PM Delaet Ingrid Chief Regulatory Officer Jul 01 '24 Option Exercise 79.02 272 21,493 7,779 Jul 02 09:09 PM Delaet Ingrid Chief Regulatory Officer Jul 01 '24 Sale 138.11 272 37,566 7,507 Jul 02 09:09 PM Delaet Ingrid Chief Regulatory Officer May 31 '24 Option Exercise 79.02 273 21,572 7,780 Jun 04 04:23 PM Delaet Ingrid Chief Regulatory Officer May 31 '24 Sale 136.55 273 37,278 7,507 Jun 04 04:23 PM SHERWIN STEPHEN A Director May 29 '24 Option Exercise 44.68 40,000 1,787,350 51,504 May 30 04:38 PM SHERWIN STEPHEN A Director May 29 '24 Sale 133.46 40,000 5,338,564 26,504 May 30 04:38 PM Sharp Shalini Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 05:35 PM Sharp Shalini Director May 17 '24 Sale 141.90 1,106 156,943 994 May 21 05:35 PM POPS RICHARD F Director May 17 '24 Option Exercise 0.00 4,199 0 33,711 May 21 05:27 PM POPS RICHARD F Director May 17 '24 Sale 141.84 2,100 297,860 31,611 May 21 05:27 PM MORROW GEORGE J Director May 17 '24 Option Exercise 0.00 4,199 0 4,199 May 21 05:15 PM Norwalk Leslie V Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 05:06 PM Norwalk Leslie V Director May 17 '24 Sale 141.82 1,106 156,850 994 May 21 05:06 PM LYONS GARY A Director May 17 '24 Option Exercise 0.00 2,100 0 119,047 May 21 04:57 PM SHERWIN STEPHEN A Director May 17 '24 Option Exercise 0.00 4,199 0 26,504 May 21 04:51 PM Mercier Johanna Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 04:46 PM LYONS GARY A Director May 14 '24 Option Exercise 42.76 12,500 534,500 129,447 May 16 04:55 PM LYONS GARY A Director May 14 '24 Sale 135.63 12,500 1,695,370 116,947 May 16 04:55 PM ABERNETHY MATT Chief Financial Officer May 14 '24 Option Exercise 73.60 15,000 1,104,000 46,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 15 '24 Option Exercise 73.60 15,000 1,104,000 46,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 15 '24 Sale 140.24 15,000 2,103,609 31,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 14 '24 Sale 135.66 15,000 2,034,826 31,528 May 16 04:40 PM Delaet Ingrid Chief Regulatory Officer May 06 '24 Option Exercise 79.02 273 21,572 7,780 May 08 04:26 PM Delaet Ingrid Chief Regulatory Officer May 06 '24 Sale 140.55 273 38,370 7,507 May 08 04:26 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Option Exercise 81.21 19,818 1,609,431 53,365 Apr 17 05:19 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Sale 133.36 19,818 2,643,020 40,778 Apr 17 05:19 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Option Exercise 79.02 272 21,493 7,779 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Sale 137.30 272 37,346 7,507 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Option Exercise 103.52 5,000 517,600 12,507 Mar 25 06:02 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Sale 145.06 5,000 725,320 7,507 Mar 25 06:02 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Option Exercise 80.90 75,000 6,067,628 110,299 Mar 15 05:33 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Sale 139.38 75,000 10,453,417 40,778 Mar 15 05:33 PM MORROW GEORGE J Director Mar 14 '24 Option Exercise 39.79 40,000 1,591,600 20,000 Mar 15 05:25 PM MORROW GEORGE J Director Mar 14 '24 Sale 139.42 40,000 5,576,710 0 Mar 15 05:25 PM POPS RICHARD F Director Mar 13 '24 Option Exercise 42.76 23,200 992,032 52,712 Mar 15 05:19 PM POPS RICHARD F Director Mar 13 '24 Sale 140.33 23,200 3,255,621 29,512 Mar 15 05:19 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Option Exercise 106.02 3,000 318,060 10,507 Mar 15 05:15 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Sale 140.14 3,000 420,419 7,507 Mar 15 05:15 PM POPS RICHARD F Director Mar 08 '24 Option Exercise 42.76 1,700 72,692 31,212 Mar 12 06:47 PM POPS RICHARD F Director Mar 11 '24 Option Exercise 42.76 100 4,276 29,612 Mar 12 06:47 PM POPS RICHARD F Director Mar 08 '24 Sale 140.05 1,700 238,078 29,512 Mar 12 06:47 PM POPS RICHARD F Director Mar 11 '24 Sale 140.00 100 14,000 29,512 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Option Exercise 106.02 1,800 190,836 9,307 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Option Exercise 106.02 200 21,204 7,707 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Sale 140.03 1,800 252,053 7,507 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Sale 140.00 200 28,000 7,507 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Option Exercise 79.02 6,544 517,107 10,007 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Option Exercise 79.02 273 21,572 7,780 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Sale 135.34 6,544 885,638 7,507 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Sale 135.51 273 36,994 7,507 Feb 29 07:02 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Option Exercise 53.67 75,000 4,025,043 93,759 Feb 29 06:55 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Sale 134.69 75,000 10,101,608 40,616 Feb 29 06:55 PM Norwalk Leslie V Director Feb 27 '24 Option Exercise 84.95 8,000 679,600 8,000 Feb 29 06:50 PM Norwalk Leslie V Director Feb 27 '24 Sale 135.67 8,000 1,085,388 0 Feb 29 06:50 PM POPS RICHARD F Director Feb 20 '24 Option Exercise 12.98 15,000 194,700 44,512 Feb 22 05:11 PM POPS RICHARD F Director Feb 20 '24 Sale 132.47 15,000 1,987,047 29,512 Feb 22 05:11 PM ROBERTS EIRY Chief Medical Officer Feb 13 '24 Sale 132.96 1,114 148,122 23,716 Feb 15 05:51 PM Onyia Jude Chief Scientific Officer Feb 13 '24 Sale 132.94 1,432 190,371 13,128 Feb 15 05:48 PM Lippoldt Darin Chief Legal Officer Feb 13 '24 Sale 132.99 1,098 146,028 39,740 Feb 15 05:45 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Sale 133.02 2,832 376,700 514,596 Feb 15 05:43 PM Gano Kyle Chief Business Development Off Feb 13 '24 Sale 132.89 1,352 179,674 135,166 Feb 15 05:40 PM Delaet Ingrid Chief Regulatory Officer Feb 13 '24 Sale 133.03 716 95,253 7,507 Feb 15 05:38 PM Cooke Julie Chief Human Resources Officer Feb 13 '24 Sale 133.04 796 105,902 17,976 Feb 15 05:35 PM Boyer David W. Chief Corp. Affairs Officer Feb 13 '24 Sale 133.07 1,811 240,996 4,895 Feb 15 05:33 PM BENEVICH ERIC Chief Commercial Officer Feb 13 '24 Sale 133.01 1,098 146,050 40,616 Feb 15 05:29 PM ABERNETHY MATT Chief Financial Officer Feb 13 '24 Sale 132.85 1,352 179,612 31,528 Feb 15 05:27 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Option Exercise 39.28 5,090 199,951 512,052 Feb 14 05:17 PM Boyer David W. Chief Corp. Affairs Officer Feb 08 '24 Sale 135.41 1,328 179,830 4,895 Feb 08 07:46 PM Boyer David W. Chief Corp. Affairs Officer Feb 06 '24 Sale 141.96 456 64,734 4,894 Feb 08 07:46 PM Cooke Julie Chief Human Resources Officer Feb 08 '24 Sale 135.44 1,329 179,995 17,263 Feb 08 07:35 PM Cooke Julie Chief Human Resources Officer Feb 06 '24 Sale 142.07 1,215 172,617 17,263 Feb 08 07:35 PM ROBERTS EIRY Chief Medical Officer Feb 06 '24 Sale 142.24 1,121 159,446 21,837 Feb 08 07:28 PM ROBERTS EIRY Chief Medical Officer Feb 08 '24 Sale 134.21 980 131,522 22,717 Feb 08 07:28 PM Lippoldt Darin Chief Legal Officer Feb 06 '24 Sale 142.17 1,041 147,995 37,939 Feb 08 07:25 PM Lippoldt Darin Chief Legal Officer Feb 08 '24 Sale 134.24 911 122,289 38,755 Feb 08 07:25 PM
Index -
P/E -
EPS (ttm) -3.19
Insider Own 10.77%
Shs Outstand 20.63M
Perf Week -8.17%
Market Cap 38.27M
Forward P/E -
EPS next Y -3.20
Insider Trans -17.84%
Shs Float 18.41M
Perf Month -2.37%
Income -40.69M
PEG -
EPS next Q -0.52
Inst Own 46.39%
Short Float 10.21%
Perf Quarter -31.55%
Sales 0.00M
P/S -
EPS this Y 14.22%
Inst Trans -2.32%
Short Ratio 11.28
Perf Half Y -51.57%
Book/sh 8.10
P/B 0.23
EPS next Y -4.49%
ROA -41.35%
Short Interest 1.88M
Perf Year -14.91%
Cash/sh 4.34
P/C 0.43
EPS next 5Y -
ROE -45.90%
52W Range 1.04 - 5.24
Perf YTD -1.07%
Dividend Est. -
P/FCF -
EPS past 5Y 39.98%
ROI -42.38%
52W High -64.60%
Beta 1.82
Dividend TTM -
Quick Ratio 16.33
Sales past 5Y 0.00%
Gross Margin -
52W Low 78.37%
ATR (14) 0.17
Dividend Ex-Date -
Current Ratio 16.33
EPS Y/Y TTM 46.34%
Oper. Margin 0.00%
RSI (14) 34.86
Volatility 6.85% 8.84%
Employees 27
Debt/Eq 0.05
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 29.50
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 55.15%
Payout -
Rel Volume 0.78
Prev Close 1.90
Sales Surprise -
EPS Surprise 43.75%
Sales Q/Q -
Earnings Aug 06 BMO
Avg Volume 166.75K
Price 1.86
SMA20 -8.15%
SMA50 -12.74%
SMA200 -29.42%
Trades
Volume 129,635
Change -2.37%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-10-23 Resumed
Guggenheim
Buy
$22
Jun-04-21 Initiated
H.C. Wainwright
Buy
$40
Feb-17-21 Initiated
Oppenheimer
Outperform
$43
Oct-19-20 Initiated
Cowen
Outperform
$50
Jul-29-20 Initiated
Guggenheim
Buy
$50
Sep-03-24 08:00AM
Aug-06-24 08:00AM
Jun-24-24 05:06PM
May-21-24 08:00AM
May-02-24 12:54PM
08:00AM
Loading…
08:00AM
Apr-12-24 09:55AM
Apr-05-24 08:04AM
08:02AM
08:00AM
Mar-13-24 08:00AM
Feb-28-24 08:00AM
Jan-31-24 07:30AM
Nov-30-23 08:30AM
Nov-03-23 09:43AM
08:00AM
Loading…
08:00AM
Oct-23-23 08:00AM
Sep-20-23 08:30AM
Sep-05-23 07:30AM
Aug-03-23 08:00AM
May-15-23 08:00AM
May-04-23 08:00AM
May-02-23 08:00AM
Apr-28-23 08:00AM
Mar-08-23 08:00AM
Mar-01-23 08:00AM
Feb-02-23 08:00AM
Jan-30-23 08:00AM
Dec-01-22 08:00AM
Nov-03-22 08:00AM
08:35AM
Loading…
Oct-24-22 08:35AM
Sep-06-22 08:00AM
Aug-09-22 08:00AM
Jun-21-22 08:00AM
May-26-22 05:11PM
May-17-22 08:00AM
07:32AM
May-12-22 08:00AM
May-05-22 08:00AM
Apr-11-22 09:55AM
Mar-24-22 08:00AM
Mar-23-22 10:00AM
Mar-09-22 07:30AM
Mar-08-22 05:50AM
Mar-02-22 08:00AM
Feb-01-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-08-21 11:15AM
Nov-04-21 08:00AM
Oct-25-21 04:45PM
Oct-12-21 07:00AM
Sep-17-21 04:05PM
Sep-13-21 07:00AM
Sep-09-21 10:31AM
Sep-07-21 08:00AM
Aug-05-21 08:00AM
Jul-07-21 08:00AM
Jun-22-21 07:30AM
Jun-10-21 08:00AM
May-13-21 08:00AM
May-06-21 07:30AM
Apr-23-21 07:00AM
Apr-19-21 04:09PM
08:00AM
Apr-12-21 11:12AM
Mar-30-21 07:01AM
Mar-11-21 07:30AM
Mar-10-21 08:00AM
Feb-04-21 08:00AM
Feb-02-21 08:00AM
08:00AM
Dec-16-20 11:07PM
Dec-07-20 04:30PM
Dec-03-20 07:00AM
Nov-24-20 07:00AM
Nov-12-20 07:15AM
Nov-11-20 07:00AM
Nov-04-20 07:00AM
Sep-28-20 03:12PM
Sep-22-20 08:13AM
Sep-21-20 04:01PM
Sep-08-20 07:00AM
Sep-02-20 05:49PM
Aug-03-20 07:00AM
Jul-28-20 07:00AM
Jul-24-20 07:00AM
Jul-03-20 06:34PM
Jul-02-20 07:59PM
04:05PM
Jun-02-20 04:05PM
May-26-20 08:30AM
May-13-20 08:00AM
May-11-20 08:38AM
May-05-20 04:05PM
Apr-02-20 07:00AM
Feb-11-20 08:00AM
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Opaleye Management Inc. 10% Owner Jul 16 '24 Sale 2.44 11,396 27,828 56,500 Jul 18 04:05 PM Opaleye Management Inc. 10% Owner Jul 11 '24 Sale 2.40 47,993 115,346 60,000 Jul 11 07:56 PM Opaleye Management Inc. 10% Owner Jul 10 '24 Sale 2.31 18,061 41,685 75,000 Jul 11 07:56 PM Opaleye Management Inc. 10% Owner Jul 09 '24 Sale 2.21 8,497 18,811 80,000 Jul 11 07:56 PM Opaleye Management Inc. 10% Owner Jul 01 '24 Sale 2.12 8,288 17,598 87,500 Jul 03 02:00 PM Opaleye Management Inc. 10% Owner Jun 27 '24 Sale 2.26 46,574 105,169 90,000 Jun 28 06:45 PM Opaleye Management Inc. 10% Owner Jun 28 '24 Sale 2.07 17,994 37,334 85,000 Jun 28 06:45 PM Opaleye Management Inc. 10% Owner Jun 25 '24 Sale 2.26 12,725 28,734 102,471 Jun 27 04:05 PM Opaleye Management Inc. 10% Owner May 30 '24 Sale 2.94 9,230 27,113 114,520 May 31 04:05 PM Opaleye Management Inc. 10% Owner May 31 '24 Sale 2.90 5,824 16,895 108,696 May 31 04:05 PM Opaleye Management Inc. 10% Owner May 21 '24 Sale 3.06 33,000 100,838 124,250 May 23 07:01 PM Opaleye Management Inc. 10% Owner May 22 '24 Sale 3.02 9,800 29,596 123,750 May 23 07:01 PM Opaleye Management Inc. 10% Owner May 17 '24 Sale 3.25 70,885 230,326 126,050 May 17 07:48 PM Opaleye Management Inc. 10% Owner May 10 '24 Sale 3.11 151,700 472,424 2,380,294 May 10 06:57 PM Opaleye Management Inc. 10% Owner May 09 '24 Sale 3.09 30,600 94,526 2,531,994 May 10 06:57 PM
Index RUT
P/E -
EPS (ttm) -3.65
Insider Own 16.89%
Shs Outstand 164.67M
Perf Week 0.10%
Market Cap 6.99B
Forward P/E -
EPS next Y -3.87
Insider Trans -0.73%
Shs Float 138.83M
Perf Month -1.02%
Income -519.21M
PEG -
EPS next Q -0.90
Inst Own 87.07%
Short Float 12.13%
Perf Quarter 4.21%
Sales 0.74M
P/S 9444.53
EPS this Y 10.44%
Inst Trans 7.50%
Short Ratio 12.05
Perf Half Y 32.70%
Book/sh 9.77
P/B 4.28
EPS next Y -11.91%
ROA -36.03%
Short Interest 16.84M
Perf Year 24.97%
Cash/sh 9.52
P/C 4.39
EPS next 5Y -
ROE -40.73%
52W Range 15.44 - 48.61
Perf YTD 45.89%
Dividend Est. -
P/FCF -
EPS past 5Y -36.05%
ROI -30.58%
52W High -13.93%
Beta 1.42
Dividend TTM -
Quick Ratio 15.42
Sales past 5Y 11.11%
Gross Margin -1323.58%
52W Low 170.98%
ATR (14) 1.71
Dividend Ex-Date -
Current Ratio 15.42
EPS Y/Y TTM -16.27%
Oper. Margin -80961.32%
RSI (14) 44.72
Volatility 4.21% 3.81%
Employees 378
Debt/Eq 0.05
Sales Y/Y TTM -97.49%
Profit Margin -69973.99%
Recom 1.19
Target Price 59.29
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q 12.28%
Payout -
Rel Volume 0.62
Prev Close 43.24
Sales Surprise -100.00%
EPS Surprise -4.56%
Sales Q/Q -100.00%
Earnings Aug 07 AMC
Avg Volume 1.40M
Price 41.84
SMA20 -2.80%
SMA50 -3.17%
SMA200 20.84%
Trades
Volume 861,523
Change -3.24%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-16-24 Reiterated
Needham
Buy
$46 → $62
Jul-12-24 Initiated
Barclays
Overweight
$52
Jul-08-24 Initiated
Jefferies
Buy
$63
Apr-12-24 Reiterated
Needham
Buy
$36 → $46
Apr-10-24 Upgrade
Raymond James
Outperform → Strong Buy
$36 → $48
Mar-11-24 Initiated
Piper Sandler
Overweight
$43
Jan-05-24 Upgrade
BofA Securities
Neutral → Buy
$31 → $34
Jan-04-24 Initiated
Wedbush
Outperform
$41
Nov-16-23 Initiated
Raymond James
Outperform
$30
Feb-28-23 Upgrade
JP Morgan
Neutral → Overweight
$32 → $38
Dec-14-22 Initiated
Needham
Buy
$31
Oct-21-22 Initiated
Oppenheimer
Outperform
$30
May-20-22 Initiated
BofA Securities
Neutral
$24
Mar-01-22 Upgrade
Stifel
Hold → Buy
$36 → $26
Sep-23-21 Initiated
Stifel
Hold
$34
Aug-12-21 Downgrade
Goldman
Buy → Neutral
$49 → $27
May-18-21 Initiated
Goldman
Buy
$49
May-21-20 Initiated
H.C. Wainwright
Buy
$55
Mar-09-20 Initiated
JP Morgan
Neutral
$32
Mar-09-20 Initiated
Guggenheim
Buy
$50
Show Previous Ratings
Aug-07-24 04:05PM
Jul-31-24 04:05PM
Jul-11-24 12:00PM
Jul-10-24 05:58AM
Jul-08-24 04:05PM
(GlobeNewswire) +5.46%
+10.97%
09:00AM
Loading…
Jun-08-24 09:00AM
Jun-05-24 04:05PM
Jun-04-24 06:00AM
May-09-24 03:41PM
May-08-24 09:58PM
04:02PM
May-01-24 04:05PM
Apr-09-24 03:34PM
Apr-08-24 11:36AM
Apr-04-24 04:05PM
04:05PM
Loading…
Mar-28-24 04:05PM
Feb-26-24 05:20PM
04:05PM
Feb-20-24 04:05PM
Feb-01-24 04:05PM
Jan-17-24 09:55AM
Jan-04-24 07:00AM
Nov-09-23 09:10AM
Nov-08-23 11:30AM
Nov-07-23 10:14AM
Nov-06-23 05:50PM
04:55PM
04:05PM
Nov-01-23 07:00AM
Oct-31-23 04:15PM
04:06PM
Loading…
Oct-23-23 04:06PM
(Investor's Business Daily) -34.38%
+14.52%
01:48PM
12:04PM
10:07AM
(Investor's Business Daily)
Oct-22-23 02:30AM
Oct-19-23 07:02AM
Oct-16-23 03:19PM
(Investor's Business Daily) +14.08%
09:45AM
Oct-13-23 02:54PM
11:50AM
Oct-04-23 04:05PM
Sep-20-23 07:01AM
Sep-19-23 07:00AM
Aug-17-23 04:05PM
Aug-09-23 02:13PM
Aug-08-23 05:50PM
04:05PM
Aug-03-23 04:05PM
Aug-01-23 02:34PM
(American City Business Journals) +20.00%
07:00AM
Jul-06-23 09:59AM
Jun-09-23 08:29AM
Jun-08-23 04:05PM
May-24-23 04:05PM
May-13-23 08:19AM
May-10-23 06:10AM
May-09-23 09:40AM
(Thomson Reuters StreetEvents)
May-08-23 05:25PM
04:02PM
May-03-23 10:00AM
09:55AM
May-01-23 04:05PM
10:01AM
Apr-19-23 07:15AM
Apr-13-23 04:05PM
Apr-06-23 07:00AM
Mar-22-23 11:29AM
Mar-11-23 03:27AM
Mar-07-23 04:02PM
Mar-02-23 09:15PM
(GlobeNewswire) -11.72%
+8.78%
Mar-01-23 04:17PM
Feb-27-23 06:25PM
04:05PM
Feb-21-23 04:05PM
Feb-02-23 12:00PM
07:00AM
Jan-23-23 05:31AM
Jan-12-23 03:25AM
Jan-03-23 07:00AM
Dec-31-22 06:15AM
Dec-26-22 08:14AM
Dec-19-22 07:00AM
Dec-08-22 06:19AM
Dec-07-22 04:05PM
Nov-10-22 05:48AM
(Simply Wall St.) +13.34%
Nov-09-22 04:05PM
Nov-07-22 05:55PM
04:05PM
Nov-02-22 10:01AM
09:54AM
Nov-01-22 04:05PM
Oct-24-22 11:07AM
Oct-13-22 11:05AM
Sep-22-22 07:00AM
Sep-01-22 04:05PM
Aug-31-22 04:05PM
Aug-30-22 09:55AM
Aug-12-22 09:55AM
Aug-10-22 08:35AM
Aug-09-22 06:15PM
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BARBARA L WEBER Officer Aug 21 '24 Proposed Sale 44.83 1,808 81,053 Aug 21 04:14 PM Kelsey Stephen Michael See Remarks Aug 13 '24 Option Exercise 4.09 16,667 68,168 285,740 Aug 15 04:48 PM Kelsey Stephen Michael See Remarks Aug 13 '24 Sale 42.98 16,667 716,389 269,073 Aug 15 04:48 PM STEPHEN M. KELSEY Officer Aug 13 '24 Proposed Sale 42.98 16,667 716,348 Aug 13 04:25 PM GOLDSMITH MARK A See Remarks Aug 01 '24 Option Exercise 4.09 10,000 40,900 321,885 Aug 02 05:35 PM GOLDSMITH MARK A See Remarks Aug 01 '24 Sale 45.88 10,000 458,827 311,885 Aug 02 05:35 PM MARK A GOLDSMITH Director Aug 01 '24 Proposed Sale 45.64 10,000 456,400 Aug 01 04:29 PM Kelsey Stephen Michael See Remarks Jul 15 '24 Option Exercise 4.09 16,667 68,168 285,740 Jul 17 04:07 PM Kelsey Stephen Michael See Remarks Jul 15 '24 Sale 46.47 16,667 774,516 269,073 Jul 17 04:07 PM GOLDSMITH MARK A See Remarks Jul 12 '24 Option Exercise 4.09 25,000 102,250 336,885 Jul 16 05:05 PM GOLDSMITH MARK A See Remarks Jul 12 '24 Sale 45.05 25,000 1,126,205 311,885 Jul 16 05:05 PM GOLDSMITH MARK A See Remarks Jul 12 '24 Sale 45.01 10,000 450,117 25,424 Jul 16 05:05 PM Cislini Jeff General Counsel Jul 09 '24 Sale 40.83 2,399 97,951 47,088 Jul 10 04:36 PM Patel Sushil Director Jul 09 '24 Option Exercise 16.80 2,155 36,204 22,103 Jul 10 04:36 PM Patel Sushil Director Jul 09 '24 Sale 44.00 2,155 94,820 19,948 Jul 10 04:36 PM Cislini Jeff General Counsel Jun 26 '24 Sale 38.47 2,000 76,940 49,487 Jun 27 06:48 PM Kelsey Stephen Michael See Remarks Jun 25 '24 Option Exercise 4.09 16,467 67,350 285,540 Jun 26 04:26 PM Kelsey Stephen Michael See Remarks Jun 24 '24 Option Exercise 4.09 200 818 269,273 Jun 26 04:26 PM Kelsey Stephen Michael See Remarks Jun 25 '24 Sale 39.06 16,467 643,152 269,073 Jun 26 04:26 PM Kelsey Stephen Michael See Remarks Jun 24 '24 Sale 39.00 200 7,800 269,073 Jun 26 04:26 PM GOLDSMITH MARK A See Remarks Jun 17 '24 Sale 37.39 11,950 446,770 311,885 Jun 20 04:14 PM Anders Jack Chief Financial Officer Jun 17 '24 Sale 37.39 1,893 70,775 101,176 Jun 20 04:13 PM Horn Margaret A Chief Operating Officer Jun 17 '24 Sale 37.39 4,415 165,064 136,651 Jun 20 04:12 PM Kelsey Stephen Michael See Remarks Jun 17 '24 Sale 37.39 3,349 125,209 269,073 Jun 20 04:11 PM Cislini Jeff General Counsel Jun 17 '24 Sale 37.39 1,757 65,690 51,487 Jun 20 04:11 PM Wei Lin Chief Medical Officer Jun 17 '24 Sale 37.39 5,589 208,954 70,851 Jun 20 04:10 PM GOLDSMITH MARK A See Remarks Jun 03 '24 Option Exercise 4.09 7,500 30,675 329,822 Jun 05 04:18 PM GOLDSMITH MARK A See Remarks Jun 03 '24 Sale 39.99 7,500 299,942 322,322 Jun 05 04:18 PM Cislini Jeff General Counsel May 21 '24 Sale 39.11 1,500 58,671 52,874 May 22 04:11 PM Anders Jack Chief Financial Officer May 03 '24 Option Exercise 2.68 10,000 26,800 111,959 May 03 07:36 PM Anders Jack Chief Financial Officer May 03 '24 Sale 40.03 10,000 400,260 101,959 May 03 07:36 PM GOLDSMITH MARK A See Remarks Apr 10 '24 Sale 35.33 10,000 353,346 30,424 Apr 12 08:08 PM GOLDSMITH MARK A See Remarks Apr 10 '24 Sale 35.48 7,500 266,122 452,879 Apr 12 08:08 PM Patel Sushil Director Apr 10 '24 Option Exercise 16.80 2,155 36,204 17,855 Apr 12 04:23 PM Patel Sushil Director Apr 10 '24 Sale 37.00 2,155 79,735 15,700 Apr 12 04:23 PM Cislini Jeff General Counsel Mar 27 '24 Sale 30.99 1,500 46,481 54,374 Mar 28 04:11 PM Cislini Jeff General Counsel Mar 18 '24 Sale 31.58 1,252 39,542 55,874 Mar 20 04:45 PM Kelsey Stephen Michael See Remarks Mar 18 '24 Sale 31.58 2,123 67,051 270,909 Mar 20 04:45 PM Horn Margaret A Chief Operating Officer Mar 18 '24 Sale 31.58 2,914 92,033 139,553 Mar 20 04:44 PM GOLDSMITH MARK A See Remarks Mar 18 '24 Sale 31.58 5,788 182,804 460,379 Mar 20 04:44 PM Anders Jack Chief Financial Officer Mar 18 '24 Sale 31.58 1,261 39,826 101,959 Mar 20 04:43 PM Horn Margaret A Chief Operating Officer Mar 11 '24 Option Exercise 4.09 15,735 64,356 158,202 Mar 13 04:32 PM Horn Margaret A Chief Operating Officer Mar 12 '24 Option Exercise 4.09 7,936 32,458 150,403 Mar 13 04:32 PM Horn Margaret A Chief Operating Officer Mar 11 '24 Sale 34.02 15,735 535,306 142,467 Mar 13 04:32 PM Horn Margaret A Chief Operating Officer Mar 12 '24 Sale 34.07 7,936 270,345 142,467 Mar 13 04:32 PM Cislini Jeff General Counsel Jan 22 '24 Sale 27.00 1,500 40,500 36,126 Jan 24 04:12 PM Kelsey Stephen Michael See Remarks Jan 08 '24 Sale 29.01 3,337 96,809 221,632 Jan 10 04:26 PM Kelsey Stephen Michael See Remarks Jan 02 '24 Sale 29.10 13,330 387,884 224,969 Jan 04 04:06 PM Kelsey Stephen Michael See Remarks Dec 27 '23 Sale 29.01 33,334 966,996 238,299 Dec 29 04:14 PM Anders Jack Chief Financial Officer Dec 18 '23 Sale 25.90 1,775 45,976 76,416 Dec 20 05:10 PM GOLDSMITH MARK A See Remarks Dec 18 '23 Sale 25.90 8,165 211,488 376,167 Dec 20 05:08 PM Cislini Jeff General Counsel Dec 18 '23 Sale 25.90 1,229 31,833 37,284 Dec 20 05:08 PM Kelsey Stephen Michael See Remarks Dec 18 '23 Sale 25.90 2,088 54,083 271,633 Dec 20 05:07 PM Horn Margaret A Chief Operating Officer Dec 15 '23 Option Exercise 4.09 5,000 20,450 109,460 Dec 19 07:30 PM Horn Margaret A Chief Operating Officer Dec 15 '23 Sale 26.64 5,000 133,183 104,460 Dec 19 07:30 PM Horn Margaret A Chief Operating Officer Dec 18 '23 Sale 25.90 2,993 77,524 101,467 Dec 19 07:30 PM Horn Margaret A Chief Operating Officer Dec 06 '23 Option Exercise 4.09 5,000 20,450 109,460 Dec 08 04:08 PM Horn Margaret A Chief Operating Officer Dec 06 '23 Sale 25.00 5,000 125,000 104,460 Dec 08 04:08 PM Cislini Jeff General Counsel Nov 20 '23 Sale 21.70 1,500 32,545 38,513 Nov 20 06:24 PM Horn Margaret A Chief Operating Officer Oct 25 '23 Option Exercise 0.54 7,500 4,050 104,460 Oct 25 06:20 PM GOLDSMITH MARK A See Remarks Oct 24 '23 Option Exercise 0.49 35,000 17,150 384,332 Oct 24 07:21 PM Anders Jack Chief Financial Officer Oct 23 '23 Option Exercise 2.98 24,524 72,967 78,191 Oct 23 06:01 PM Horn Margaret A Chief Operating Officer Oct 16 '23 Option Exercise 4.09 25,000 102,250 121,960 Oct 18 04:23 PM Horn Margaret A Chief Operating Officer Oct 16 '23 Sale 33.95 25,000 848,806 96,960 Oct 18 04:23 PM Kelsey Stephen Michael See Remarks Oct 11 '23 Sale 29.05 16,667 484,130 273,721 Oct 13 04:20 PM Cislini Jeff General Counsel Sep 28 '23 Sale 28.20 2,000 56,394 40,013 Oct 02 04:12 PM Kelsey Stephen Michael See Remarks Sep 18 '23 Sale 31.31 2,060 64,500 290,388 Sep 20 04:13 PM GOLDSMITH MARK A See Remarks Sep 18 '23 Sale 31.31 8,054 252,175 349,332 Sep 20 04:12 PM Cislini Jeff General Counsel Sep 18 '23 Sale 31.31 1,214 38,011 42,013 Sep 20 04:11 PM Anders Jack Chief Financial Officer Sep 18 '23 Sale 31.31 1,427 44,680 53,667 Sep 20 04:11 PM Horn Margaret A Chief Operating Officer Sep 15 '23 Option Exercise 4.09 5,000 20,450 104,474 Sep 19 04:17 PM Horn Margaret A Chief Operating Officer Sep 15 '23 Sale 32.08 5,000 160,408 99,474 Sep 19 04:17 PM Horn Margaret A Chief Operating Officer Sep 18 '23 Sale 31.31 2,514 78,715 96,960 Sep 19 04:17 PM
Index RUT
P/E -
EPS (ttm) -2.41
Insider Own 10.33%
Shs Outstand 63.76M
Perf Week -5.91%
Market Cap 2.89B
Forward P/E -
EPS next Y -3.25
Insider Trans -17.23%
Shs Float 57.17M
Perf Month 12.63%
Income -157.85M
PEG -
EPS next Q -0.83
Inst Own 97.19%
Short Float 16.57%
Perf Quarter 38.12%
Sales 88.55M
P/S 32.69
EPS this Y -16.28%
Inst Trans 3.48%
Short Ratio 16.14
Perf Half Y 6.32%
Book/sh 11.12
P/B 4.08
EPS next Y -10.93%
ROA -22.42%
Short Interest 9.47M
Perf Year 136.83%
Cash/sh 8.00
P/C 5.68
EPS next 5Y 1.90%
ROE -28.18%
52W Range 9.60 - 50.19
Perf YTD 78.32%
Dividend Est. -
P/FCF -
EPS past 5Y -39.18%
ROI -20.75%
52W High -9.53%
Beta 2.22
Dividend TTM -
Quick Ratio 8.45
Sales past 5Y 241.22%
Gross Margin 94.17%
52W Low 372.92%
ATR (14) 2.54
Dividend Ex-Date -
Current Ratio 8.45
EPS Y/Y TTM 12.58%
Oper. Margin -204.01%
RSI (14) 50.68
Volatility 5.34% 5.16%
Employees 187
Debt/Eq 0.13
Sales Y/Y TTM 71.38%
Profit Margin -178.27%
Recom 1.59
Target Price 53.69
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 13.45%
Payout -
Rel Volume 0.40
Prev Close 46.60
Sales Surprise 104.31%
EPS Surprise 14.87%
Sales Q/Q 55.33%
Earnings Aug 07 BMO
Avg Volume 586.71K
Price 45.40
SMA20 -0.81%
SMA50 8.03%
SMA200 29.03%
Trades
Volume 232,096
Change -2.58%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-26-24 Upgrade
Wolfe Research
Peer Perform → Outperform
$65
Apr-22-24 Initiated
Oppenheimer
Outperform
$53
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Jan-04-24 Upgrade
JP Morgan
Neutral → Overweight
Jan-03-24 Downgrade
BofA Securities
Buy → Neutral
$45 → $30
Dec-19-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$26
Jun-30-23 Initiated
Truist
Buy
$50
May-05-23 Upgrade
Raymond James
Mkt Perform → Outperform
Dec-06-22 Downgrade
Credit Suisse
Outperform → Neutral
$47 → $32
Nov-08-22 Initiated
Raymond James
Mkt Perform
Aug-15-22 Initiated
Jefferies
Buy
$40
Aug-03-22 Initiated
Goldman
Buy
$40
Jul-20-22 Initiated
SVB Leerink
Mkt Perform
$26
Apr-28-22 Initiated
Credit Suisse
Outperform
$63
Mar-10-22 Initiated
JP Morgan
Neutral
$44
Feb-10-22 Initiated
Wells Fargo
Overweight
$62
Sep-30-21 Initiated
Stifel
Buy
$80
Sep-30-21 Initiated
B. Riley Securities
Neutral
$67
Sep-10-21 Downgrade
BofA Securities
Buy → Neutral
$65 → $80
May-21-21 Initiated
UBS
Buy
$80
Show Previous Ratings
Sep-06-24 11:31AM
Aug-28-24 07:00AM
Aug-21-24 11:15AM
Aug-20-24 01:02PM
07:44AM
10:45PM
Loading…
Aug-19-24 10:45PM
04:01PM
Aug-08-24 09:55AM
Aug-07-24 08:10AM
07:00AM
Jul-31-24 07:00AM
Jul-10-24 08:10AM
Jul-09-24 01:30PM
12:22PM
10:44AM
09:59AM
Loading…
09:59AM
07:00AM
Jul-08-24 04:05PM
Jun-20-24 08:45AM
Jun-14-24 07:00AM
Jun-01-24 08:00AM
May-29-24 07:00AM
May-23-24 05:00PM
May-22-24 11:20AM
May-14-24 10:00AM
May-08-24 07:00AM
May-03-24 12:23PM
09:57AM
09:55AM
08:44AM
03:19AM
Loading…
03:19AM
May-02-24 12:18PM
11:57AM
07:00AM
Apr-25-24 10:02AM
09:20AM
07:00AM
Apr-08-24 07:00AM
Mar-08-24 10:00AM
Mar-04-24 11:27PM
Feb-28-24 07:00AM
Feb-23-24 11:59AM
Feb-22-24 11:24PM
(Thomson Reuters StreetEvents)
07:35AM
07:00AM
Feb-21-24 11:52PM
Feb-15-24 10:00AM
07:00AM
Feb-10-24 02:56AM
Jan-31-24 07:00AM
Jan-24-24 12:20AM
Jan-17-24 08:00AM
Jan-09-24 09:17AM
09:15AM
Jan-05-24 04:03PM
(Investor's Business Daily)
06:00AM
Jan-04-24 04:01PM
07:00AM
Jan-02-24 07:00AM
Dec-22-23 10:45AM
Dec-18-23 02:58PM
Dec-13-23 07:00AM
Dec-10-23 09:00PM
Dec-08-23 11:13AM
Dec-07-23 07:00AM
Nov-13-23 11:00AM
Nov-07-23 09:05AM
Nov-05-23 02:38PM
Nov-02-23 09:00AM
08:43AM
07:00AM
Nov-01-23 07:00AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
07:00AM
Oct-19-23 09:35AM
Oct-18-23 09:35AM
Oct-16-23 07:00AM
Oct-04-23 06:23AM
Oct-03-23 04:48PM
Sep-18-23 07:00AM
Aug-28-23 07:00AM
Aug-03-23 08:25AM
07:00AM
Jul-28-23 03:57PM
Jul-27-23 07:00AM
Jul-09-23 09:09AM
Jun-22-23 08:30AM
Jun-14-23 02:30AM
Jun-09-23 06:00PM
03:00AM
Jun-01-23 07:00AM
May-29-23 12:24PM
May-22-23 07:00AM
May-19-23 07:00AM
May-18-23 07:00AM
May-14-23 02:57PM
May-09-23 03:15PM
May-04-23 08:25AM
07:00AM
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Albers Jeffrey W. Director Aug 26 '24 Option Exercise 10.34 5,000 51,700 5,000 Aug 26 06:31 PM Albers Jeffrey W. Director Aug 26 '24 Sale 49.10 5,000 245,508 0 Aug 26 06:31 PM JOANNA HOROBIN Director Aug 26 '24 Proposed Sale 49.16 12,000 589,896 Aug 26 04:32 PM JEFFREY ALBERS Director Aug 26 '24 Proposed Sale 47.78 5,000 238,900 Aug 26 04:25 PM BAKER BROS. ADVISORS LP Director Aug 20 '24 Buy 46.41 1 46 5,516,986 Aug 22 04:03 PM Gollob Jared Chief Medical Officer Jul 16 '24 Option Exercise 2.08 23,145 48,142 118,885 Jul 16 06:00 PM Gollob Jared Chief Medical Officer Jul 15 '24 Option Exercise 2.08 16,455 34,226 112,195 Jul 16 06:00 PM Gollob Jared Chief Medical Officer Jul 16 '24 Sale 45.81 23,145 1,060,218 95,470 Jul 16 06:00 PM Gollob Jared Chief Medical Officer Jul 15 '24 Sale 45.15 16,455 742,925 95,740 Jul 16 06:00 PM Booth Bruce Director Jul 09 '24 Sale 38.21 453,960 17,346,919 723,246 Jul 09 05:15 PM Mainolfi Nello Chief Executive Officer Jul 01 '24 Option Exercise 5.33 18,773 100,060 649,959 Jul 01 04:30 PM Jacobs Bruce N. Chief Financial Officer Jun 27 '24 Option Exercise 2.08 25,000 52,000 168,554 Jun 28 08:30 AM Mainolfi Nello Chief Executive Officer Jun 18 '24 Option Exercise 2.08 14,413 29,979 631,186 Jun 20 08:30 AM Booth Bruce Director Jun 12 '24 Sale 35.45 16,740 593,378 803,792 Jun 14 06:01 PM Booth Bruce Director Jun 13 '24 Sale 34.98 10,200 356,796 802,022 Jun 14 06:01 PM Horobin Joanna Director Jun 07 '24 Option Exercise 2.08 8,500 17,680 8,500 Jun 07 06:36 PM Horobin Joanna Director Jun 07 '24 Sale 32.99 8,500 280,400 0 Jun 07 06:36 PM Chadwick Jeremy G Chief Operating Officer May 23 '24 Sale 34.99 2,575 90,105 44,183 May 23 04:10 PM Booth Bruce Director Mar 15 '24 Sale 40.46 71,764 2,903,336 806,697 Mar 15 07:23 PM Booth Bruce Director Mar 14 '24 Sale 39.98 55,779 2,229,927 819,151 Mar 15 07:23 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 134,647 5,652,072 4,791,165 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 115,090 4,859,993 4,676,075 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 42,302 1,812,586 4,925,812 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 28,271 1,186,741 852,995 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 24,165 1,020,422 828,830 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 8,882 380,562 881,266 Mar 13 07:53 PM Booth Bruce Director Mar 12 '24 Sale 41.98 162,918 6,838,813 852,995 Mar 13 07:52 PM Booth Bruce Director Mar 13 '24 Sale 42.23 139,255 5,880,415 828,830 Mar 13 07:52 PM Booth Bruce Director Mar 11 '24 Sale 42.85 51,184 2,193,148 881,266 Mar 13 07:52 PM Gollob Jared Chief Medical Officer Mar 04 '24 Sale 41.86 3,344 139,967 95,740 Mar 04 06:21 PM Jacobs Bruce N. Chief Financial Officer Mar 04 '24 Sale 41.86 3,934 164,664 142,351 Mar 04 06:12 PM Albers Jeffrey W. Director Feb 21 '24 Option Exercise 10.34 4,385 45,341 4,385 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Option Exercise 10.34 615 6,359 615 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 21 '24 Sale 39.05 4,385 171,227 0 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Sale 39.07 615 24,031 0 Feb 21 06:46 PM Gollob Jared Chief Medical Officer Feb 09 '24 Option Exercise 2.08 46,137 95,965 120,846 Feb 09 07:47 PM Gollob Jared Chief Medical Officer Feb 09 '24 Sale 35.50 46,137 1,638,071 74,709 Feb 09 07:47 PM Albers Jeffrey W. Director Jan 23 '24 Option Exercise 10.34 10,000 103,400 10,000 Jan 23 07:37 PM Albers Jeffrey W. Director Jan 23 '24 Sale 30.05 10,000 300,470 0 Jan 23 07:37 PM Chiniara Ellen Chief Legal Officer Jan 04 '24 Sale 22.58 3,295 74,416 34,205 Jan 05 05:15 PM Mainolfi Nello Chief Executive Officer Jan 02 '24 Option Exercise 2.08 9,000 18,720 615,570 Jan 02 05:43 PM BVF PARTNERS L P/IL Director Nov 03 '23 Buy 14.07 197,699 2,781,407 2,656,191 Nov 06 06:07 PM BVF PARTNERS L P/IL Director Nov 02 '23 Buy 11.64 216,406 2,519,918 2,552,306 Nov 06 06:07 PM Mainolfi Nello Chief Executive Officer Nov 03 '23 Option Exercise 2.08 20,000 41,600 606,570 Nov 06 06:00 PM
Index RUT
P/E -
EPS (ttm) -2.71
Insider Own 33.63%
Shs Outstand 26.65M
Perf Week -6.20%
Market Cap 360.35M
Forward P/E -
EPS next Y -2.93
Insider Trans -0.63%
Shs Float 21.94M
Perf Month -7.00%
Income -77.22M
PEG -
EPS next Q -0.69
Inst Own 66.03%
Short Float 8.82%
Perf Quarter -37.54%
Sales 0.00M
P/S -
EPS this Y 77.51%
Inst Trans -
Short Ratio 6.32
Perf Half Y -25.75%
Book/sh 4.99
P/B 2.18
EPS next Y -4.96%
ROA -60.10%
Short Interest 1.94M
Perf Year -
Cash/sh 5.29
P/C 2.06
EPS next 5Y -
ROE -74.84%
52W Range 9.00 - 22.33
Perf YTD -18.78%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -44.60%
52W High -51.19%
Beta -
Dividend TTM -
Quick Ratio 9.38
Sales past 5Y 19.69%
Gross Margin -
52W Low 21.11%
ATR (14) 0.79
Dividend Ex-Date -
Current Ratio 9.38
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 39.25
Volatility 5.60% 6.16%
Employees 58
Debt/Eq 0.07
Sales Y/Y TTM -
Profit Margin -
Recom 1.17
Target Price 22.83
Option/Short No / Yes
LT Debt/Eq 0.05
EPS Q/Q -27.58%
Payout -
Rel Volume 0.52
Prev Close 11.40
Sales Surprise -
EPS Surprise 7.43%
Sales Q/Q -
Earnings Aug 12 BMO
Avg Volume 306.29K
Price 10.90
SMA20 -7.14%
SMA50 -15.20%
SMA200 -23.35%
Trades
Volume 159,958
Change -4.39%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-13-24 Initiated
Robert W. Baird
Outperform
$28
Jun-06-24 Initiated
H.C. Wainwright
Buy
$22
Nov-28-23 Initiated
Stifel
Buy
$20
Nov-28-23 Initiated
RBC Capital Mkts
Outperform
$22
Nov-28-23 Initiated
Leerink Partners
Outperform
$19
Nov-28-23 Initiated
JP Morgan
Overweight
$20
Nov-28-23 Initiated
Chardan Capital Markets
Buy
$23
Sep-05-24 07:30AM
Aug-12-24 07:00AM
Jul-16-24 11:03AM
Jul-15-24 04:17PM
(Investor's Business Daily) -26.08%
10:11AM
(Investor's Business Daily)
06:36AM
Loading…
06:36AM
06:00AM
Jul-11-24 08:00AM
Jul-08-24 07:00AM
May-14-24 12:00PM
09:55AM
May-09-24 07:00AM
May-07-24 07:30AM
Apr-22-24 07:30AM
Apr-16-24 07:30AM
04:22PM
Loading…
Mar-13-24 04:22PM
(GlobeNewswire) +5.67%
-5.43%
Mar-11-24 07:42AM
07:30AM
Feb-05-24 07:00AM
Jan-03-24 07:00AM
Dec-18-23 07:00AM
Dec-13-23 04:59AM
Dec-11-23 12:05PM
07:00AM
Nov-30-23 08:42AM
Nov-02-23 09:51PM
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Townsend Richard Nolan Chief Executive Officer Aug 12 '24 Option Exercise 2.33 5,000 11,650 125,695 Aug 13 06:34 PM Townsend Richard Nolan Chief Executive Officer Aug 12 '24 Sale 11.53 5,000 57,634 120,695 Aug 13 06:34 PM Townsend Richard Nolan Chief Executive Officer Jul 10 '24 Option Exercise 2.33 5,000 11,650 175,695 Jul 12 04:55 PM Townsend Richard Nolan Chief Executive Officer Jul 11 '24 Sale 17.07 28,031 478,409 120,695 Jul 12 04:55 PM Townsend Richard Nolan Chief Executive Officer Jul 10 '24 Sale 16.50 26,969 444,979 148,726 Jul 12 04:55 PM Townsend Richard Nolan Chief Executive Officer Jun 10 '24 Option Exercise 2.33 5,000 11,650 175,695 Jun 12 05:00 PM Townsend Richard Nolan Chief Executive Officer Jun 10 '24 Sale 17.65 5,000 88,264 170,695 Jun 12 05:00 PM Townsend Richard Nolan Chief Executive Officer May 13 '24 Option Exercise 2.33 5,000 11,650 175,695 May 14 04:04 PM Townsend Richard Nolan Chief Executive Officer May 13 '24 Sale 13.22 5,000 66,093 170,695 May 14 04:04 PM Omega Fund VI, L.P. 10% Owner Nov 07 '23 Buy 11.00 454,545 4,999,995 2,157,623 Nov 09 08:36 PM Lundbeckfond Invest A/S 10% Owner Nov 07 '23 Buy 11.00 227,272 2,499,992 1,835,959 Nov 09 08:33 PM Longitude Capital Partners IV, 10% Owner Nov 07 '23 Buy 11.00 454,545 4,999,995 2,567,100 Nov 09 08:32 PM
Index RUT
P/E -
EPS (ttm) -3.10
Insider Own 33.47%
Shs Outstand 42.90M
Perf Week -4.67%
Market Cap 1.04B
Forward P/E -
EPS next Y -3.26
Insider Trans -0.37%
Shs Float 38.57M
Perf Month 8.71%
Income -142.16M
PEG -
EPS next Q -0.79
Inst Own 77.55%
Short Float 21.15%
Perf Quarter -20.23%
Sales 0.00M
P/S -
EPS this Y 12.51%
Inst Trans -1.13%
Short Ratio 10.29
Perf Half Y 9.97%
Book/sh 11.34
P/B 1.59
EPS next Y -0.89%
ROA -23.63%
Short Interest 8.16M
Perf Year 61.98%
Cash/sh 11.43
P/C 1.57
EPS next 5Y -
ROE -24.60%
52W Range 7.64 - 30.19
Perf YTD 76.45%
Dividend Est. -
P/FCF -
EPS past 5Y -62.42%
ROI -21.61%
52W High -40.44%
Beta -0.09
Dividend TTM -
Quick Ratio 28.87
Sales past 5Y -20.00%
Gross Margin -
52W Low 135.34%
ATR (14) 1.05
Dividend Ex-Date -
Current Ratio 28.87
EPS Y/Y TTM 7.74%
Oper. Margin 0.00%
RSI (14) 48.62
Volatility 5.85% 5.72%
Employees 85
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 32.71
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 5.32%
Payout -
Rel Volume 0.48
Prev Close 17.93
Sales Surprise -
EPS Surprise -3.43%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 792.71K
Price 17.98
SMA20 1.49%
SMA50 1.09%
SMA200 6.49%
Trades
Volume 383,859
Change 0.28%
Date
Action
Analyst
Rating Change
Price Target Change
May-01-24 Initiated
Stifel
Buy
$40
Apr-15-24 Initiated
William Blair
Outperform
Feb-15-24 Initiated
Wedbush
Outperform
$30
Jun-15-23 Initiated
TD Cowen
Outperform
Nov-21-22 Initiated
BTIG Research
Buy
$20
Apr-27-21 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$40
Feb-02-21 Initiated
SVB Leerink
Outperform
$52
Feb-02-21 Initiated
Morgan Stanley
Equal-Weight
$38
Feb-02-21 Initiated
Evercore ISI
Outperform
$55
Feb-01-21 Initiated
H.C. Wainwright
Buy
$47
Aug-28-24 08:00AM
Aug-08-24 07:00AM
Jun-03-24 06:26AM
Jun-01-24 07:00AM
May-24-24 08:00AM
05:04PM
Loading…
May-23-24 05:04PM
May-16-24 12:03PM
May-15-24 10:54PM
04:05PM
May-09-24 03:09AM
May-01-24 07:05AM
Apr-29-24 07:00AM
Apr-24-24 04:29PM
10:09AM
Apr-16-24 03:32PM
07:00AM
Loading…
07:00AM
06:59AM
04:48AM
Mar-16-24 05:31AM
Mar-14-24 12:53PM
07:00AM
Mar-01-24 07:00AM
Feb-27-24 08:00AM
Feb-21-24 09:21AM
Feb-02-24 11:01PM
Jan-30-24 11:01PM
Jan-24-24 07:02PM
Dec-18-23 04:53PM
Dec-14-23 04:30PM
Nov-08-23 07:00AM
12:01PM
Loading…
Nov-03-23 12:01PM
Oct-30-23 08:00AM
Sep-06-23 08:00AM
Aug-10-23 07:00AM
Aug-09-23 07:00AM
Aug-03-23 04:15PM
Jul-31-23 08:00AM
Jun-09-23 04:07PM
May-25-23 05:00PM
May-11-23 04:01PM
Apr-26-23 10:08AM
Apr-20-23 07:00AM
Mar-29-23 10:13AM
Mar-27-23 07:00AM
Mar-14-23 04:35PM
Mar-09-23 07:00AM
Feb-27-23 08:00AM
Feb-13-23 07:00PM
Feb-02-23 04:01PM
Feb-01-23 04:42PM
Jan-24-23 08:00AM
Jan-23-23 11:07AM
Jan-03-23 05:13PM
Dec-28-22 10:31PM
Dec-02-22 05:00PM
Nov-14-22 07:00AM
Nov-02-22 08:00AM
Nov-01-22 05:23PM
07:00AM
Oct-25-22 07:00AM
Oct-03-22 04:50PM
Sep-07-22 08:00AM
Sep-01-22 05:27PM
Aug-15-22 04:57PM
Aug-10-22 07:00AM
Aug-01-22 04:55PM
08:00AM
Jul-29-22 05:00AM
(American City Business Journals)
05:00AM
(American City Business Journals)
Jul-05-22 04:01PM
Jul-01-22 04:37PM
Jun-23-22 08:00AM
Jun-01-22 05:00PM
May-31-22 08:00AM
May-26-22 08:45AM
May-19-22 08:00AM
May-16-22 06:45AM
May-12-22 11:18AM
02:00AM
May-08-22 09:23AM
May-02-22 05:00PM
Apr-27-22 10:00AM
Apr-05-22 08:00AM
Apr-04-22 04:34PM
Mar-29-22 07:54AM
Mar-28-22 04:01PM
Mar-17-22 07:08AM
07:00AM
Mar-09-22 08:00AM
Mar-08-22 05:30PM
Feb-28-22 08:00AM
Feb-12-22 06:50AM
Feb-07-22 06:30AM
Jan-10-22 06:30AM
Jan-05-22 09:00AM
Jan-04-22 07:34AM
07:00AM
Dec-16-21 01:04PM
06:30AM
Dec-13-21 07:00AM
Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
JENNIFER MICHAELSON & MARC D M Officer Sep 05 '24 Proposed Sale 18.68 16,000 298,880 Sep 05 04:27 PM Michaelson Jennifer Chief Scientific Officer Jul 05 '24 Sale 16.33 8,000 130,640 123,942 Jul 09 05:30 PM Ebeling Thomas Director Jun 10 '24 Option Exercise 13.00 18,450 239,850 186,653 Jun 11 06:00 PM Michaelson Jennifer Chief Scientific Officer May 06 '24 Option Exercise 4.30 50,000 215,000 187,582 May 08 07:30 PM Michaelson Jennifer Chief Scientific Officer May 07 '24 Option Exercise 4.30 5,606 24,106 135,188 May 08 07:30 PM Michaelson Jennifer Chief Scientific Officer May 06 '24 Sale 28.07 58,000 1,628,159 129,582 May 08 07:30 PM Michaelson Jennifer Chief Scientific Officer May 07 '24 Sale 30.06 5,606 168,516 129,582 May 08 07:30 PM Savill Corrine Chief Business Officer Feb 01 '24 Option Exercise 4.30 40,000 172,000 205,990 Feb 02 09:35 PM Savill Corrine Chief Business Officer Feb 01 '24 Sale 16.18 40,000 647,200 165,990 Feb 02 09:35 PM Savill Corrine Chief Business Officer Jan 29 '24 Option Exercise 4.30 40,000 172,000 205,990 Jan 30 07:00 PM Savill Corrine Chief Business Officer Jan 29 '24 Sale 14.09 40,000 563,600 165,990 Jan 30 07:00 PM Savill Corrine Chief Business Officer Jan 23 '24 Option Exercise 4.30 21,316 91,659 187,306 Jan 24 05:00 PM Savill Corrine Chief Business Officer Jan 22 '24 Option Exercise 4.30 14,559 62,604 184,674 Jan 24 05:00 PM Savill Corrine Chief Business Officer Jan 23 '24 Sale 12.46 21,316 265,597 165,990 Jan 24 05:00 PM Savill Corrine Chief Business Officer Jan 22 '24 Sale 12.14 18,684 226,911 165,990 Jan 24 05:00 PM AHMED NADIM President and CEO Dec 26 '23 Sale 9.24 4,272 39,473 111,550 Dec 27 06:30 PM Jones Jeffrey Alan Chief Medical Officer Dec 21 '23 Sale 8.50 1,860 15,810 56,191 Dec 22 05:30 PM SUMER JACQUELYN L Chief Legal Officer Dec 21 '23 Sale 8.50 1,400 11,900 44,133 Dec 22 05:30 PM Trigilio Jeffrey Chief Financial Officer Dec 21 '23 Sale 8.50 1,920 16,320 83,919 Dec 22 05:30 PM Michaelson Jennifer Chief Scientific Officer Dec 21 '23 Sale 8.50 1,145 9,732 87,582 Dec 22 05:30 PM Jones Jeffrey Alan Chief Medical Officer Dec 18 '23 Sale 8.22 386 3,173 58,051 Dec 20 06:00 PM Michaelson Jennifer Chief Scientific Officer Dec 18 '23 Sale 8.22 238 1,956 88,727 Dec 20 06:00 PM SUMER JACQUELYN L Chief Legal Officer Dec 18 '23 Sale 8.22 290 2,384 45,533 Dec 20 06:00 PM Trigilio Jeffrey Chief Financial Officer Dec 18 '23 Sale 8.22 398 3,272 85,839 Dec 20 06:00 PM Trigilio Jeffrey Chief Financial Officer Dec 12 '23 Sale 7.81 1,926 15,042 86,237 Dec 13 08:00 PM Michaelson Jennifer Chief Scientific Officer Dec 12 '23 Sale 7.81 1,068 8,341 88,965 Dec 13 08:00 PM
Index RUT
P/E -
EPS (ttm) -2.24
Insider Own 30.23%
Shs Outstand 50.14M
Perf Week -10.95%
Market Cap 349.20M
Forward P/E -
EPS next Y -1.83
Insider Trans -0.02%
Shs Float 42.82M
Perf Month 57.62%
Income -130.41M
PEG -
EPS next Q -0.47
Inst Own 62.19%
Short Float 6.52%
Perf Quarter 35.80%
Sales 5.76M
P/S 60.62
EPS this Y 27.69%
Inst Trans 0.82%
Short Ratio 12.08
Perf Half Y -3.23%
Book/sh 3.66
P/B 1.55
EPS next Y 3.77%
ROA -41.88%
Short Interest 2.79M
Perf Year -5.79%
Cash/sh 4.27
P/C 1.33
EPS next 5Y -
ROE -59.51%
52W Range 2.44 - 8.84
Perf YTD 0.71%
Dividend Est. -
P/FCF -
EPS past 5Y -96.71%
ROI -49.11%
52W High -35.63%
Beta 1.43
Dividend TTM -
Quick Ratio 6.56
Sales past 5Y 0.00%
Gross Margin -32.61%
52W Low 133.20%
ATR (14) 0.59
Dividend Ex-Date -
Current Ratio 6.56
EPS Y/Y TTM 12.96%
Oper. Margin -2420.91%
RSI (14) 52.81
Volatility 9.13% 12.29%
Employees 133
Debt/Eq 0.20
Sales Y/Y TTM -
Profit Margin -2264.53%
Recom 1.00
Target Price 13.67
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q 40.21%
Payout -
Rel Volume 0.50
Prev Close 6.01
Sales Surprise 255.79%
EPS Surprise 17.50%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 231.01K
Price 5.69
SMA20 3.40%
SMA50 21.38%
SMA200 10.67%
Trades
Volume 116,612
Change -5.32%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Wedbush
Outperform
$11
Jan-03-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$18
Oct-13-22 Initiated
UBS
Buy
$22
Aug-15-22 Initiated
Jefferies
Buy
$20
Apr-28-22 Initiated
Credit Suisse
Neutral
$19
Feb-10-22 Initiated
Wells Fargo
Equal Weight
$19
Oct-14-21 Initiated
SVB Leerink
Mkt Perform
$20
Aug-28-24 07:00AM
Aug-19-24 07:00AM
Aug-08-24 08:15AM
07:15AM
(Associated Press Finance)
07:00AM
08:36AM
Loading…
Jul-08-24 08:36AM
Jun-27-24 07:00AM
Jun-14-24 08:45AM
May-30-24 07:00AM
07:00AM
May-21-24 07:00AM
May-16-24 01:09PM
07:00AM
May-15-24 04:01PM
May-10-24 03:26PM
01:55PM
Loading…
May-09-24 01:55PM
07:21AM
(Associated Press Finance)
07:00AM
May-02-24 04:01PM
Apr-29-24 10:36AM
Apr-10-24 08:50AM
Apr-04-24 09:55AM
Mar-22-24 08:50AM
Mar-19-24 09:55AM
Mar-16-24 05:31AM
Mar-14-24 01:53PM
07:22AM
(Associated Press Finance)
07:00AM
Mar-11-24 07:00AM
Jan-31-24 07:00AM
09:00AM
Loading…
Jan-16-24 09:00AM
Jan-08-24 07:15AM
Jan-03-24 07:00AM
Nov-21-23 07:00AM
Nov-09-23 08:10AM
07:10AM
(Associated Press Finance)
07:00AM
Nov-07-23 10:00AM
Oct-27-23 07:00AM
Oct-26-23 04:30PM
Oct-24-23 09:35AM
Oct-17-23 08:03AM
07:00AM
07:00AM
Aug-10-23 07:27AM
(Associated Press Finance)
07:15AM
Jul-26-23 07:30AM
Jul-16-23 09:50AM
May-30-23 04:30PM
(GlobeNewswire) +5.16%
+13.19%
May-23-23 07:30AM
May-11-23 07:50AM
07:30AM
Apr-17-23 04:30PM
Mar-23-23 07:30AM
Mar-16-23 07:52AM
07:30AM
Feb-06-23 08:30AM
Feb-03-23 07:30AM
Jan-25-23 09:55AM
Jan-09-23 07:30AM
Jan-04-23 07:30AM
Nov-17-22 01:58PM
Nov-10-22 07:30AM
Nov-01-22 07:30AM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Sep-06-22 07:30AM
Aug-30-22 08:35AM
(Simply Wall St.) -10.32%
Aug-11-22 07:30AM
Jun-14-22 05:16AM
(American City Business Journals) +5.08%
May-11-22 07:30AM
Apr-08-22 01:00PM
Mar-29-22 07:30AM
Mar-23-22 11:32AM
Feb-03-22 04:30PM
Jan-25-22 07:30AM
Jan-04-22 07:30AM
Dec-02-21 07:30AM
Nov-22-21 07:30AM
Nov-10-21 07:30AM
Nov-08-21 07:00AM
(American City Business Journals)
Oct-20-21 07:30AM
Oct-07-21 09:00AM
Sep-30-21 04:30PM
Sep-24-21 08:49AM
Sep-10-21 07:30AM
Sep-08-21 07:30AM
Aug-12-21 07:30AM
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dunn Edmund Principal Accounting Officer Jul 05 '24 Sale 3.83 1,610 6,166 13,944 Jul 09 04:15 PM Dunn Edmund Principal Accounting Officer Jun 03 '24 Sale 4.04 1,207 4,876 15,554 Jun 05 04:10 PM
Index RUT
P/E 134.61
EPS (ttm) 0.04
Insider Own 16.21%
Shs Outstand 27.03M
Perf Week -4.34%
Market Cap 144.73M
Forward P/E 30.52
EPS next Y 0.17
Insider Trans -6.47%
Shs Float 22.93M
Perf Month -8.16%
Income 2.74M
PEG -
EPS next Q -0.12
Inst Own 53.05%
Short Float 8.31%
Perf Quarter -22.77%
Sales 48.89M
P/S 2.96
EPS this Y 118.61%
Inst Trans 0.72%
Short Ratio 19.58
Perf Half Y -44.95%
Book/sh -0.05
P/B -
EPS next Y 55.22%
ROA 6.62%
Short Interest 1.91M
Perf Year -33.54%
Cash/sh 1.57
P/C 3.36
EPS next 5Y -
ROE -
52W Range 5.00 - 11.92
Perf YTD -52.85%
Dividend Est. -
P/FCF 6.29
EPS past 5Y -2.95%
ROI 9.63%
52W High -55.62%
Beta 0.27
Dividend TTM -
Quick Ratio 7.75
Sales past 5Y 236.90%
Gross Margin 95.55%
52W Low 5.80%
ATR (14) 0.32
Dividend Ex-Date -
Current Ratio 8.02
EPS Y/Y TTM 110.07%
Oper. Margin 12.00%
RSI (14) 38.40
Volatility 5.64% 6.13%
Employees 29
Debt/Eq -
Sales Y/Y TTM 647.88%
Profit Margin 5.59%
Recom 1.17
Target Price 15.50
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 1.17%
Payout -
Rel Volume 0.96
Prev Close 5.37
Sales Surprise -33.91%
EPS Surprise -700.00%
Sales Q/Q 118.41%
Earnings Aug 13 BMO
Avg Volume 97.31K
Price 5.29
SMA20 -6.64%
SMA50 -11.88%
SMA200 -37.62%
Trades
Volume 93,714
Change -1.49%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-22-22 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$9 → $12
Sep-07-22 Initiated
CapitalOne
Overweight
$11
Aug-08-22 Resumed
Craig Hallum
Buy
$14
Jun-05-20 Initiated
Cantor Fitzgerald
Overweight
$18
Oct-11-18 Initiated
Goldman
Buy
Sep-05-24 06:56AM
Aug-14-24 01:57AM
(Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM
Aug-06-24 04:31PM
Aug-05-24 06:26AM
06:15AM
Loading…
Jul-29-24 06:15AM
Jul-15-24 08:32AM
Jul-01-24 06:00AM
Jun-25-24 04:35PM
May-15-24 08:44AM
May-14-24 10:53AM
07:20AM
06:03AM
May-07-24 06:15PM
Apr-23-24 08:01AM
07:00PM
Loading…
Apr-05-24 07:00PM
Mar-27-24 07:00PM
Mar-26-24 01:00AM
Mar-22-24 09:49AM
05:04AM
(Thomson Reuters StreetEvents)
Mar-21-24 02:52PM
06:00AM
Mar-19-24 10:14AM
06:01AM
Mar-17-24 09:00PM
Feb-29-24 07:04AM
Feb-01-24 05:55AM
Jan-06-24 03:01AM
Dec-05-23 05:55AM
Nov-09-23 04:50PM
09:40AM
Loading…
Nov-07-23 09:40AM
02:10AM
(Thomson Reuters StreetEvents)
Nov-06-23 05:59AM
Oct-30-23 06:45AM
Sep-07-23 05:59AM
Aug-10-23 12:53PM
Aug-03-23 05:59AM
Jul-31-23 05:30AM
Jun-12-23 05:00PM
Jun-08-23 02:53PM
Jun-06-23 05:44AM
May-11-23 06:01AM
May-08-23 06:15AM
Apr-28-23 09:26AM
Apr-01-23 08:12AM
Mar-31-23 08:03AM
Mar-30-23 05:55AM
Mar-24-23 06:30AM
Feb-23-23 08:44AM
Jan-31-23 06:00AM
Jan-25-23 07:19AM
Jan-23-23 11:57AM
(American City Business Journals)
Dec-17-22 09:55AM
Nov-11-22 07:10AM
Nov-01-22 10:28AM
Oct-17-22 08:00AM
Sep-26-22 07:35AM
Sep-21-22 02:19PM
(American City Business Journals) +11.93%
01:05PM
07:00AM
06:05AM
Aug-22-22 07:04AM
Aug-12-22 06:59AM
Aug-01-22 02:59PM
(American City Business Journals)
07:30AM
Jul-10-22 08:42AM
Jun-14-22 06:00PM
May-23-22 07:29AM
May-12-22 06:00AM
May-06-22 05:17PM
(American City Business Journals)
May-03-22 09:55AM
Apr-27-22 06:00AM
Mar-25-22 07:00AM
Mar-24-22 06:00AM
Feb-28-22 06:00AM
Jan-31-22 06:00AM
Jan-27-22 05:38PM
Dec-14-21 07:50PM
Dec-13-21 10:08AM
Dec-01-21 07:06AM
(American City Business Journals) -11.39%
Nov-30-21 04:20PM
10:57AM
06:00AM
05:49AM
Nov-29-21 07:23PM
07:24AM
06:00AM
Nov-10-21 06:00AM
Oct-05-21 08:30AM
Sep-29-21 02:27PM
Sep-09-21 06:00AM
Aug-10-21 06:00AM
Aug-02-21 03:18AM
Jun-29-21 05:30PM
Jun-24-21 06:00AM
Jun-22-21 07:17AM
06:00AM
Jun-03-21 03:33AM
May-28-21 06:00AM
May-13-21 06:00AM
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Haigh Adrian Director Sep 05 '24 Proposed Sale 5.00 20,246 101,230 Sep 05 05:02 PM Raykov Rosty Director Sep 04 '24 Sale 5.52 2,431 13,419 66,432 Sep 04 06:48 PM ROSTISLAV RAYKOV Director Sep 04 '24 Proposed Sale 5.52 2,431 13,419 Sep 04 04:05 PM ROSTISLAV RAYKOV Officer Aug 01 '24 Proposed Sale 6.26 2,431 15,206 Aug 01 04:21 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Aug 01 '24 Sale 6.25 2,431 15,206 187,471 Aug 01 04:08 PM RALLIS CHRIS A Director Jul 05 '24 Option Exercise 2.79 1,792 5,000 47,630 Jul 08 04:05 PM RALLIS CHRIS A Director Jul 05 '24 Sale 6.03 1,173 7,073 46,457 Jul 08 04:05 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Jul 02 '24 Sale 6.13 2,431 14,902 187,471 Jul 02 05:55 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Jun 03 '24 Sale 6.76 2,431 16,434 187,471 Jun 03 05:12 PM Raykov Rosty CHIEF EXECUTIVE OFFICER May 01 '24 Sale 9.11 2,431 22,152 187,471 May 02 04:59 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 22 '24 Option Exercise 2.31 22,223 51,335 22,223 Apr 22 07:34 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 19 '24 Option Exercise 2.31 22,222 51,333 22,222 Apr 22 07:34 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 19 '24 Sale 9.34 22,222 207,442 0 Apr 22 07:34 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 22 '24 Sale 9.32 22,223 207,029 0 Apr 22 07:34 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 17 '24 Sale 9.91 22,222 220,220 22,222 Apr 18 09:43 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 18 '24 Sale 9.62 22,222 213,776 0 Apr 18 09:43 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 15 '24 Sale 10.30 22,222 228,793 22,222 Apr 16 06:00 PM Haigh Adrian CHIEF OPERATING OFFICER Apr 16 '24 Sale 10.28 22,222 228,389 0 Apr 16 06:00 PM RALLIS CHRIS A Director Apr 15 '24 Option Exercise 10.45 1,389 14,515 45,838 Apr 15 06:15 PM RALLIS CHRIS A Director Apr 15 '24 Sale 10.45 800 8,360 44,449 Apr 15 06:15 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Apr 04 '24 Sale 10.89 44,283 482,400 231,771 Apr 05 04:56 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Apr 05 '24 Sale 10.75 44,300 476,269 187,471 Apr 05 04:56 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Apr 03 '24 Sale 10.78 40,584 437,451 276,054 Apr 03 05:37 PM RALLIS CHRIS A Director Mar 26 '24 Option Exercise 2.31 4,329 10,000 45,249 Mar 27 04:24 PM RALLIS CHRIS A Director Mar 26 '24 Sale 10.97 2,114 23,191 40,920 Mar 27 04:24 PM Andrade Robert CHIEF FINANCIAL OFFICER Mar 26 '24 Sale 10.90 13,975 152,346 91,771 Mar 27 04:22 PM Andrade Robert CHIEF FINANCIAL OFFICER Mar 25 '24 Sale 11.00 13,975 153,690 105,746 Mar 25 07:31 PM Andrade Robert CHIEF FINANCIAL OFFICER Jan 04 '24 Sale 10.64 15,000 159,600 134,721 Jan 05 05:24 PM Andrade Robert CHIEF FINANCIAL OFFICER Jan 05 '24 Sale 10.41 15,000 156,150 119,721 Jan 05 05:24 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Dec 28 '23 Option Exercise 1.59 8,540 13,579 291,127 Dec 29 04:30 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 11.55 3,656 42,227 287,471 Dec 29 04:30 PM RALLIS CHRIS A Director Dec 26 '23 Option Exercise 1.59 3,144 4,999 46,178 Dec 28 04:02 PM RALLIS CHRIS A Director Dec 26 '23 Sale 10.90 1,390 15,151 44,788 Dec 28 04:02 PM RALLIS CHRIS A Director Nov 20 '23 Sale 8.25 269 2,219 43,034 Nov 20 09:20 PM Islam Khalid Director Nov 16 '23 Option Exercise 2.06 213,825 441,400 213,825 Nov 16 04:05 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Nov 08 '23 Sale 7.76 25,044 194,267 282,587 Nov 09 04:38 PM Raykov Rosty CHIEF EXECUTIVE OFFICER Nov 03 '23 Option Exercise 1.59 74,793 118,921 307,631 Nov 03 05:19 PM
Index RUT
P/E -
EPS (ttm) -2.28
Insider Own 36.53%
Shs Outstand 37.17M
Perf Week -4.41%
Market Cap 2.76B
Forward P/E -
EPS next Y -3.54
Insider Trans -0.56%
Shs Float 37.12M
Perf Month 15.61%
Income -118.48M
PEG -
EPS next Q -0.78
Inst Own 76.98%
Short Float 22.05%
Perf Quarter 12.19%
Sales 0.00M
P/S -
EPS this Y 16.91%
Inst Trans -
Short Ratio 18.47
Perf Half Y -27.58%
Book/sh 13.65
P/B 3.46
EPS next Y -26.63%
ROA -25.44%
Short Interest 8.19M
Perf Year 99.62%
Cash/sh 11.56
P/C 4.09
EPS next 5Y -
ROE -33.41%
52W Range 14.19 - 72.29
Perf YTD 69.11%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -15.27%
52W High -34.64%
Beta 2.86
Dividend TTM -
Quick Ratio 27.70
Sales past 5Y 0.00%
Gross Margin -
52W Low 232.98%
ATR (14) 2.60
Dividend Ex-Date -
Current Ratio 27.70
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 50.68
Volatility 5.39% 5.61%
Employees -
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 84.83
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -60.56%
Payout -
Rel Volume 0.51
Prev Close 48.24
Sales Surprise -
EPS Surprise -3.58%
Sales Q/Q -
Earnings Aug 12 BMO
Avg Volume 443.27K
Price 47.25
SMA20 1.00%
SMA50 4.00%
SMA200 10.98%
Trades
Volume 225,530
Change -2.05%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Initiated
BofA Securities
Buy
$80
Dec-20-23 Initiated
BTIG Research
Buy
$43
Aug-08-23 Initiated
Wedbush
Outperform
$40
Aug-08-23 Initiated
TD Cowen
Outperform
Aug-08-23 Initiated
Stifel
Buy
$34
Aug-08-23 Initiated
Jefferies
Buy
$29
Aug-08-23 Initiated
Guggenheim
Buy
$29
Today 01:45AM
Aug-24-24 01:30AM
Aug-19-24 07:00AM
Aug-12-24 06:30AM
Aug-10-24 01:00AM
01:00AM
Loading…
01:00AM
Jul-18-24 08:00AM
Jul-06-24 01:00AM
01:00AM
May-28-24 07:30AM
May-23-24 07:30AM
May-15-24 04:01PM
May-13-24 01:53PM
07:42AM
07:00AM
10:13AM
Loading…
May-10-24 10:13AM
May-08-24 01:28PM
May-06-24 08:00AM
Apr-03-24 07:49AM
Mar-28-24 11:01AM
Mar-25-24 07:00AM
07:00AM
Mar-12-24 04:01PM
Mar-07-24 06:49PM
Mar-05-24 10:53PM
(InvestorPlace) +42.07%
+12.46%
04:23PM
04:16PM
(Investor's Business Daily)
07:35AM
(Investor's Business Daily)
07:35AM
(Investor's Business Daily)
06:10AM
06:00AM
Loading…
06:00AM
06:00AM
Mar-04-24 04:01PM
Jan-02-24 07:30AM
Nov-15-23 04:44AM
Nov-13-23 07:30AM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Sep-27-23 08:42AM
Sep-14-23 07:30AM
Aug-29-23 08:00AM
Aug-28-23 07:30AM
Aug-21-23 07:30AM
Aug-10-23 02:29PM
Aug-08-23 10:02AM
Aug-07-23 07:30AM
Aug-04-23 06:30PM
Aug-02-23 07:30AM
Jul-18-23 04:01PM
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dambkowski Carl Chief Medical Officer Sep 04 '24 Sale 47.56 6,665 316,969 280,793 Sep 06 08:03 PM HENDERSON MICHAEL THOMAS Chief Executive Officer Sep 04 '24 Sale 47.62 40,000 1,904,841 1,394,487 Sep 06 08:02 PM HENDERSON MICHAEL THOMAS Officer Sep 04 '24 Proposed Sale 47.62 40,000 1,904,848 Sep 04 01:35 PM Henderson Jane Chief Financial Officer Aug 23 '24 Sale 48.26 6,000 289,560 200,871 Aug 23 08:05 PM JANE V HENDERSON Officer Aug 23 '24 Proposed Sale 48.26 6,000 289,570 Aug 23 04:09 PM Dambkowski Carl Chief Medical Officer Aug 07 '24 Sale 40.67 7,335 298,336 287,458 Aug 09 08:05 PM HENDERSON MICHAEL THOMAS Chief Executive Officer Aug 07 '24 Sale 40.62 40,000 1,624,764 1,434,487 Aug 09 08:05 PM HENDERSON MICHAEL THOMAS Officer Aug 07 '24 Proposed Sale 40.62 40,000 1,624,784 Aug 07 01:18 PM HENDERSON MICHAEL THOMAS Chief Executive Officer Jul 05 '24 Sale 37.26 15,000 558,900 1,474,487 Jul 05 08:01 PM Dambkowski Carl Chief Medical Officer Jul 03 '24 Sale 37.60 5,995 225,418 294,793 Jul 05 08:01 PM
Index -
P/E -
EPS (ttm) -18.03
Insider Own 32.54%
Shs Outstand 38.13M
Perf Week -20.31%
Market Cap 297.08M
Forward P/E -
EPS next Y -7.45
Insider Trans -8.09%
Shs Float 35.47M
Perf Month -48.52%
Income -897.68M
PEG -
EPS next Q -2.74
Inst Own 44.82%
Short Float 10.81%
Perf Quarter -74.32%
Sales 184.34M
P/S 1.61
EPS this Y 43.06%
Inst Trans -
Short Ratio 2.49
Perf Half Y -88.23%
Book/sh 17.01
P/B 0.33
EPS next Y 28.84%
ROA -45.83%
Short Interest 3.84M
Perf Year -93.69%
Cash/sh 13.94
P/C 0.41
EPS next 5Y 31.20%
ROE -76.83%
52W Range 6.00 - 90.40
Perf YTD -91.64%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -69.84%
52W High -93.75%
Beta 1.06
Dividend TTM -
Quick Ratio 4.71
Sales past 5Y 104.75%
Gross Margin 45.10%
52W Low -5.83%
ATR (14) 1.09
Dividend Ex-Date -
Current Ratio 4.71
EPS Y/Y TTM 35.80%
Oper. Margin -348.09%
RSI (14) 28.63
Volatility 8.88% 12.93%
Employees 1218
Debt/Eq 0.54
Sales Y/Y TTM -43.45%
Profit Margin -486.98%
Recom 3.83
Target Price 36.80
Option/Short Yes / Yes
LT Debt/Eq 0.54
EPS Q/Q -17.99%
Payout -
Rel Volume 1.27
Prev Close 6.14
Sales Surprise 30.28%
EPS Surprise -42.05%
Sales Q/Q -30.24%
Earnings Aug 08 AMC
Avg Volume 1.54M
Price 5.65
SMA20 -33.63%
SMA50 -49.40%
SMA200 -84.55%
Trades
Volume 1,951,907
Change -7.98%
Date
Action
Analyst
Rating Change
Price Target Change
May-15-24 Downgrade
BTIG Research
Neutral → Sell
May-10-24 Downgrade
William Blair
Mkt Perform → Underperform
Nov-14-23 Downgrade
Raymond James
Outperform → Mkt Perform
$3.50 → $2.50
Nov-09-23 Downgrade
BTIG Research
Buy → Neutral
Jun-02-23 Downgrade
Goldman
Neutral → Sell
$3 → $1.25
May-11-23 Downgrade
William Blair
Outperform → Mkt Perform
Nov-29-22 Initiated
Berenberg
Buy
$6
Oct-04-22 Initiated
Morgan Stanley
Equal-Weight
$5
May-18-22 Downgrade
BofA Securities
Neutral → Underperform
$3
Mar-02-22 Resumed
Cowen
Outperform
$12
Feb-23-22 Initiated
Goldman
Neutral
$7
Feb-01-22 Initiated
BofA Securities
Neutral
$6
Jan-28-22 Initiated
BofA Securities
Buy
$8
Jan-07-22 Initiated
BTIG Research
Buy
$12
Nov-29-21 Initiated
Jefferies
Buy
$16
Oct-13-21 Initiated
Raymond James
Outperform
$14.50
Oct-12-21 Initiated
William Blair
Outperform
Sep-20-21 Initiated
HSBC Securities
Buy
$14
Show Previous Ratings
Sep-04-24 04:30PM
Aug-30-24 07:00AM
Aug-19-24 07:56AM
Aug-08-24 05:01PM
04:00PM
07:00AM
Loading…
Aug-02-24 07:00AM
Aug-01-24 07:01AM
Jul-16-24 07:01AM
Jul-11-24 06:00AM
Jul-10-24 04:08PM
06:35AM
Jul-08-24 07:00AM
Jul-05-24 07:30AM
Jun-27-24 03:38PM
Jun-26-24 12:48PM
12:29PM
Loading…
12:29PM
Jun-24-24 10:52AM
10:31AM
Jun-20-24 12:31PM
Jun-19-24 12:00PM
Jun-07-24 09:35AM
May-31-24 07:00AM
May-17-24 01:58PM
May-15-24 07:01AM
May-14-24 06:00PM
May-13-24 04:05PM
May-10-24 07:30AM
May-09-24 05:45PM
04:01PM
May-08-24 01:46PM
12:31PM
Loading…
May-07-24 12:31PM
11:43AM
07:01AM
May-06-24 07:01AM
May-02-24 07:00AM
Apr-29-24 05:24PM
(InvestorPlace) +15.08%
-9.97%
04:01PM
Apr-25-24 08:01AM
Apr-16-24 07:02AM
Apr-11-24 07:01AM
07:01AM
Apr-10-24 07:02AM
07:01AM
Apr-08-24 07:00AM
Apr-04-24 07:01AM
Apr-03-24 07:02AM
Apr-02-24 07:02AM
Mar-28-24 07:02AM
Mar-27-24 07:02AM
Mar-26-24 07:02AM
Mar-13-24 05:04AM
Mar-12-24 07:01AM
Feb-29-24 05:01PM
Feb-28-24 07:12AM
07:03AM
07:02AM
07:02AM
07:02AM
07:01AM
Feb-27-24 09:00AM
07:05AM
Feb-22-24 07:00AM
Feb-15-24 07:02AM
07:00AM
Feb-13-24 07:01AM
Feb-01-24 07:00AM
Jan-31-24 07:00AM
Jan-15-24 07:00AM
Jan-10-24 07:35AM
Jan-08-24 07:00AM
Jan-04-24 07:00AM
Jan-03-24 07:00AM
Dec-20-23 07:00AM
Dec-19-23 07:01AM
07:01AM
07:01AM
Dec-13-23 07:01AM
Dec-12-23 07:01AM
Dec-08-23 09:00AM
07:02AM
Dec-06-23 05:00PM
Nov-30-23 12:25PM
Nov-27-23 07:00AM
Nov-14-23 04:30PM
(GlobeNewswire) +12.50%
+8.33%
Nov-11-23 01:55PM
Nov-09-23 07:01AM
Nov-08-23 05:01PM
Nov-06-23 07:00AM
Nov-01-23 09:00AM
07:00AM
Oct-24-23 07:00AM
Oct-19-23 04:01PM
Oct-17-23 07:01AM
Oct-16-23 07:01AM
Oct-12-23 07:01AM
Oct-05-23 07:00AM
Oct-02-23 07:01AM
Sep-29-23 07:00AM
Sep-28-23 09:54AM
07:01AM
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Che Austin Officer Sep 06 '24 Proposed Sale 6.06 99 600 Sep 06 09:47 AM Che Austin Officer Sep 05 '24 Proposed Sale 6.24 99 618 Sep 05 10:50 AM Che Austin Officer Sep 04 '24 Proposed Sale 6.00 99 594 Sep 04 10:43 AM Che Austin Officer Sep 03 '24 Proposed Sale 6.57 99 650 Sep 03 12:59 PM Che Austin Officer Aug 30 '24 Proposed Sale 7.24 99 717 Aug 30 10:31 AM Che Austin Officer Aug 29 '24 Proposed Sale 7.19 99 712 Aug 29 10:31 AM Che Austin Officer Aug 28 '24 Proposed Sale 7.45 99 738 Aug 28 11:25 AM Che Austin Officer Aug 27 '24 Proposed Sale 7.77 99 769 Aug 27 10:01 AM Che Austin Officer Aug 26 '24 Proposed Sale 8.08 99 800 Aug 26 11:51 AM Che Austin Officer Aug 23 '24 Proposed Sale 8.38 396 3,318 Aug 23 10:46 AM Che Austin Officer Aug 19 '24 Proposed Sale 0.23 3,968 915 Aug 19 11:05 AM Che Austin Officer Aug 16 '24 Proposed Sale 0.25 3,968 982 Aug 16 11:23 AM Che Austin Officer Aug 15 '24 Proposed Sale 0.24 3,968 932 Aug 15 11:59 AM Che Austin Officer Aug 14 '24 Proposed Sale 0.28 3,968 1,108 Aug 14 10:10 AM Che Austin Officer Aug 13 '24 Proposed Sale 0.26 3,968 1,034 Aug 13 10:33 AM Che Austin Officer Aug 12 '24 Proposed Sale 0.27 3,968 1,057 Aug 12 09:57 AM Che Austin Officer Aug 09 '24 Proposed Sale 0.31 3,968 1,230 Aug 09 12:37 PM Che Austin Officer Aug 08 '24 Proposed Sale 0.30 3,968 1,182 Aug 08 10:14 AM Che Austin Officer Aug 07 '24 Proposed Sale 0.29 3,968 1,149 Aug 07 10:38 AM Coen Steven P. See remarks Aug 02 '24 Sale 0.29 17,486 5,018 207,318 Aug 06 04:39 PM Dmytruk Mark E. See remarks Aug 02 '24 Sale 0.29 63,567 18,244 1,088,186 Aug 06 04:37 PM Che Austin Officer Aug 06 '24 Proposed Sale 0.30 3,968 1,190 Aug 06 10:12 AM Che Austin Officer Aug 05 '24 Proposed Sale 0.27 3,968 1,052 Aug 05 11:05 AM Dmytruk Mark E. Officer Aug 02 '24 Proposed Sale 0.29 63,567 18,225 Aug 02 03:56 PM Che Austin Officer Aug 02 '24 Proposed Sale 0.34 3,968 1,349 Aug 02 10:22 AM Che Austin Officer Aug 01 '24 Proposed Sale 0.38 3,968 1,502 Aug 01 01:49 PM Che Austin Officer Jul 31 '24 Proposed Sale 0.37 3,968 1,450 Jul 31 10:39 AM Che Austin Officer Jul 30 '24 Proposed Sale 0.37 3,968 1,470 Jul 30 11:17 AM Che Austin Officer Jul 29 '24 Proposed Sale 0.38 3,968 1,508 Jul 29 10:34 AM Che Austin Officer Jul 26 '24 Proposed Sale 0.33 3,968 1,326 Jul 26 09:56 AM Coen Steven P. See remarks Jul 02 '24 Sale 0.33 13,520 4,408 195,058 Jul 05 04:02 PM Dmytruk Mark E. See remarks Jul 02 '24 Sale 0.33 49,162 16,027 1,043,626 Jul 05 04:01 PM Coen Steven P. See remarks Jun 03 '24 Sale 0.55 13,440 7,379 178,832 Jun 05 05:06 PM Dmytruk Mark E. See remarks Jun 03 '24 Sale 0.55 48,866 26,827 984,662 Jun 05 05:04 PM DEKKERS MARIJN E Director May 16 '24 Sale 0.83 265,000 220,030 5,515,364 May 20 04:54 PM Sankar Shyam Director May 15 '24 Buy 0.82 625,000 514,750 2,356,874 May 16 05:08 PM SLOAN HARRY Director May 14 '24 Buy 0.91 297,619 271,815 718,540 May 14 05:16 PM DEKKERS MARIJN E Director May 14 '24 Sale 0.93 1,727,056 1,606,162 281,217 May 14 05:13 PM Dmytruk Mark E. See remarks May 02 '24 Sale 0.84 47,806 40,396 925,400 May 06 04:55 PM Coen Steven P. See remarks May 02 '24 Sale 0.84 131,928 111,479 162,527 May 06 04:53 PM Dmytruk Mark E. See remarks Apr 02 '24 Sale 1.05 51,169 53,727 865,079 Apr 04 04:40 PM Dmytruk Mark E. See remarks Mar 04 '24 Sale 1.26 38,826 48,765 808,125 Mar 06 05:08 PM Dmytruk Mark E. See remarks Feb 02 '24 Sale 1.21 39,569 47,799 761,737 Feb 06 05:06 PM Kelly Jason R See remarks Jan 04 '24 Sale 1.55 100,000 155,500 3,894,680 Jan 05 05:11 PM Kelly Jason R See remarks Jan 03 '24 Sale 1.54 100,000 154,400 3,994,680 Jan 05 05:11 PM Dmytruk Mark E. See remarks Jan 03 '24 Sale 1.54 45,794 70,523 716,098 Jan 05 05:09 PM Canton Barry 10% Owner Dec 20 '23 Sale 1.79 37,650 67,582 12,374,554 Dec 22 04:59 PM Canton Barry 10% Owner Dec 21 '23 Sale 1.74 37,650 65,398 12,374,544 Dec 22 04:59 PM Kelly Jason R See remarks Dec 20 '23 Sale 1.79 100,000 179,400 4,194,680 Dec 22 04:57 PM Kelly Jason R See remarks Dec 21 '23 Sale 1.74 100,000 173,700 4,094,680 Dec 22 04:57 PM Shetty Reshma P. See remarks Dec 20 '23 Sale 1.79 37,650 67,582 12,374,554 Dec 22 04:55 PM Shetty Reshma P. See remarks Dec 21 '23 Sale 1.74 37,650 65,398 12,374,544 Dec 22 04:55 PM Canton Barry 10% Owner Dec 14 '23 Sale 1.63 37,650 61,257 12,412,194 Dec 15 05:07 PM Canton Barry 10% Owner Dec 13 '23 Sale 1.34 36,829 49,351 12,413,025 Dec 15 05:07 PM Canton Barry 10% Owner Dec 14 '23 Sale 1.48 821 1,215 12,412,204 Dec 15 05:07 PM Kelly Jason R See remarks Dec 14 '23 Sale 1.62 100,980 164,092 4,294,680 Dec 15 05:05 PM Kelly Jason R See remarks Dec 13 '23 Sale 1.34 99,020 132,786 4,395,660 Dec 15 05:05 PM Shetty Reshma P. See remarks Dec 14 '23 Sale 1.63 37,650 61,257 12,412,194 Dec 15 05:02 PM Shetty Reshma P. See remarks Dec 13 '23 Sale 1.34 36,829 49,351 12,413,025 Dec 15 05:02 PM Shetty Reshma P. See remarks Dec 14 '23 Sale 1.48 821 1,215 12,412,204 Dec 15 05:02 PM Canton Barry 10% Owner Dec 06 '23 Sale 1.32 37,650 49,811 12,449,854 Dec 08 05:17 PM Canton Barry 10% Owner Dec 07 '23 Sale 1.31 37,650 49,510 12,449,844 Dec 08 05:17 PM Kelly Jason R See remarks Dec 06 '23 Sale 1.32 100,000 132,300 4,594,680 Dec 08 05:15 PM Kelly Jason R See remarks Dec 07 '23 Sale 1.31 100,000 131,300 4,494,680 Dec 08 05:15 PM Shetty Reshma P. See remarks Dec 06 '23 Sale 1.32 37,650 49,811 12,449,854 Dec 08 05:14 PM Shetty Reshma P. See remarks Dec 07 '23 Sale 1.31 37,650 49,510 12,449,844 Dec 08 05:14 PM Dmytruk Mark E. See remarks Dec 04 '23 Sale 1.39 42,402 58,812 676,844 Dec 06 05:09 PM Shetty Reshma P. See remarks Nov 29 '23 Sale 1.45 37,650 54,592 12,487,504 Dec 01 05:02 PM Shetty Reshma P. See remarks Nov 30 '23 Sale 1.35 37,650 50,940 12,487,494 Dec 01 05:02 PM Kelly Jason R See remarks Nov 29 '23 Sale 1.45 100,000 145,200 4,794,680 Dec 01 04:59 PM Kelly Jason R See remarks Nov 30 '23 Sale 1.35 100,000 135,300 4,694,680 Dec 01 04:59 PM Canton Barry 10% Owner Nov 29 '23 Sale 1.45 37,650 54,592 12,487,504 Dec 01 04:54 PM Canton Barry 10% Owner Nov 30 '23 Sale 1.35 37,650 50,940 12,487,494 Dec 01 04:54 PM Canton Barry 10% Owner Nov 24 '23 Sale 1.42 37,650 53,275 12,525,144 Nov 27 05:00 PM Canton Barry 10% Owner Nov 22 '23 Sale 1.40 37,650 52,785 12,525,154 Nov 27 05:00 PM Kelly Jason R See remarks Nov 24 '23 Sale 1.41 100,000 141,300 4,894,680 Nov 27 04:58 PM Kelly Jason R See remarks Nov 22 '23 Sale 1.40 100,000 140,400 4,994,680 Nov 27 04:58 PM Shetty Reshma P. See remarks Nov 24 '23 Sale 1.42 37,650 53,275 12,525,144 Nov 27 04:57 PM Shetty Reshma P. See remarks Nov 22 '23 Sale 1.40 37,650 52,785 12,525,154 Nov 27 04:57 PM Canton Barry 10% Owner Nov 15 '23 Sale 1.54 37,650 58,132 12,562,804 Nov 17 04:59 PM Canton Barry 10% Owner Nov 16 '23 Sale 1.45 37,650 54,705 12,562,794 Nov 17 04:59 PM Kelly Jason R See remarks Nov 15 '23 Sale 1.54 100,000 154,200 5,194,680 Nov 17 04:56 PM Kelly Jason R See remarks Nov 16 '23 Sale 1.45 100,000 145,200 5,094,680 Nov 17 04:56 PM Shetty Reshma P. See remarks Nov 15 '23 Sale 1.54 37,650 58,132 12,562,804 Nov 17 04:53 PM Shetty Reshma P. See remarks Nov 16 '23 Sale 1.45 37,650 54,705 12,562,794 Nov 17 04:53 PM Shetty Reshma P. See remarks Nov 08 '23 Sale 1.50 37,650 56,626 12,600,454 Nov 13 08:02 AM Shetty Reshma P. See remarks Nov 09 '23 Sale 1.29 37,650 48,531 12,600,444 Nov 13 08:02 AM Kelly Jason R See remarks Nov 08 '23 Sale 1.50 100,000 150,200 5,394,680 Nov 13 08:01 AM Kelly Jason R See remarks Nov 09 '23 Sale 1.29 100,000 129,100 5,294,680 Nov 13 08:01 AM Canton Barry 10% Owner Nov 08 '23 Sale 1.50 37,650 56,626 12,600,454 Nov 13 08:00 AM Canton Barry 10% Owner Nov 09 '23 Sale 1.29 37,650 48,531 12,600,444 Nov 13 08:00 AM HENRY CHRISTIAN O Director Nov 02 '23 Sale 1.39 4,500 6,255 1,234,378 Nov 06 05:23 PM Dmytruk Mark E. See remarks Nov 02 '23 Sale 1.50 37,229 55,918 634,206 Nov 06 05:21 PM Shetty Reshma P. See remarks Nov 02 '23 Sale 1.52 37,650 57,077 12,638,094 Nov 03 05:09 PM Shetty Reshma P. See remarks Nov 01 '23 Sale 1.34 37,650 50,564 12,638,104 Nov 03 05:09 PM Canton Barry 10% Owner Nov 02 '23 Sale 1.52 37,650 57,077 12,638,094 Nov 03 05:04 PM Canton Barry 10% Owner Nov 01 '23 Sale 1.34 37,650 50,564 12,638,104 Nov 03 05:04 PM Kelly Jason R See remarks Nov 02 '23 Sale 1.52 100,000 151,600 5,494,680 Nov 03 05:01 PM Kelly Jason R See remarks Nov 01 '23 Sale 1.34 100,000 134,200 5,594,680 Nov 03 05:01 PM Shetty Reshma P. See remarks Oct 25 '23 Sale 1.48 37,650 55,609 12,675,754 Oct 27 04:56 PM
Index RUT
P/E -
EPS (ttm) -2.85
Insider Own 16.89%
Shs Outstand 138.39M
Perf Week 3.48%
Market Cap 3.61B
Forward P/E -
EPS next Y -2.68
Insider Trans -0.72%
Shs Float 118.98M
Perf Month 16.47%
Income -419.65M
PEG -
EPS next Q -0.62
Inst Own 84.17%
Short Float 7.03%
Perf Quarter 18.49%
Sales 1.27M
P/S 2846.29
EPS this Y -139.57%
Inst Trans -0.74%
Short Ratio 7.56
Perf Half Y 22.99%
Book/sh 9.69
P/B 2.61
EPS next Y -5.70%
ROA -29.89%
Short Interest 8.36M
Perf Year 2.23%
Cash/sh 6.26
P/C 4.03
EPS next 5Y -
ROE -32.61%
52W Range 14.56 - 25.90
Perf YTD 17.66%
Dividend Est. -
P/FCF -
EPS past 5Y -21.99%
ROI -29.39%
52W High -2.51%
Beta 1.36
Dividend TTM -
Quick Ratio 12.46
Sales past 5Y 264.19%
Gross Margin -570.72%
52W Low 73.42%
ATR (14) 1.09
Dividend Ex-Date -
Current Ratio 12.46
EPS Y/Y TTM -173.06%
Oper. Margin -39085.40%
RSI (14) 59.58
Volatility 3.86% 4.28%
Employees 445
Debt/Eq 0.04
Sales Y/Y TTM -99.63%
Profit Margin -33121.86%
Recom 1.13
Target Price 39.77
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q -145.07%
Payout -
Rel Volume 0.57
Prev Close 25.25
Sales Surprise -100.00%
EPS Surprise 13.96%
Sales Q/Q -100.00%
Earnings Aug 01 BMO
Avg Volume 1.11M
Price 25.25
SMA20 5.19%
SMA50 8.80%
SMA200 25.35%
Trades
Volume 628,703
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-23 Initiated
Citigroup
Buy
$32
Nov-20-23 Resumed
JP Morgan
Overweight
$28
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$85 → $35
Sep-06-23 Initiated
B. Riley Securities
Buy
$38
Jan-30-23 Initiated
SVB Securities
Outperform
$50
Dec-05-22 Initiated
Cowen
Outperform
Nov-02-22 Upgrade
BTIG Research
Neutral → Buy
$38
Nov-02-22 Initiated
BofA Securities
Buy
$40
Jun-23-22 Initiated
Berenberg
Buy
$39
Dec-10-21 Resumed
Raymond James
Mkt Perform
Sep-21-21 Initiated
Oppenheimer
Outperform
$85
Sep-01-21 Initiated
SMBC Nikko
Outperform
$78
May-18-21 Initiated
UBS
Buy
$70
Feb-26-21 Reiterated
H.C. Wainwright
Buy
$80 → $95
Feb-10-21 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$105
Nov-11-20 Reiterated
H.C. Wainwright
Buy
$65 → $80
Oct-16-20 Downgrade
BTIG Research
Buy → Neutral
Sep-14-20 Resumed
JP Morgan
Overweight
$35
Aug-20-20 Reiterated
H.C. Wainwright
Buy
$28 → $45
Mar-13-20 Upgrade
Evercore ISI
In-line → Outperform
$20
Show Previous Ratings
Sep-04-24 08:15AM
Sep-03-24 08:00AM
Aug-19-24 10:13AM
Aug-14-24 02:00PM
Aug-06-24 09:55AM
06:45AM
Loading…
Aug-01-24 06:45AM
Jul-23-24 06:13AM
Jul-16-24 03:19PM
(Investor's Business Daily)
Jul-08-24 07:09PM
Jun-28-24 08:37AM
Jun-24-24 09:07AM
Jun-12-24 07:00AM
Jun-06-24 11:31AM
Jun-04-24 01:17PM
Jun-03-24 08:00AM
07:00AM
Loading…
May-09-24 07:00AM
May-08-24 11:17AM
09:16AM
08:20AM
May-07-24 10:56PM
05:56PM
04:01PM
May-01-24 08:00AM
Apr-09-24 08:46AM
Apr-08-24 08:00AM
Mar-28-24 11:30AM
Mar-19-24 08:30AM
Feb-28-24 08:08AM
Feb-27-24 08:31AM
08:05AM
08:00AM
Loading…
08:00AM
06:53AM
Feb-16-24 08:39AM
08:22AM
07:13AM
Feb-07-24 08:00AM
Feb-01-24 08:00AM
Jan-31-24 11:04PM
Jan-26-24 10:00AM
Jan-11-24 01:11PM
Jan-09-24 08:44AM
Jan-08-24 08:00AM
06:30AM
06:30AM
Jan-02-24 01:57PM
Dec-22-23 06:22AM
Dec-21-23 09:55AM
Dec-07-23 11:31AM
Nov-27-23 07:01PM
09:55AM
Nov-21-23 06:00AM
Nov-07-23 05:50PM
04:01PM
Nov-06-23 09:55AM
Nov-01-23 10:30AM
Oct-19-23 10:30AM
Oct-06-23 04:41AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-09-23 03:59PM
Sep-07-23 11:30AM
Aug-30-23 08:30AM
Aug-29-23 09:00AM
Aug-11-23 11:36AM
Aug-10-23 12:02PM
06:03AM
Aug-08-23 06:05PM
04:01PM
Jun-29-23 05:13AM
Jun-27-23 02:23PM
Jun-26-23 10:00AM
(The Wall Street Journal)
Jun-21-23 03:21PM
06:00AM
Jun-20-23 04:20PM
07:00AM
Jun-09-23 11:30AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-05-23 06:15PM
May-31-23 01:30PM
May-16-23 06:00AM
May-15-23 04:31PM
May-09-23 01:24PM
May-08-23 05:15PM
04:01PM
May-04-23 01:21PM
May-01-23 10:00AM
Apr-27-23 10:02AM
Apr-14-23 07:03AM
Apr-12-23 08:00AM
Apr-10-23 08:00AM
Apr-04-23 05:12AM
Mar-29-23 11:30AM
Mar-04-23 07:35AM
Feb-28-23 09:01AM
Feb-27-23 05:35PM
04:01PM
Feb-23-23 11:15AM
Feb-22-23 04:33PM
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SATO VICKI L Director Sep 03 '24 Sale 25.00 3,080 77,007 116,176 Sep 04 06:26 PM Watts Ryan J. President and CEO Aug 20 '24 Sale 23.79 2,260 53,765 235,807 Aug 22 04:16 PM Krognes Steve E. Director Aug 20 '24 Sale 23.79 1,727 41,085 32,677 Aug 22 04:15 PM Schuth Alexander O. COFO and Secretary Aug 20 '24 Sale 23.65 5,806 137,286 180,613 Aug 22 04:14 PM Schuth Alexander O. COFO and Secretary Aug 21 '24 Sale 24.78 2,547 63,115 178,066 Aug 22 04:14 PM Ho Carole Chief Medical Officer Aug 21 '24 Sale 24.57 20,005 491,571 118,810 Aug 22 04:14 PM Ho Carole Chief Medical Officer Aug 20 '24 Sale 23.79 2,453 58,357 138,815 Aug 22 04:14 PM CAROLE HO Officer Aug 21 '24 Proposed Sale 23.65 20,005 473,118 Aug 21 04:42 PM ALEXANDER SCHUTH Officer Aug 21 '24 Proposed Sale 23.65 2,547 60,237 Aug 21 04:40 PM Krognes Steve E. Director Aug 20 '24 Proposed Sale 23.79 1,727 41,085 Aug 20 08:09 PM Schuth Alexander O. Officer Aug 20 '24 Proposed Sale 23.79 2,453 58,357 Aug 20 08:09 PM Watts Ryan J. Director Aug 20 '24 Proposed Sale 23.79 2,260 53,765 Aug 20 08:08 PM Ho Carole Officer Aug 20 '24 Proposed Sale 23.79 2,453 58,356 Aug 20 08:08 PM ALEXANDER SCHUTH Officer Aug 20 '24 Proposed Sale 23.95 3,353 80,304 Aug 20 04:27 PM Schuth Alexander O. COFO and Secretary Aug 13 '24 Sale 22.89 2,272 52,006 186,419 Aug 15 04:10 PM Ho Carole Chief Medical Officer Aug 13 '24 Sale 22.89 2,337 53,494 141,268 Aug 15 04:09 PM Schuth Alexander O. Officer Aug 13 '24 Proposed Sale 22.89 2,272 52,006 Aug 13 08:37 PM Ho Carole Officer Aug 13 '24 Proposed Sale 22.89 2,337 53,494 Aug 13 08:36 PM Krognes Steve E. Director Jul 01 '24 Sale 22.12 30,000 663,668 34,404 Jul 03 09:13 PM Krognes Steve E. Director Jun 13 '24 Sale 21.79 688 14,992 52,620 Jul 03 09:13 PM SATO VICKI L Director Jul 01 '24 Sale 22.14 3,080 68,204 119,256 Jul 03 09:13 PM Cook Jennifer E. Director Jun 06 '24 Sale 21.73 1,458 31,682 20,038 Jun 10 08:06 PM SATO VICKI L Director May 15 '24 Sale 20.39 1,674 34,133 116,369 May 17 04:28 PM SATO VICKI L Director Apr 15 '24 Sale 18.29 1,666 30,471 118,043 Apr 17 05:14 PM Krognes Steve E. Director Apr 01 '24 Sale 20.50 92,500 1,896,250 47,341 Apr 02 06:07 PM SATO VICKI L Director Mar 15 '24 Sale 20.10 1,666 33,487 119,709 Mar 19 04:27 PM SATO VICKI L Director Feb 15 '24 Sale 18.37 1,666 30,604 121,375 Feb 20 05:38 PM Krognes Steve E. Director Feb 13 '24 Sale 17.29 2,750 47,548 139,841 Feb 15 09:16 PM Watts Ryan J. President and CEO Feb 13 '24 Sale 17.29 9,589 165,794 238,067 Feb 15 09:15 PM Ho Carole Chief Medical Officer Feb 13 '24 Sale 17.29 2,784 48,135 145,010 Feb 15 09:14 PM Ho Carole Chief Medical Officer Feb 14 '24 Sale 17.79 1,405 24,995 143,605 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 14 '24 Sale 17.66 20,128 355,460 187,341 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 13 '24 Sale 17.29 2,716 46,960 207,469 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 08 '24 Option Exercise 0.68 50,000 34,000 210,185 Feb 12 04:48 PM SATO VICKI L Director Jan 16 '24 Sale 18.42 1,666 30,688 123,041 Jan 18 06:26 PM Ho Carole Chief Medical Officer Jan 10 '24 Sale 19.02 4,668 88,785 147,794 Jan 12 08:18 PM Watts Ryan J. President and CEO Jan 09 '24 Sale 19.78 7,818 154,640 2,268,363 Jan 11 05:28 PM Ho Carole Chief Medical Officer Jan 05 '24 Sale 19.43 9,972 193,756 198,777 Jan 09 07:35 PM Krognes Steve E. Director Jan 05 '24 Sale 19.43 3,208 62,331 142,591 Jan 09 07:34 PM Schuth Alexander O. COFO and Secretary Jan 05 '24 Sale 19.43 9,972 193,756 539,307 Jan 09 07:34 PM Watts Ryan J. President and CEO Jan 05 '24 Sale 19.43 17,483 339,695 2,276,181 Jan 09 07:33 PM SATO VICKI L Director Dec 15 '23 Sale 23.39 1,666 38,968 124,707 Dec 18 07:30 PM SATO VICKI L Director Nov 15 '23 Sale 19.13 1,666 31,871 126,373 Nov 16 06:14 PM SATO VICKI L Director Oct 16 '23 Sale 20.66 1,666 34,420 128,039 Oct 18 04:44 PM SATO VICKI L Director Sep 15 '23 Sale 23.62 1,666 39,348 129,705 Sep 19 04:45 PM
Index RUT
P/E -
EPS (ttm) -1.80
Insider Own 13.15%
Shs Outstand 81.63M
Perf Week -13.15%
Market Cap 1.92B
Forward P/E -
EPS next Y -4.66
Insider Trans -1.60%
Shs Float 71.58M
Perf Month -4.70%
Income -143.01M
PEG -
EPS next Q -1.19
Inst Own 81.50%
Short Float 15.62%
Perf Quarter -3.16%
Sales 352.57M
P/S 5.45
EPS this Y -173.05%
Inst Trans -0.68%
Short Ratio 9.15
Perf Half Y -36.93%
Book/sh 10.37
P/B 2.25
EPS next Y 0.84%
ROA -10.94%
Short Interest 11.18M
Perf Year -5.47%
Cash/sh 12.23
P/C 1.91
EPS next 5Y -3.70%
ROE -17.17%
52W Range 16.95 - 49.50
Perf YTD -14.36%
Dividend Est. -
P/FCF -
EPS past 5Y 5.58%
ROI -14.21%
52W High -52.91%
Beta 1.87
Dividend TTM -
Quick Ratio 5.81
Sales past 5Y 43297.50%
Gross Margin 93.24%
52W Low 37.52%
ATR (14) 1.51
Dividend Ex-Date Feb 04, 2014
Current Ratio 5.81
EPS Y/Y TTM 60.97%
Oper. Margin -52.31%
RSI (14) 39.62
Volatility 5.99% 5.21%
Employees 436
Debt/Eq 0.19
Sales Y/Y TTM 339.83%
Profit Margin -40.56%
Recom 1.88
Target Price 50.14
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q -2.01%
Payout -
Rel Volume 0.38
Prev Close 24.18
Sales Surprise -16.95%
EPS Surprise 1.52%
Sales Q/Q -41.48%
Earnings Aug 06 BMO
Avg Volume 1.22M
Price 23.31
SMA20 -7.19%
SMA50 -10.59%
SMA200 -15.36%
Trades
Volume 467,199
Change -3.60%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-23-24 Initiated
H.C. Wainwright
Buy
$80
Jan-29-24 Upgrade
JP Morgan
Neutral → Overweight
$38 → $40
Dec-15-23 Downgrade
BofA Securities
Buy → Neutral
$35
Dec-08-23 Downgrade
Jefferies
Buy → Hold
$75 → $30
Oct-20-23 Downgrade
Leerink Partners
Outperform → Market Perform
$75 → $20
Oct-20-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Mar-21-23 Initiated
Bernstein
Mkt Perform
$37
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$62
Dec-20-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$61 → $66
Dec-13-22 Initiated
Citigroup
Buy
$62
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$41
Apr-28-22 Initiated
Credit Suisse
Neutral
$62
Jan-05-22 Initiated
Guggenheim
Buy
$130
Oct-19-21 Initiated
SVB Leerink
Outperform
$117
Sep-24-21 Resumed
Stifel
Buy
$85 → $120
Sep-10-21 Initiated
BofA Securities
Buy
$150
May-11-21 Initiated
Redburn
Buy
May-04-21 Initiated
RBC Capital Mkts
Sector Perform
$85
Mar-01-21 Downgrade
Barclays
Overweight → Equal Weight
$47 → $90
Feb-16-21 Initiated
Wells Fargo
Overweight
$145
Show Previous Ratings
Sep-05-24 11:31AM
Aug-14-24 10:27AM
Aug-09-24 10:19AM
Aug-07-24 10:50AM
Aug-06-24 01:54PM
07:45AM
Loading…
07:45AM
06:30AM
Jul-26-24 07:43AM
Jul-24-24 06:28PM
(Investor's Business Daily)
+7.92%
08:53AM
08:23AM
Jul-22-24 04:45PM
Jul-17-24 07:45AM
Jul-16-24 10:12AM
Jul-15-24 06:30AM
12:56PM
Loading…
Jul-11-24 12:56PM
Jul-09-24 12:00PM
07:00AM
06:25AM
Jul-04-24 02:13PM
Jul-03-24 09:12AM
Jun-27-24 10:02PM
10:26AM
Jun-26-24 06:30AM
Jun-14-24 03:00AM
Jun-06-24 11:31AM
May-30-24 06:30AM
May-14-24 04:00PM
May-13-24 02:18PM
May-09-24 06:49AM
10:52AM
Loading…
May-08-24 10:52AM
06:30AM
May-07-24 09:02PM
01:54PM
10:17AM
06:30AM
May-01-24 10:01AM
Mar-28-24 11:30AM
Mar-26-24 06:30AM
Feb-28-24 06:30AM
Feb-27-24 04:01PM
(Investor's Business Daily) +25.89%
02:57PM
(Investor's Business Daily)
12:33PM
07:11AM
06:30AM
Feb-20-24 10:00AM
Feb-16-24 02:46PM
(Investor's Business Daily)
Feb-10-24 05:09PM
Feb-07-24 07:35AM
Feb-05-24 06:30AM
Jan-29-24 06:21PM
(Motley Fool) +16.47%
-8.66%
Jan-16-24 01:51PM
09:00AM
Jan-11-24 04:38PM
Jan-08-24 06:30AM
05:52AM
Jan-02-24 06:30AM
Dec-27-23 10:30AM
Dec-15-23 10:22AM
Dec-14-23 06:30AM
Dec-08-23 11:30AM
Nov-30-23 09:55AM
Nov-23-23 11:03AM
09:42AM
Nov-20-23 05:43PM
(InvestorPlace) +11.98%
-9.14%
Nov-18-23 07:15AM
06:49AM
Nov-17-23 12:00PM
Nov-14-23 05:50AM
Nov-10-23 09:55AM
Nov-09-23 01:04PM
Nov-08-23 06:30AM
06:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-05-23 08:30AM
Nov-01-23 05:40AM
Oct-31-23 07:09PM
04:04PM
(Investor's Business Daily)
10:01AM
10:00AM
06:00AM
05:00AM
Oct-30-23 03:46PM
10:00AM
09:18AM
Oct-27-23 07:15AM
Oct-25-23 06:30AM
05:50AM
01:45AM
Oct-21-23 08:45AM
Oct-20-23 11:43AM
09:37AM
Oct-19-23 09:03AM
08:54AM
08:45AM
Oct-18-23 09:30AM
Oct-05-23 08:45AM
Oct-03-23 06:27AM
Sep-29-23 10:30AM
Sep-27-23 08:30AM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Simon Amy Chief Medical Officer Jul 02 '24 Sale 22.95 748 17,167 68,805 Jul 03 04:05 PM Simon Amy Chief Medical Officer Jul 01 '24 Sale 23.76 502 11,928 69,553 Jul 03 04:05 PM Evans John M. CEO Jun 27 '24 Sale 24.50 60,000 1,470,156 998,343 Jun 28 04:15 PM Simon Amy Chief Medical Officer Apr 02 '24 Sale 30.54 16,530 504,851 70,060 Apr 03 07:43 PM Simon Amy Chief Medical Officer Apr 01 '24 Sale 32.13 7,157 229,954 86,590 Apr 03 07:43 PM Bellon Christine Chief Legal Officer Apr 01 '24 Sale 32.12 3,401 109,240 104,594 Apr 03 07:40 PM Burrell Terry-Ann Chief Financial Officer Apr 01 '24 Sale 32.12 5,446 174,926 70,137 Apr 03 07:39 PM Evans John M. CEO Apr 01 '24 Sale 32.13 18,102 581,617 1,058,343 Apr 03 07:36 PM Ciaramella Giuseppe President Apr 01 '24 Sale 32.12 4,534 145,632 169,616 Apr 03 07:33 PM Evans John M. CEO Mar 28 '24 Sale 33.86 60,000 2,031,402 998,262 Apr 01 04:10 PM FMR LLC See Remark 1 Feb 14 '24 Sale 30.55 900,000 27,496,912 1,235,511 Feb 15 02:34 PM FMR LLC See Remark 1 Feb 13 '24 Sale 30.76 1,565 48,139 2,771,913 Feb 15 02:34 PM Evans John M. CEO Jan 31 '24 Sale 25.33 60,000 1,519,800 1,058,262 Feb 02 04:05 PM Bellon Christine Chief Legal Officer Jan 03 '24 Sale 26.42 1,907 50,383 80,495 Jan 05 04:30 PM Bellon Christine Chief Legal Officer Nov 20 '23 Option Exercise 7.22 10,000 72,200 92,402 Nov 22 04:05 PM Bellon Christine Chief Legal Officer Nov 20 '23 Sale 30.50 10,000 305,000 82,402 Nov 22 04:05 PM Simon Amy Chief Medical Officer Oct 30 '23 Sale 18.70 3,448 64,478 65,469 Nov 01 04:30 PM Ciaramella Giuseppe President and CSO Oct 20 '23 Option Exercise 0.67 90,900 60,903 139,150 Oct 24 04:05 PM Bellon Christine Chief Legal Officer Oct 02 '23 Sale 22.85 388 8,866 82,402 Oct 04 04:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite